
<html lang="en"     class="pb-page"  data-request-id="c2200f7f-ef55-4e7c-83ce-76c8a72a6539"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b01852;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease" /></meta><meta name="dc.Creator" content="Justin R.  Harrison" /></meta><meta name="dc.Creator" content="Sandipan  Sarkar" /></meta><meta name="dc.Creator" content="Shahienaz  Hampton" /></meta><meta name="dc.Creator" content="Jennifer  Riley" /></meta><meta name="dc.Creator" content="Laste  Stojanovski" /></meta><meta name="dc.Creator" content="Christer  Sahlberg" /></meta><meta name="dc.Creator" content="Pia  Appelqvist" /></meta><meta name="dc.Creator" content="Jessey  Erath" /></meta><meta name="dc.Creator" content="Vinodhini  Mathan" /></meta><meta name="dc.Creator" content="Ana  Rodriguez" /></meta><meta name="dc.Creator" content="Marcel  Kaiser" /></meta><meta name="dc.Creator" content="Dolores Gonzalez  Pacanowska" /></meta><meta name="dc.Creator" content="Kevin D.  Read" /></meta><meta name="dc.Creator" content="Nils Gunnar  Johansson" /></meta><meta name="dc.Creator" content="Ian H.  Gilbert" /></meta><meta name="dc.Description" content="Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronic..." /></meta><meta name="Description" content="Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronic..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 5, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01852" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01852" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01852" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01852" /></link>
        
    
    

<title>Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01852" /></meta><meta property="og:title" content="Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0034.jpeg" /></meta><meta property="og:description" content="Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01852"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01852">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01852&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01852&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01852&amp;href=/doi/10.1021/acs.jmedchem.9b01852" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 3066-3089</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01809" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01866" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of a Compound Series Active against <i>Trypanosoma cruzi</i>, the Causative Agent of Chagas Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Justin R. Harrison</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Justin R. Harrison</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Justin+R.++Harrison">Justin R. Harrison</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandipan Sarkar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandipan Sarkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Syngene International Ltd, Biocon Park, SEZ, Bommasandra Industrial Area, Phase-IV, Bommasandra-Jigani Link Road, Bangalore 560 099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandipan++Sarkar">Sandipan Sarkar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shahienaz Hampton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shahienaz Hampton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shahienaz++Hampton">Shahienaz Hampton</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6600-9492" title="Orcid link">http://orcid.org/0000-0002-6600-9492</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer Riley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Riley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Riley">Jennifer Riley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laste Stojanovski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laste Stojanovski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laste++Stojanovski">Laste Stojanovski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christer Sahlberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christer Sahlberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medivir, Lunastigen 7, 141 44 Huddinge, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christer++Sahlberg">Christer Sahlberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pia Appelqvist</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pia Appelqvist</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medivir, Lunastigen 7, 141 44 Huddinge, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pia++Appelqvist">Pia Appelqvist</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessey Erath</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessey Erath</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">New York University School of Medicine, 430 East 29th Street, Alexandria Center West Tower, Room 511, Lab 524, New York, New York 10010, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessey++Erath">Jessey Erath</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vinodhini Mathan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vinodhini Mathan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Syngene International Ltd, Biocon Park, SEZ, Bommasandra Industrial Area, Phase-IV, Bommasandra-Jigani Link Road, Bangalore 560 099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vinodhini++Mathan">Vinodhini Mathan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ana Rodriguez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana Rodriguez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">New York University School of Medicine, 430 East 29th Street, Alexandria Center West Tower, Room 511, Lab 524, New York, New York 10010, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Rodriguez">Ana Rodriguez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marcel Kaiser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcel Kaiser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, Basel CH-4051, Switzerland</div><div class="loa-info-affiliations-info">University of Basel, Petersplatz 1, Basel CH-4003, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcel++Kaiser">Marcel Kaiser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dolores Gonzalez Pacanowska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dolores Gonzalez Pacanowska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra”, Avda. Conocimiento S/N, Parque Tecnológico Ciencias de la Salud18016 Armilla, Granada Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dolores+Gonzalez++Pacanowska">Dolores Gonzalez Pacanowska</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin D. Read</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin D. Read</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+D.++Read">Kevin D. Read</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8536-0130" title="Orcid link">http://orcid.org/0000-0002-8536-0130</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nils Gunnar Johansson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nils Gunnar Johansson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medivir, Lunastigen 7, 141 44 Huddinge, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nils+Gunnar++Johansson">Nils Gunnar Johansson</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ian H. Gilbert</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ian H. Gilbert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +44-1382-386-240. Email: <a href="/cdn-cgi/l/email-protection#c8a1e6a0e6afa1a4aaadbabc88acbda6acadade6a9abe6bda3"><span class="__cf_email__" data-cfemail="620b4c0a4c050b0e000710162206170c0607074c03014c1709">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ian+H.++Gilbert">Ian H. Gilbert</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-1314" title="Orcid link">http://orcid.org/0000-0002-5238-1314</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01852&amp;href=/doi/10.1021%2Facs.jmedchem.9b01852" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 3066–3089</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 5, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 November 2019</li><li><span class="item_label"><b>Published</b> online</span>5 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01852" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01852</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3066%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJustin%2BR.%2BHarrison%252C%2BSandipan%2BSarkar%252C%2BShahienaz%2BHampton%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D6%26contentID%3Dacs.jmedchem.9b01852%26title%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BCompound%2BSeries%2BActive%2Bagainst%2BTrypanosoma%2Bcruzi%252C%2Bthe%2BCausative%2BAgent%2Bof%2BChagas%2BDisease%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3089%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01852"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1236</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01852" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Justin&quot;,&quot;last_name&quot;:&quot;R. Harrison&quot;},{&quot;first_name&quot;:&quot;Sandipan&quot;,&quot;last_name&quot;:&quot;Sarkar&quot;},{&quot;first_name&quot;:&quot;Shahienaz&quot;,&quot;last_name&quot;:&quot;Hampton&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Riley&quot;},{&quot;first_name&quot;:&quot;Laste&quot;,&quot;last_name&quot;:&quot;Stojanovski&quot;},{&quot;first_name&quot;:&quot;Christer&quot;,&quot;last_name&quot;:&quot;Sahlberg&quot;},{&quot;first_name&quot;:&quot;Pia&quot;,&quot;last_name&quot;:&quot;Appelqvist&quot;},{&quot;first_name&quot;:&quot;Jessey&quot;,&quot;last_name&quot;:&quot;Erath&quot;},{&quot;first_name&quot;:&quot;Vinodhini&quot;,&quot;last_name&quot;:&quot;Mathan&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Rodriguez&quot;},{&quot;first_name&quot;:&quot;Marcel&quot;,&quot;last_name&quot;:&quot;Kaiser&quot;},{&quot;first_name&quot;:&quot;Dolores&quot;,&quot;last_name&quot;:&quot;Gonzalez Pacanowska&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;D. Read&quot;},{&quot;first_name&quot;:&quot;Nils&quot;,&quot;last_name&quot;:&quot;Gunnar Johansson&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;H. Gilbert&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;3066-3089&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01852&quot;},&quot;abstract&quot;:&quot;Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01852&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01852" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01852&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01852" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01852&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01852" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01852&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01852&amp;href=/doi/10.1021/acs.jmedchem.9b01852" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01852" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01852" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01852%26sid%3Dliteratum%253Aachs%26pmid%3D32134269%26genre%3Darticle%26aulast%3DHarrison%26date%3D2020%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BCompound%2BSeries%2BActive%2Bagainst%2BTrypanosoma%2Bcruzi%252C%2Bthe%2BCausative%2BAgent%2Bof%2BChagas%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D6%26spage%3D3066%26epage%3D3089%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291528" title="Parasites">Parasites</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/jmcmar.2020.63.issue-6/20200326/jmcmar.2020.63.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0034.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Chagas disease is caused by the protozoan parasite <i>Trypanosoma cruzi</i>. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against <i>T. cruzi</i>. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50804" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50804" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chagas disease is caused by the parasite <i>Trypanosoma cruzi</i> and is endemic in South and Central America, although the disease has spread across the globe, through migration of infected individuals.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Chagas disease is defined as a neglected tropical disease. It is estimated that about 8 million people are currently infected, and it gives rise to approximately 8000 deaths per year.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a></div><div class="NLM_p">The parasite has a complex life cycle. Transmission from the vector (triatomine or reduvvid bug) occurs when the extracellular metacyclic trypomastigotes, which are found in faeces or urine from the vector, penetrate human skin, typically through damaged skin where the insect has taken a blood meal. However, penetration can occur through mucosal membranes such as the conjunctiva.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The vector is particularly associated with poorer quality housing. Vector control through the use of insecticides and improvements in housing are key methods to reduce transmission.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Transmission can also occur from mother to unborn child and through blood transfusion. Infection can also occur orally; there have been reported incidences of transmission through drinking fruit juice, thought to be due to contamination of the fruit by triatomine faeces or insects contaminating the fruit during preparation.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a></div><div class="NLM_p">In the human host, the parasites can multiply in different cell types, and there is evidence that they invade many different organs within the body. Within the cells, the parasites are predominantly found as rounded intracellular amastigotes. The intracellular amastigotes divide. Eventually, they transform into trypomastigotes, which burst out of the cells, and can then invade other cells within the human host. The life cycle is explained in detail on the Centers for Disease Control and Progression Web site.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">The disease has an acute stage and a chronic indeterminate stage. The acute stage is typified by the presence of parasites in the blood. Most people do not have symptoms, but it has a high fatality rate among children. However, as many of the symptoms are relatively nonspecific, the disease is often not diagnosed. The parasite then enters a chronic stage, where the level of parasitemia is very low and essentially becomes undetectable. The chronic stage is not well understood. However, it is becoming apparent that there are slow-growing or dormant forms.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> It is thought about 30% of patients with chronic Chagas disease go on to develop heart disease (failure) or megacolon, and this is only found when the patient is critically ill or even dead.</div><div class="NLM_p">Unfortunately, the current treatment options are very limited and are confined to the nitro-aromatics benznidazole and nifurtimox (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref3 ref9 ref10">(3,9,10)</a> These drugs are reasonably effective for acute Chagas disease, but evidence suggests limited efficacy against chronic disease. The efficacy of benznidazole on patients with chronic Chagas disease was recently studied in detail with the BENEFIT trial,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> in which patients with Chagas disease cardiomyothapy were treated with either a placebo or benznidazole and then followed up for about 5 years. While those in the benznidazole arm had reduced the levels of parasites detected in the blood, there was essentially no difference in cardiac clinical outcomes between the two groups. Benznidazole and nifurtimox have significant side effects, which means that many patients cannot finish the treatment. A recent study, the BENDITA trial,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> has looked at reducing the length of treatment or dose levels with benznidazole. There are some promising indications from this trial.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of compounds used to treat Chagas disease.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, there have been clinical trials of two azoles, posaconazole (NCT01377480)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and fosravuconazole (E1224) (NCT01489228),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> which inhibit an enzyme involved in ergosterol biosynthesis, called CYP51. Despite initially causing a significant drop in parasitemia, there were very high levels of relapse, meaning that these sorts of drugs are not suitable for further development.<a onclick="showRef(event, 'ref3 ref16'); return false;" href="javascript:void(0);" class="ref ref3 ref16">(3,16)</a> The BENDITA trial has looked at combinations of fosravuconazole with benznidazole. The analysis of this data is ongoing. A phase II clinical study using fexinidazole (NCT03587766),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> a drug developed for human African trypanosomiasis, was carried out for Chagas disease but was stopped due to safety concerns at high doses. A new study (NCT02498782) at lower doses and shorter regimens is underway.</div><div class="NLM_p">The pipeline for new chemical entities (NCEs) for Chagas disease is very sparse. DNDi has no NCEs in regulatory preclinical studies or Phase 1.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">In this work, we report the results of a screen against <i>T. cruzi</i> and subsequent optimization of the hits, to the stage of activity in a mouse model of infection, in an attempt to discover new starting points for drug discovery projects.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Screening and Initial Hit Expansion</h3><div class="NLM_p">The project was initiated by screening a small, diverse chemical library of about 7000 compounds from Medivir against the parasite. This library was a general diversity set, not specifically targeted toward <i>T. cruzi.</i> The screening was carried out against the clinically relevant intracellular stage; in this case, the parasites were cultured in L6 cells, which are rat skeletal muscle myoblasts (ATCC CRL1458). Compounds were also screened against L6 to deprioritize compounds, which are generally cytotoxic.</div><div class="NLM_p">From the screen, quinazolinedione (<b>1</b>) was identified as a selective hit, where the compound is more active against <i>T. cruzi</i> than the mammalian L6-cells (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In the early stages of a medicinal chemistry project, the selectivity should be >10-fold, and this value should be increased to >100-fold during the hits to lead the process. Compound <b>1</b> is chemically tractable and multiple analogues can be readily prepared.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Hit molecule and generic structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Variation around the R<sup>3</sup> Position<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0020.gif" alt="" id="GRAPHIC-d7e496-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0021.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds: benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">In the first phase of hit expansion, SAR was investigated for substituents R<sup>1</sup>–R<sup>6</sup> of the core quinazolinedione (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Variations of R<sup>3</sup> and R<sup>6</sup> are reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, respectively. These two substituent positions are central for SAR efficacy development.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR at the R<sup>6</sup> Position<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0022.gif" alt="" id="GRAPHIC-d7e556-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0023.gif" alt="" id="gr21" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds: benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">The activity of the hit compound <b>1</b> was confirmed with close analogues, such as compounds <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, <b>12</b>, <b>14</b>, <b>15</b>, <b>16</b>, <b>17</b>, and <b>18</b>, all of which are lipophilic alkyl or cycloalkyl substituents. At most, the potency was increased about 5-fold among these (compounds <b>4</b> and <b>6</b>). Joining the cycloalkyl directly to the quinazolinedione caused some loss of activity (compounds <b>16</b>, <b>17</b>, and <b>18</b>) relative to the cycloalkyl compounds <b>4</b> and <b>6</b>. The loss activity was more pronounced with the <i>tert</i>-butyl group directly attached to the core (compound <b>13</b>). The cycloalkyl group could be replaced to some extent with phenyl as in compounds <b>9</b>, <b>10</b>, and <b>11</b>, whereas more polar functions such as ether (compound <b>7</b>) or amide (compound <b>8</b>) resulted in significantly diminished or loss of activity. Given the lipophilic character of some of the substituents, it is important to keep an eye on the logP values and, in particular, the lipophilic ligand efficiency (LLE).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The latter is defined as LLE = pEC<sub>50</sub> – clogP and is a suitable measure to ensure that activity is not being driven by lipophilicity. For drugs, LLE is generally >5.</div><div class="NLM_p">A breakthrough came with further increasing the lipophilic character by adding a <i>tert</i>-butyl to the cyclohexyl substituent (compound <b>19</b>), which caused a near 100-fold increase in potency relative to the hit compound <b>1</b>. This compound had a good selectivity (180-fold), and although there was a small increase in the lipophilicity (clogP = 3.3), the LLE of 4.4 was the highest in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_p">Several synthetic routes were developed to the quinazolinediones. Heating isatoic anhydride <b>20</b> with amines gave intermediate amides, which were cyclized by treatment with carbonyldiimidazole in refluxing THF (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). This route allowed the rapid exploration of the R<sup>3</sup> substituent. An alternative route that allowed the installation of the R<sup>6</sup> amide as the final step commenced with acid <b>22</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Amide formation with the appropriate R<sup>3</sup> amine and propylphosphonic anhydride, followed by cyclization with either carbonyldiimidazole or ethyl chloroformate, gave the 6-nitroquinazolinediones <b>24</b>. Hydrogenation of the nitro group then gave anilines <b>25</b>, which were then coupled with carboxylic acids to give amides <b>26</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Procedure B for the Synthesis of 6-Acetamide-R3-Substituted Quinazolinediones</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternative Quinazolinedione Synthesis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of 4-substituted cyclohexylamines started from the corresponding cyclohexanones <b>27</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Reductive amination with benzylamine and sodium borohydride gave a ca. 2:1 ratio of <i>trans</i> to <i>cis</i> isomers of <b>28</b>, which were separated by column chromatography on silica. Hydrogenolysis of the benzyl protecting group gave the amine intermediate <b>29</b>, which was incorporated into the quinazolinedione scaffold using our standard methods described above.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Procedure C for the Synthesis of 4-Substituted Cyclohexylamines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Simultaneous to the SAR R<sup>3</sup> investigations, hit expansion was also carried out to investigate the R<sup>6</sup> position (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This was initially carried out using the ethylcyclohexyl substituent on the <i>N-</i>3-position (<b>4</b>). Replacing the acetamide with amino (<b>30</b>) gave a compound with similar activity, although with about 10-fold less selectivity compared to L6 cells. The amino substituent at R<sup>6</sup> was subsequently employed (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>) in addition to the acetamide substituent (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR at the R<sup>3</sup> Position Based on <b>19</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0024.gif" alt="" id="GRAPHIC-d7e811-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0025.gif" alt="" id="gr22" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds: benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">Replacing the acetamide with more bulky substituents (<b>31</b>, <b>32</b>) led to a drop in activity and selectivity. Interestingly the acetamide could be replaced by either a 3- or 4-pyridine (<b>35</b>, <b>37</b>) with relatively little loss in activity, but a loss in selectivity. In contrast, the pyrimidine analogue (<b>36</b>) and the isoxazole (<b>34</b>) both lost activity. The methylene nitrile <b>33</b> gave a similar activity as <b>4</b> with a smaller loss in selectivity. This latter compound has a different pattern of H-bond donors at the R<sup>6</sup> position. All of these modifications led to a loss in selectivity and LLE.</div><div class="NLM_p">The heteroaryl groups were introduced at the R<sup>6</sup> position by Suzuki coupling of 6-iodo intermediate <b>40</b> with the appropriate boronic acid (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). When isozazol-4-yl boronic acid was reacted under these conditions, the 6-acetonitrile product <b>33</b> was obtained as the product of a tandem Suzuki coupling–isoxazole fragmentation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Aryl Substituent at R<sup>6</sup><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) cyclohexylethylamine, HATU, NMM, DMF, rt, 16 h; (b) ethyl chloroformate, 90 °C, 1.5 h, then KOH, EtOH, 85 °C, 3.5 h; (c) ArB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub>, water, dioxane, 90 °C, 16 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Hits to Lead Chemistry</h3><div class="NLM_p">Given the promising activity of compound <b>19</b>, and on the basis of the SAR data in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, we set about optimizing this further. A particular concern with this molecule is the hydrophobic nature of the substituent on R<sup>3</sup>. This gave a compound with lower solubility than desired, and while the stability of compound <b>19</b> in mouse liver microsomes was <5 mL/min/g, we ideally wanted this to be <1 mL/min/g. A series of compounds was made to understand the SAR at the R<sup>3</sup> position and to address the issues raised (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Compounds were prepared with <i>trans-</i> or <i>cis-</i>relationship at the cyclohexyl ring. The <i>tert-</i>butyl group could be replaced by an <i>iso-</i>propyl group (<b>43</b>, <b>44</b>), a propyl group (<b>47</b>, <b>48</b>), or an ethyl group (<b>45</b>, <b>46</b>) with similar or marginally lower activity. In the case of the <i>iso-</i>propyl group, the <i>cis</i> isomer (<b>44</b>) was slightly less active, but this was not the case with the other substituents. <i>cis</i>-Cyclohexyl derivative <b>42</b> showed a particularly good level of stability. The methyl substituent (<b>49</b>) gave a 60-fold loss of activity, while the dimethyl compound (<b>50</b>), however, showed only 8-fold reduced activity compared to <b>19</b>. This suggests some lipophilic substituents should be present on the 4-position of the cyclohexyl group. Replacing the cyclohexyl with a cyclopentyl (<b>51</b>) retained activity, while replacing the cyclohexyl with a phenyl (<b>52</b>) led to a loss in activity. All of the compounds in the table retained good selectivity (>100-fold) and good LLE, except compounds <b>49</b>, <b>50</b>, and <b>52</b>.</div><div class="NLM_p">All of the compounds tested had very similar levels of poor solubility. Our aim in terms of microsomal stability was to have a compound with sufficient stability for an <i>in vivo</i> proof of concept (Cli <5 mL/min/g, although a candidate would probably require <1 mL/min/g). Interestingly the mouse microsomal stability varied significantly from compound to compound in a way that was not directly linked to lipophilicity. The different diastereoisomers had different levels of microsomal stability.</div><div class="NLM_p">3-(<i>tert</i>-Butyl)cyclopentanamine <b>56</b>, required for the synthesis of <b>51</b>, was prepared in four steps (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Oxidative cleavage of 4-(<i>tert</i>-butyl)cyclohexan-1-ol <b>53</b> with sodium nitrite in trifluoroacetic acid by the method of Matsumura et al. gave the diacid <b>54</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Ketonic decarboxylation with sodium carbonate at 240 °C gave cyclopentanone <b>55</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Our standard reductive amination/hydrogenolysis procedure then gave <b>56</b> as a racemic mixture of all diastereomers.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0013.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 3-(<i>tert</i>-Butyl)cyclopentanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to reduce the lipophilicity, with the aim of increasing the solubility and in the cases of metabolic stability of the cyclohexyl moiety, heteroatoms were introduced into the cycloalkyl ring (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In summary, all such modifications resulted in less activity or a loss of activity, similar to the findings for polar substituents reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, and also a loss in selectivity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Introduction of Heteroatoms into R<sup>3</sup><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0026.gif" alt="" id="GRAPHIC-d7e1090-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0027.gif" alt="" id="gr23" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds: benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">Replacement of the <i>tert-</i>butyl with trifluoromethyl (<b>57</b>, <b>58</b>) led to a loss in activity. Even replacement of one of the methyls of the <i>tert-</i>butyl with a fluoro (<b>59</b>) led to a 100-fold loss in activity. Replacing one of the methyls with a hydroxyl (<b>60</b>) led to a much larger loss in activity. Similarly, adding an ether oxygen between the cyclohexyl and the substituent (<b>63</b>, <b>64</b>) led to a loss in activity,</div><div class="NLM_p">We also put two oxygen atoms in the cyclohexyl ring (<b>61</b>, <b>62</b>), although both lost activity; the <i>trans-</i>isomer was 10-fold more active than the <i>cis-</i>isomer. This compound (<b>61</b>) also had improved solubility and LLE. Putting just one oxygen led to reduced activity (<b>65</b>), albeit the <i>tert-</i>butyl substituent was at the 3-position rather than the 4-position, which introduced an additional chiral center. Similarly, nitrogen was not tolerated in the ring (<b>66</b>). Various analogues of <b>66</b> were made with the aim of reducing the basicity, in case charge was not tolerated at this position: the carbamates (<b>67</b>, <b>71</b>), the amide (<b>68</b>), and the sulphonamide (<b>69</b>). All of these lost more than 1000-fold in activity compared to <b>19</b>. Finally, when an amine was not in the cyclohexyl ring (<b>70</b>), the compound was also inactive.</div><div class="NLM_p">Synthesis of compounds is as follows. Prins-cyclization of 3-buten-1-ol with pivaldehyde gave tetrahydropyranol <b>73</b>, which was oxidized with Dess–Martin Periodinane to the tetrahydropyranone <b>74</b>. Our standard methodology then converted this into the racemic <i>cis</i> and <i>trans</i> amines <b>75</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>), which were separated by chromatography of the benzyl intermediates.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0014.jpeg" id="GRAPHIC-d7e1223-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of 2-(<i>tert</i>-Butyl)tetrahydro-2<i>H</i>-pyran-4-amines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The 2-fluoropropanyl intermediate <b>80</b> was obtained via deoxyfluorination of 2-propylalcohol <b>78</b> with XtalFluorE followed by hydrogenolysis of the Cbz protecting group (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Compound <b>78</b> was prepared, in turn, by the addition of methylmagnesium bromide to ester <b>77</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0015.jpeg" id="GRAPHIC-d7e1260-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of (1<i>R</i>,4<i>R</i>)-4-(2-Fluoropropan-2-yl)cyclohexanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The reaction of benzyl (1,3-dihydroxypropan-2-yl)carbamate <b>81</b> with pivaldehyde gave the 1,3-dioxane <b>82</b> as a mixture of <i>cis</i> and <i>trans</i> diastereomers. Hydrogenolysis of the Cbz protecting group gave the amines <b>83</b>, which were separated by chromatography (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of 2-(<i>tert</i>-Butyl)-1,3-dioxan-5-amines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alcohol <b>84</b> was alkylated by heating with Boc anhydride in the presence of catalytic zinc perchlorate hexahydrate according to the method of Bartoli et al.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> to give <i>tert-</i>butyl ether <b>85</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). The isopropyl ether <b>87</b> was obtained from the same alcohol by reaction with isopropyltrichloroacetimidate and catalytic trifluoroacetic acid (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).</div><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of (1<i>R</i>,4<i>R</i>)-4-(<i>tert</i>-Butoxy)cyclohexanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of (1<i>R</i>,4R)-4-Isopropoxycyclohexanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When there was an amine at the 6-position instead of an acetamide, the compounds were also active (<b>30</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Therefore crossover compounds were made with the <b>19</b> R<sup>1</sup> substituents (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These compounds were also very potent and had activities similar to the acetamide derivatives (<b>89</b> and <b>19</b>; <b>90</b> and <b>42</b>; <b>91</b> and <b>43</b>; <b>92</b> and <b>45</b>; <b>93</b> and <b>46</b>). Where tested, these compounds appeared to show a small increase in solubility (compare <b>45</b> with <b>92</b> and <b>46</b> with <b>93</b>). They also had good LLE values.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Key R<sup>3</sup> Substituents with R<sup>6</sup> = NH<sub>2</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0028.gif" alt="" id="GRAPHIC-d7e1423-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0029.gif" alt="" id="gr24" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds: benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">It was also discovered that the pyrido version of the compound, with the pyridine in the 8-position, was also tolerated, although there was a slightly different SAR with these compounds (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The pyridine analogue of <b>19</b> was much less active. However, the <i>cis-</i>isomer (<b>95</b>) was only slightly less active than <b>19</b>. With the <i>iso-</i>propyl analogues (<b>96</b>, <b>97</b>), the <i>trans-</i>isomer was more active than the <i>cis-</i>isomer. These compounds, in general, retained the LLE. However, despite the extra heteroatom, these compounds had poorer solubility.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Key R<sup>3</sup> Substituent Pyrido System with R<sup>5</sup> = NHAc<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0030.gif" alt="" id="GRAPHIC-d7e1493-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0031.gif" alt="" id="gr25" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds: benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">Examples were also made in which the pyrido-analogues were prepared with the amino group on the 6-position, rather than the amide (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). These compounds were also active, but in general, slightly less active than <b>19</b>. Solubility was, in general, poor.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Key R<sup>3</sup> Substituent Pyrido System with R<sup>6</sup> = NH<sub>2</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0032.gif" alt="" id="GRAPHIC-d7e1541-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0033.gif" alt="" id="gr26" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">The EC<sub>50</sub> values are means of two independent determinations ± deviation from the mean. Control compounds benznidazole for the <i>T. cruzi</i> assay EC<sub>50</sub> ± SD 1.94 ± 0.49 μM, podophyllotoxin for the cytotoxicity assay EC<sub>50</sub> ± SD 0.014 ± 0.005 μM. clogP was calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">www.optibrium.com</a>)</p></div></div><div></div></div><div class="NLM_p">The pyrido-analogues were prepared by a synthetic sequence starting from methyl 2-aminonicotinate <b>101</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). Thus, nitration with gave methyl 2-amino-5-nitronicotinate <b>102</b>. Ester hydrolysis and coupling with the appropriate cyclohexyl amines gave amides <b>103</b>, which were cyclized with carbonyl diimidazole to give pyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-diones <b>104</b>. Hydrogenation of the nitro group gave anilines <b>105</b>, which were acylated with acetic anhydride to give the target compounds <b>106</b>.</div><figure id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Pyrido-Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) concentrated HNO<sub>3</sub>, concentrated H<sub>2</sub>SO<sub>4</sub>, 0 °C to rt, 16 h then 70 °C, 4 h; (b) LiOH, THF, MeOH, water, rt, 17 h; (c) amine, BOP, Et<sub>3</sub>N, DMF, rt, 24 h; (d) carbonyl diimidazole, THF, 85 °C, 48 h; (e) Pd/C, H<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, MeOH, rt, 2 h; (f) Ac<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Pharmacokinetics and Efficacy Studies</h3><div class="NLM_p">Two compounds were selected for a more detailed evaluation to establish the proof of concept in a rodent model of Chagas disease, <b>43</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and <b>89</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compound <b>19</b> had a very similar profile to compound <b>43</b>, but the latter has a slightly lower lipophilicity. These compounds had the following profiles shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Profiles of Compounds <b>43</b> and <b>89</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>43</b></th><th class="colsep0 rowsep0" align="center"><b>89</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T. cruzi</i> (EC<sub>50</sub> μM)</td><td class="colsep0 rowsep0" align="left">0.026</td><td class="colsep0 rowsep0" align="left">0.063</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">L6 cells (EC<sub>50</sub> μM)</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinetic aqueous solubility (μM)</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">240</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse Cli (mL/min/g)</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse PPB (Fu)</td><td class="colsep0 rowsep0" align="left">0.028</td><td class="colsep0 rowsep0" align="left">0.011</td></tr></tbody></table></div></div><div class="NLM_p">Compound <b>43</b> was dosed intraperitoneally (IP) and orally to female NMRI mice at 10 mg/kg (<i>n</i> = 3 mice/dose route). The dose formulation chosen was 10% DMSO; 60% PEG400; 30% distilled water (to maintain the dose as a solution; aqueous solubility is poor). Blood concentration–time profiles following IP and oral dosing are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, respectively. Higher exposure is seen when the compound was dosed IP, compared to oral dosing. Interestingly when dosed IP, the compound took longer to reach the maximum concentration compared to when dosed orally. This may be due to a depot effect, due to a relatively slow dissolution.</div><figure id="fig3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mean blood concentration–time profile of <b>43</b> following single IP administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mean blood concentration–time profile of <b>43</b> following single oral administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>43</b> has an EC<sub>90</sub> of 38 ng/mL. Considering the fraction unbound in mouse plasma (Fu = 0.028), 30 mg/kg IP once a day is predicted to maintain <i>C</i><sub>trough</sub> free concentration at approximately EC<sub>90</sub>. A twice-daily dose at 30 mg/kg orally is predicted to deliver <i>C</i><sub>trough</sub> free concentration at approximately EC<sub>50</sub>. These doses were used for 10 days in the mouse model of acute Chagas disease as the best options, considering all of the above-mentioned constraints to maximize the probability of success.</div><div class="NLM_p">Compound <b>89</b> demonstrated improved solubility and could be formulated in 10% DMSO; 60% PEG400; 30% distilled water or as a fine suspension in 0.5% w/v HPMC with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol (when nanomilled). Intraperitoneal pharmacokinetics were assessed in mice using both formulations to optimize exposure for the efficacy study (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Oral pharmacokinetics were also assessed (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) but offered no improvement in the exposure. When dosed orally, the compound took a long time to reach the maximum concentration. The slow rate of absorption could be due to slow solubilization in the gastrointestinal tract</div><figure id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mean blood concentration–time profile of <b>89</b> following single intraperitoneal administration at 30 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data. Dose Formulation: 10% DMSO; 60% PEG400; 30% Milli-Q water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mean blood concentration–time profile of <b>89</b> following single intraperitoneal administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data. Dose formulation: 0.5% w/v HPMC with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mean blood concentration–time profile of <b>89</b> following single oral administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data. Dose formulation: 0.5% w/v HPMC with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The EC<sub>90</sub> for compound <b>89</b> is high at 1200 ng/mL, and the compound has a low fraction unbound in mouse plasma (Fu = 0.011). It was, therefore, decided to progress this compound to the mouse model of acute Chagas disease at the maximum tolerated dose (MTD), which was 30 mg/kg intraperitoneally once daily using the DMSO/PEG400/water formulation. Additionally, it was also decided to explore a 50 mg/kg twice-daily oral regimen in the better-tolerated vehicle (0.5% HPMC with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol), which would offer an improved duration of exposure. This would provide the best opportunity for proof of concept, although acknowledging likelihood was low because of the low free exposure versus potency both ip and orally.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Efficacy Studies</h3><div class="NLM_p">A murine model for acute Chagas disease was used. In brief, groups of 5 Balb/c female mice were infected with 10<sup>5</sup> trypomastigote forms of <i>T. cruzi</i> Brazil strain expressing luciferase, and the infection was quantified 3 days later by an imaging device sensitive to luminescence (IVIS Lumina imager). The signal is proportional to the load of parasites. The treatment began on the fourth day of infection. The results were expressed as the ratio of infection at the end of treatment versus the base infection before treatment for each animal.</div><div class="NLM_p"><i>In vivo</i> efficacy studies were carried out with both <b>89</b> and <b>43</b> in this mouse model of acute Chagas disease at the dose levels defined above with the aim to determine <i>in vivo</i> proof of concept for this series of chemistry. Dosing was continued for 10 days. Animals were imaged at 5 days and 10 days.</div><div class="NLM_p">Compound <b>43</b> shows a significant reduction in parasite levels compared to the vehicle control when dosed both IP (30 mg/kg qd) or PO (30 mg/kg bid) for 5 or 10 days (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Compound <b>89</b> showed no significant reduction in parasite levels at these doses, likely due to the fact that it did not maintain <i>C</i><sub>trough</sub> levels above the EC<sub>50</sub>, via either dosing regimen.</div><figure id="fig8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Ratio of parasitemia levels for mice infected with <i>T. cruzi</i> after treatment with compounds for 5 days and 10 days compared to starting levels of parasitemia. Data is based on 5 mice in each group, except for vehicles with MC (4 mice) and oral <b>43</b> (3 mice). The error bars show the standard deviation. PEG is 10% DMSO; 60% PEG400; 30% water; MC is 0.5% MC, 0.4% Tween 80, and 0.5% benzyl alcohol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An <i>in vivo</i> proof of concept has been achieved with <b>43</b> demonstrating efficacy orally in a mouse model of infection. However, the compounds need further optimization in terms of both solubility and selectivity, for progression, as dosing was limited by solubility, and the efficacious dose was close to the maximum tolerated dose (MTD). Mode of action studies, published separately, have revealed that the target of compound <b>43</b> is cytochrome <i>b</i>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p last">Furthermore, in light of more recent advances in the development of better translational mouse models of Chagas disease, it will be important to investigate future analogues of these compounds in these improved models, which can differentiate between benznidazole-like and posaconazole-like compounds.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Subsequently to this work being carried out, new <i>in vitro</i> assays have been introduced to help select compounds for further development.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> These include the rate of kill assays, activity against a range of different strains, and studies in washout experiments.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Chemistry Methods</h4><div class="NLM_p last">Chemicals and solvents were purchased from commercial vendors and were used as received, unless otherwise stated. Dry solvents were purchased in Sure Seal bottles stored over molecular sieves. Analytical thin-layer chromatography (TLC) was performed on precoated TLC plates (Kieselgel 60 F254, BDH). Developed plates were air-dried and analyzed under a UV lamp (UV 254/365 nm), and/or KMnO<sub>4</sub> was used for visualization. Flash chromatography was performed using Combiflash Companion or Combiflash Rf machines (Teledyne ISCO), and prepacked silica gel columns were purchased from Grace Davison Discovery Science or SiliCycle. Mass-directed preparative HPLC separations were performed using a Waters HPLC (2545 binary gradient pumps, 515 HPLC makeup pump, 2767 sample manager) connected to a Waters 2998 photodiode array and a Waters 3100 mass detector. HPLC chromatographic separations were conducted using Waters XBridge C18 columns, 19 mm × 100 mm, 5 μm particle size, using 0.1% ammonia in water (solvent A) and acetonitrile (solvent B) as a mobile phase. Chiral HPLC separations were performed using CHIRAL Phenomenox Lux Cellulose-4 (250 × 4.6) mm and CHIRAL PAK IC (250 × 4.6) mm, 5 μm particle size columns. <sup>1</sup>H NMR spectra were recorded on a Bruker Advance II 500 or 400 spectrometer operating at 500 and 400 MHz using CDCl<sub>3</sub>, methanol-<i>d</i><sub>4</sub>, or DMSO-<i>d</i><sub>6</sub> solutions. Chemical shifts (δ) are expressed in ppm recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), multiplet (m), broadened (b), or a combination thereof. Coupling constants (<i>J</i>) are quoted to the nearest 0.1 Hz (hertz). High-resolution mass spectroscopy (HRMS) was performed using a Bruker Daltonics MicrOTOF mass spectrometer. LC–MS analysis and chromatographic separation were conducted with a Bruker Daltonics MicrOTOF mass spectrometer or an Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 quadrupole LC/MS, where both instruments were connected to an Agilent diode array detector. All assay compounds had a measured purity of ≥95% as determined using these analytical LC–MS systems. The column used was a Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle size), and the compounds were eluted with a gradient of 5–95% acetonitrile/water + 0.1% ammonia.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure A for the Synthesis of 5-Acetamide-R<sup>1</sup>-Substituted Quinazolinediones Using Ethyl Chloroformate</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0035.gif" alt="" id="gr27" /></img><div class="NLM_p">To exemplify General Procedure A the preparation of compound <b>1</b> is described: <i>N-</i>[3-(2-cyclohex-1-enyl-ethyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-6-yl]-acetamide (<b>1</b>).</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Step a: <i>N-</i>(2,4-Dioxo-1,4-dihydro-2<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)-acetamide (<b>20</b>)</h5><div class="NLM_p last">Triphosgene (3.8 g, 1.28 mmol) was added to a solution of 5-acetamido-2-amino-benzoic-acid (5 g, 25.7 mmol) in 1,4-dioxane (100 mL), and the solution was heated at 110 °C for 6 h. The solution was then cooled to room temperature; then, a saturated aqueous solution of NaHCO<sub>3</sub> (20 mL) was added. The mixture was filtered, and the filtered solid was washed with water, followed by hexanes. The solid was dried at 60 °C under a vacuum to afford the title compound as a solid (5 g, 89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.66 (s, 1H), 10.17 (s, 1H), 8.24 (d, <i>J</i> = 2.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 2.04 (3H, s). MS: <i>m</i>/<i>z</i> 221 [M + 1]<sup>+</sup>.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Step b: 5-Acetamido-2-amino-<i>N-</i>(2-(cyclohex-1-en-1-yl)ethyl)benzamide (<b>113</b>)</h5><div class="NLM_p last">DMAP (0.5 mmol) was added to a solution of cyclohexenyl ethylamine (0.087 g, 0.7 mmol), and isatoic anhydride <b>20</b> (0.1 g, 0.45 mmol) was dissolved in DMF (10 mL). The solution was stirred at room temperature for 3 h. After removal of the solvent under reduced pressure, water was added to the crude and extracted with EtOAc (3 × 10 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude material was taken to the next step without further purification.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Step c: <i>N-</i>[3-(2-Cyclohex-1-enyl-ethyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-6-yl]-acetamide (<b>1</b>)</h5><div class="NLM_p last">The crudeamide from step b (3.1 mmol) and ethyl chloroformate (4 mL) was heated at 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the crude was dissolved in EtOH (40 mL), followed by the addition of KOH (0.35 g, 6.3 mmol). The mixture was heated at 85 °C for 2 h. The solvent was removed under reduced pressure, followed by the addition of water (10 mL) and extraction with EtOAc (3 × 20 mL). The combined organics were washed with a 10% aqueous solution of acetic acid until pH 6. This was followed by extraction with EtOAc (3 × 20 mL); the combined organics were dried over sodium sulfate, and the solvent was concentrated. The crude was purified by flash column chromatography on silica gel eluted with MeOH in CHCl<sub>3</sub>, which gave the title compound (0.045 g, 30%) over two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.33 (s, 1H), 10.09 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8 Hz, 2.4 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 5.29 (m, 1H), 3.97–3.93 (m, 2H), 1.19–2.14 (m, 2H), 2.03 (s, 3H), 1.98 (m, 2H), 1.85 (m, 2H), 1.58–1.52 (m, 4H). MS: <i>m</i>/<i>z</i> 326 [M – 1]<sup>−</sup>.</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure B for the Synthesis of 5-Acetamide-R<sup>1</sup>-Substituted Quinazolinediones Using Carbonyldiimidazole</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0036.gif" alt="" id="gr28" /></img><div class="NLM_p last"><i>N</i>-(2,4-Dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide <b>20</b> (150 mg, 0.682 mmol) was combined with the relevant amine (0.675 mmol, 0.99 equiv) in THF (5 mL) and heated under reflux overnight. Upon cooling, carbonyldiimidazole (162.2 mg, 1.02 mmol, 1.5 equiv) was added, and the mixture was heated under reflux for 24 h. Upon reaction completion, the reaction mixture was cooled, and the resulting precipitate was collected by filtration, washed with water, CH<sub>2</sub>Cl<sub>2</sub>, and Et<sub>2</sub>O, and dried <i>in vacuo</i>. If a precipitate did not form, then the reaction mixture was concentrated <i>in vacuo</i>. The resultant residue was diluted with water and extracted with EtOAc. The organic layer was then dried (MgSO<sub>4</sub>) and concentrated. Purification by flash chromatography gave the desired compound.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure C for the Synthesis of 4-Substituted Cyclohexylamines</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0037.gif" alt="" id="gr29" /></img><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 1: Reductive Amination</h5><div class="NLM_p">A solution of the ketone (32 mmol, 1 equiv) in anhydrous methanol (160 mL) was treated with benzylamine (4.9 mL, 38 mmol, 1.2 equiv) and 4 Å molecular sieves (6 g). The mixture was stirred at room temperature overnight. The mixture was then cooled to 0 °C and treated with sodium borohydride (6.0 g, 160 mmol, 5 equiv) in small portions over 30 min (caution: exothermic, effervescence). The mixture was allowed to warm slowly to room temperature and stirred at room temperature for ca. 4 h. The reaction was quenched by the addition of water and then filtered through a plug of Celite. The filtrate was concentrated, treated with water (150 mL), and extracted with dichloromethane (4 × 150 mL). The combined organic phases were filtered through a hydrophobic frit and concentrated.</div><div class="NLM_p last">The diastereomers were separated by flash chromatography on silica using a gradient elution of 0–10% methanol/ammonia in dichloromethane, with the eluent held at 2% methanol/ammonia until the first diastereomer had eluted. In the cases investigated, the <i>cis</i>-product eluted before the <i>trans</i>-product.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 2: Debenzylation</h5><div class="NLM_p last">The reaction vessel containing a solution of the benzylamine (8.5 mmol) in THF (20 mL) was purged with three vacuum/argon cycles. Palladium on carbon (0.41 g) was added, and the vessel was purged three times with vacuum/argon cycles and then three times with vacuum/hydrogen cycles. The mixture was stirred at room temperature for 2 days and then filtered through a plug of Celite. The filter cake was washed with ethyl acetate, and the combined organic phases were concentrated to give the product, which was used without further purification.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> General Procedure D: Amidations</h4><div class="NLM_p last">5-Acetamido-2-aminobenzoic acid (100 mg, 0.515 mmol, 1 equiv) and the relevant amine (0.566 mmol, 1.1 equiv) in DCM (5 mL) were combined at room temperature and stirred. A 50% solution of propylphosphonic anhydride in EtOAc (196.6 mg, 0.618 mmol, 1.2 equiv) was added dropwise, and the reaction was stirred at room temperature overnight. The mixture was treated with aq NaHCO<sub>3</sub> and vigorously stirred for approximately 30 min. The phases were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (×2). The combined organic layers were washed with water, dried (MgSO<sub>4</sub>), and concentrated to give the crude product. Purification was carried out by flash chromatography.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure E: Preparation of 6-Aminopyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-diones</h4><div class="NLM_p">To exemplify General Procedure E, the preparation of compound <b>107</b> is described: 6-amino-3-(<i>transtrans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-2,4-dione (<b>107</b>)</div><div id="sec4_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step a: 2-Amino-5-nitronicotinic Acid Methyl Ester (<b>102</b>)</h5><div class="NLM_p last">A solution of 2-amino-3-nicotinic acid methyl ester (4 g, 26 mmol) in a mixture of concentrated HNO<sub>3</sub> (2.8 mL) and H<sub>2</sub>SO<sub>4</sub> (10 mL) was stirred for 45 min at 0 °C, followed by room temperature for 19 h, and at 70 °C for 4 h. The reaction mixture was cooled to 0 °C, and a saturated aqueous solution of NaHCO<sub>3</sub> (40 mL) was added until basic (pH 8). Extraction with EtOAc (3 × 40 mL), filteration, and concentration of the combined organics afforded the title compound (3.5 g, 68%), which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.05 (d, <i>J</i> = 2.8 Hz, 1H), 8.69 (d, <i>J</i> = 2.8 Hz, 1H), 8.64 (br s, 1H), 8.15 (br s, 1H), 3.88 (s, 3H). MS: <i>m</i>/<i>z</i> 198 [M + 1]<sup>+</sup>.</div></div><div id="sec4_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step b: Lithium Salt of 2-Amino-5-nitronicotinic Acid</h5><div class="NLM_p last">LiOH (0.12 g, 5 mmol) was added to a solution of the methyl ester <b>102</b> (1 g, 5 mmol) in a mixture of 1% MeOH in THF (10 mL). The solution was stirred at room temperature for 17 h and then concentrated under reduced pressure. The solid obtained (0.8 g) was used in the next step without further purification.</div></div><div id="sec4_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step c: 2-Amino-<i>N-</i>(<i>transtrans</i>-4-<i>tert</i>-butyl-cyclohexyl)-5-nitro-nicotinamide (<b>103</b>)</h5><div class="NLM_p last">BOP (2.7 g, 6 mmol) was added to a suspension of the above lithium salt (0.8 g, 4 mmol), <i>trans</i>-4-<i>tert</i>-butylcyclohexylamine hydrochloride salt (1.16 g, 6 mmol), and triethylamine (1.2 g, 12 mmol) in DMF. The suspension was stirred at room temperature for 6 h and then concentrated under reduced pressure. Water (15 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude obtained was purified by flash column chromatography on silica gel, which gave the title compound (0.8 g, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.57 (s, 1H), 7.93 (d, <i>J</i> = 8 Hz, 1H), 7.38 (d, <i>J</i> = 2.4 Hz, 1H), 5.91 (2H, s), 3.65–3.60 (m, 1H), 1.86–1.84 (m, 2H), 1.77–1.73 (m, 2H), 1.35–1.20 (m, 2), 1.09–0.95 (m, 3H), 0.84 (s, 9H). MS: <i>m</i>/<i>z</i> 321 [M + 1]<sup>+</sup>.</div></div><div id="sec4_1_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step d: 3-(<i>transtrans</i>-4-<i>tert</i>-Butyl-cyclohexyl)-6-nitro-1<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-2,4-dione (<b>104</b>)</h5><div class="NLM_p last">1,1′-Carbonyldiimidazole (1.06 g, 6.5 mmol) was added to a solution of compound <b>103</b> (0.7 g, 2.1 mmol) in THF (7 mL), and the solution was heated at 90 °C for 48 h. The solvent was removed under reduced pressure, water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic phases were concentrated under reduced pressure, and the afforded crude was purified by flash column chromatography on silica gel, which gave the title compound (0.6 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.89 (s, 1H), 7.07 (d, <i>J</i> = 2.4 Hz, 1H), 6.89 (d, <i>J</i> = 2.4 Hz, 1H), 4.72–4.65 (m, 1H), 2.50–2.38 (m, 2H), 1.83–1.80 (m, 2H), 1.60–1.57 (m, 2H), 1.08–1.04 (m, 3H), 0.85 (m, 9H). MS: <i>m</i>/<i>z</i> 345 [M – 1]<sup>−</sup>.</div></div><div id="sec4_1_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step e: 6-Amino-3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-2,4-dione (<b>107</b>)</h5><div class="NLM_p last">A solution of the nitro compound <b>104</b> (0.6 g, 1.7 mmol) in 30% CH<sub>2</sub>Cl<sub>2</sub> in MeOH (9 mL) was purged with N<sub>2</sub> (g), followed by the addition of 10% Pd in C (0.12 g). The reaction was hydrogenated at atmospheric pressure for 3 h and then filtered through a Celite bed, and the filtrate was concentrated under reduced pressure. The crude was purified by flash column chromatography on silica gel, which gave the title compound (0.11 g, 21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.36 (s, 1H), 8.00 (s, 1H), 7.44 (s, 1H), 5.36 (s, 2H), 4.68–4.62 (m, 1H), 2.42–2.32 (m, 2H), 1.83–1.81 (m, 2H), 1.62–1.59 (m, 2H), 1.10–1.04 (m, 3H), 0.86 (s, 9H). MS: <i>m</i>/<i>z</i> 317 [M + 1]<sup>+</sup></div></div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> General Procedure F: Acetylation of 6-Aminopyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione</h4><div class="NLM_p last">To exemplify General Procedure F, the preparation of compound <b>94</b> is described: <i>N-</i>[3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrido[2,3-<i>d</i>]pyrimidin-6-yl]-acetamide (<b>94</b>). Triethylamine (0.076 g, 0.75 mmol) was added at 0 °C to a solution of 6-amino-3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-2,4-dione <b>107</b> (0.08 g, 0.25 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL). The solution was stirred for 5 min; then Ac<sub>2</sub>O (0.10 g, 1 mmol) was added, and the stirring was continued at room temperature for 3 h. A saturated aqueous solution of NaHCO<sub>3</sub> (15 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic phases were concentrated, and the afforded crude was purified by flash column chromatography on silica gel, which gave the title compound (0.042 g, 47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.70 (br s, 1H), 10.29 (s, 1H), 8.68 (d, <i>J</i> = 2 Hz, 1H), 8.53 (d, <i>J</i> = 2 Hz, 1H), 4.69–4.62 (m, 1H), 2.41–2.32 (m, 2H), 2.07 (s, 3H), 1.84–1.81 (m, 2H), 1.65–1.62 (m, 2H), 1.10–1.04 (m, 3H), 0.86 (s, 9H). MS: <i>m</i>/<i>z</i> 359 [M + 1]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Synthesis of Compounds</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>R</i>)-<i>N-</i>(3-(1-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>3</b>)</h4><div class="NLM_p last">Isatoic anhydride <b>20</b> (0.2 g, 0.9 mmol) and (<i>R</i>)-1-cyclohexylethan-1-amine (0.11 g, 0.9 mmol) were reacted according to the procedure described in General Procedure A, steps b and c, which gave the title compound (0.1 g, 34%) over two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.50–11.10 (br m, 1H), 10.08 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.77–7.75 (m, 1H, m), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 4.75–4.55 (m, 1H), 2.18–2.09 (m, 1H), 2.04 (s, 3H), 1.89–1.86 (m, 1H), 1.73–1.70 (m, 1H), 1.59–1.57 (m, 2H), 1.40–1.34 (m, 4H), 1.35–1.20 (m, 2H), 1.17–1.11 (m, 2H), 0.91–0.88 (m, 2H). MS: <i>m</i>/<i>z</i> 328 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N-</i>[3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]acetamide (<b>4</b>)</h4><div class="NLM_p last">Isatoic anhydride <b>20</b> (1.0 g, 4.5 mmol) and cyclohexyl ethylamine (0.89 g, 7 mmol) were reacted according to the procedure described in General Procedure A, steps b and c, which gave the title compound (0.8 g, 54%) over two steps. <sup>1</sup>H NMR (400 MHz DMSO-<i>d</i><sub>6</sub>,): δ 11.35 (s, 1H), 10.09 (s, 1H), 8.21 (d, <i>J</i> = 2 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 3.92–3.88 (m, 2H), 2.04 (s, 3H), 1.76–1.72 (m, 3H), 1.66–1.64 (m, 3H), 1.45–1.42 (m, 2H), 1.33–1.23 (m, 3H), 1.22–1.18 (m, 2H). MS <i>m</i>/<i>z</i> 328 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N-</i>(3-Isopentyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>5</b>)</h4><div class="NLM_p last">Isatoic anhydride <b>20</b> (0.3 g, 1.3 mmol) and isopentyl amine (0.11 g, 1.3 mmol) were reacted according to the procedure described in General Procedure A steps b and c, which gave the title compound (0.15 g, 38%) over two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (s, 1H), 10.09 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 3.90–3.86 (m, 1H), 2.03 (s, 3H), 1.60–1.53 (m, 1H), 1.45–1.40 (m, 2H), 0.91–0.90 (d, <i>J</i> = 6.4 Hz, 6H). MS <i>m</i>/<i>z</i> 290 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N-</i>[3-(3-Cyclohexyl-propyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-6-yl]-acetamide (<b>6</b>)</h4><div class="NLM_p last">Isatoic anhydride <b>20</b> (0.1 g, 0.45 mmol) and cyclohexyl ethylamine (0.098 g, 0.7 mmol) were reacted according to the procedure described in General Procedure A, steps b and c, which gave the title compound (0.045 g, 29%) over two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (s, 1H), 10.10 (s, 1H), 8.22 (d, <i>J</i> = 2 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2 Hz, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 3.86–3.82 (m, 1H), 2.04 (s, 3H), 1.70–1.5 (m, 7H), 1.22–1.13 (m, 6H), 0.9–0.8 (m, 2H). MS <i>m</i>/<i>z</i> 342 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N-</i>(3-(2-Methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>7</b>)</h4><div class="NLM_p last">Isatoic anhydride <b>20</b> (0.8 g, 3.6 mmol) and 2-methoxyethyl amine (0.41 g, 5.4 mmol) were reacted according to the procedure described in General Procedure A, steps b and c, which gave the title compound (0.28 g, 28%) over two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 10.09 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 4.07 (t, <i>J</i> = 6 Hz, 2H), 3.51 (t, <i>J</i> = 6 Hz, 2H), 3.24 (s, 3H), 2.04 (s, 3H). MS <i>m</i>/<i>z</i> 278 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-(6-Acetamido-2,4-dioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)-3-cyclohexylpropanamide (<b>8</b>)</h4><div class="NLM_p last">Isatoic anhydride <b>20</b> (0.1 g, 0.45 mmol) and 2-amino-3-cyclohexylpropanamide (0.13 g, 0.67 mmol) were reacted according to the procedure described in General Procedure A, steps b and c, which gave the title compound (0.025 g, 15%) over two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.33 (br s, 1H), 10.10 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.31 (s, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 6.90 (s, 1H), 5.28–5.25 (m, 1H), 2.04 (s, 3H), 2.0–1.80 (m, 3H), 1.62–1.49 (m, 4H), 1.19–0.09 (m, 4H), 0.89–0.79 (m, 2H). MS <i>m</i>/<i>z</i> 371 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N-</i>(3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>9</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (100 mg, 0.45 mmol), benzylamine (0.050 mL, 0.49 mmol), THF (4 mL), and carbonyldiimidazole (105 mg, 0.65 mmol). Purification by flash chromatography (0–20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as an off-white powder (78.3 mg, 0.25 mmol, 56%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.49 (s, 1H), 10.12 (s, 1H), 8.26 (d, <i>J</i> = 2.4 Hz, 1H), 7.81 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.31 (m, 4H), 7.25 (m, 1H), 7.16 (d, <i>J</i> = 8.8 Hz, 1H), 5.09 (s, 2H), 2.05 (s, 3H). LC–MS <i>m</i>/<i>z</i>: 310 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.3 min.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N-</i>(2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>10</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using 2-phenylethylamine (85 μL). Purification by flash chromatography (0–5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> + 0.1% NH<sub>3</sub>) gave the title compound as an off-white powder (90 mg, 0.278 mmol, 41%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.39 (s, 1H), 10.11 (s, 1H), 8.24 (d, <i>J</i> = 2.3 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.32–7.20 (m, 5H), 7.13 (d, <i>J</i> = 8.8 Hz, 1H), 4.12–4.09 (m, 2H), 2.89–2.86 (m, 2H), 2.15 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 161.6, 149.7, 138.6, 134.9, 134.3, 128.5, 128.4, 126.5, 126.3, 114.6, 115.5, 113.7, 41.2, 33.3, 23.8. LC–MS <i>m</i>/<i>z</i>: 324 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.6 min.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N-</i>(2,4-Dioxo-3-(3-phenylpropyl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>11</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (100 mg, 0.45 mmol), benzenepropanamine (0.065 mL, 0.46 mmol), THF (4 mL), and carbonyldiimidazole (105 mg, 0.65 mmol) to give the title compound as a white solid (110.2 mg, 0.33 mmol, 72%), which needed no further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 10.10 (s, 1H), 8.23 (d, <i>J</i> = 1.8 Hz, 1H), 7.79 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 7.27 (t, <i>J</i> = 7.4 Hz, 2H), 7.23 (d, <i>J</i> = 7.1 Hz, 2H), 7.17 (d, <i>J</i> = 7.5 Hz, 1H), 7.12 (d, <i>J</i> = 8.7 Hz, 1H), 3.93 (t, <i>J</i> = 7.3 Hz, 2H), 2.64 (t, <i>J</i> = 7.6 Hz, 2H), 2.05 (s, 3H), 1.88 (m, 2H). LC–MS <i>m</i>/<i>z</i>: 338 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N-</i>(3-(Cyclohexylmethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>12</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using cyclohexylmethylamine (76.41 mg). Purification by flash chromatography (0–100% EtOAc/hexane) gave the title compound as a pale pink off-white powder (167 mg, 0.530 mmol, 78%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.33 (s, 1H), 10.08 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 3.77 (d, <i>J</i> = 7.3 Hz, 2H), 2.05 (s, 3H), 1.76–1.73 (m, 1H), 1.67–1.65 (m, 2H), 1.59–1.56 (m, 3H), 1.19–1.10 (m, 3H), 1.02–0.96 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 162.0, 150.1, 134.9, 134.2, 126.5, 116.6, 115.4, 113.6, 45.5, 35.8, 30.2, 25.8, 25.2, 23.8. LC–MS <i>m</i>/<i>z</i>: 316 [M + H]<sup>+</sup>, 631 [2M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N-</i>(3-(<i>tert</i>-Butyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>13</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>tert</i>-butylamine (49.37 mg). Purification by flash chromatography (0–60% EtOAc/hexane) gave the title compound as an off-white powder (36 mg, 0.131 mmol, 19%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.15 (s, 1H), 8.29 (d, <i>J</i> = 2.5 Hz, 1H), 7.82 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 7.68 (s, 1H), 7.23 (d, <i>J</i> = 8.8, 1H), 2.06 (s, 3H), 1.47 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 159.7, 145.9, 134.6, 128.2, 124.4, 116.4, 112.5, 50.8, 28.3, 23.8. LC–MS <i>m</i>/<i>z</i>: 276 [M + H]<sup>+</sup>, 551 [2M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.8 min. HRMS (ES<sup>+</sup>): found 276.1335 [M + H]<sup>+</sup>; C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, requires 276.1343.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N-</i>(3-(4-Methylpentyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>14</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using 4-methylpentan-1-amine (69 mg, 0.68 mmol), and gave the title compound as a tan-colored powder (132.3 mg, 0.44 mmol, 64%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 10.10 (s, 1H), 8.23 (d, <i>J</i> = 2.3 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 3.86 (t, <i>J</i> = 7.5 Hz, 2H), 2.05 (s, 3H), 1.54 (m, 3H), 1.18 (m, 2H), 0.86 (d, <i>J</i> = 6.6 Hz, 6H). LC–MS <i>m</i>/<i>z</i>: 304 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.9 min.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N-</i>(3-Hexyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>15</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using 1-hexylamine (0.090 mL, 0.68 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (58.3 mg, 0.21 mmol, 31%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 10.10 (s, 1H), 8.23 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 3.87 (t, <i>J</i> = 7.5 Hz, 2H), 2.05 (s, 3H), 1.56 (m, 2H), 1.28 (m, 6H), 0.87 (t, <i>J</i> = 7.8 Hz, 3H). LC–MS <i>m</i>/<i>z</i>: 304 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.9 min.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N-</i>(3-Cyclopentyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>16</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using cyclopentylamine (57.48 mg). Purification by flash chromatography (0–80% EtOAc/hexane) gave the title compound as a white powder (127 mg, 0.442 mmol, 65%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.28 (s, 1H), 10.09 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.11 (d, <i>J</i> = 8.8, 1H), 5.30 (quintet, <i>J</i> = 8.7 Hz, 1H), 2.10–2.05 (m, 5H), 1.94–1.86 (m, 2H), 1.80–1.73 (m, 2H), 1.60–1.52 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 162.0, 149.8, 134.8, 134.1, 126.4, 116.5, 115.2, 114.0, 51.9, 28.0, 25.3, 23.8. LC–MS <i>m</i>/<i>z</i>: 288 [M + H]<sup>+</sup>, 305 [M + NH<sub>4</sub>]<sup>+</sup>, 575 [2M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.3 min. HRMS (ES<sup>+</sup>): found 288.1337 [M + H]<sup>+</sup>; C<sub>15</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, requires 288.1343.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N-</i>(3-Cyclohexyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>17</b>)</h4><div class="NLM_p last">The compound was prepared by following General Procedure B, using cyclohexylamine (66.95 mg). Purification by flash chromatography (0–60% EtOAc/hexane) gave the title compound as a white powder (101 mg, 0.335 mmol, 49%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.25 (s, 1H), 10.09 (s, 1H), 8.19(d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.76–4.71 (m, 1H), 2.43–2.35 (dq, <i>J</i> = 15.8, 3.3 Hz, 2H), 2.04 (s, 3H), 1.80 (d, <i>J</i> = 12.9 Hz, 2H), 1.64 (d, <i>J</i> = 12.6 Hz, 1H), 1.58 (d, <i>J</i> = 10.5 Hz, 2H), 1.35–1.27 (m, 2H), 1.19–1.14 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 162.1, 150.0, 135.0, 134.1, 126.4, 116.6, 115.1, 114.1, 52.7, 28.3, 25.9, 25.0, 23.8. LC–MS <i>m</i>/<i>z</i>: 302 [M + H]<sup>+</sup>, 319 [M + NH<sub>4</sub>]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.5 min. HRMS (ES<sup>+</sup>): found 302.1499 [M + H]<sup>+</sup>; C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, requires 302.1499.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N-</i>(3-Cycloheptyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>18</b>)</h4><div class="NLM_p last">The compound was prepared by following General Procedure B, using cycloheptylamine (76.41 mg). Purification by flash chromatography (0–60% EtOAc/hexane) gave the title compound as a beige powder (137 mg, 0.434 mmol, 64%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.25 (s, 1H), 10.08 (s, 1H), 8.20(d, <i>J</i> = 2.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.09 (d, <i>J</i> = 8.8, 1H), 4.89 (bs, 1H), 2.35–2.27(m, 2H), 2.04 (s, 3H), 1.76–1.66 (m, 4H), 1.61–1.54 (m, 4H), 1.52–1.41 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 161.7, 149.8, 135.0, 134.1, 126.4, 116.7, 115.1, 54.0, 31.3, 27.5, 25.9, 23.8. LC–MS <i>m</i>/<i>z</i>: 316 [M + H]<sup>+</sup>, 648 [M + NH<sub>3</sub>]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N-</i>(3-(<i>trans</i>-4-<i>tert</i>-Butyl)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>19</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (110 mg, 0.50 mmol), <i>trans</i>-4-(<i>tert-</i>butyl)cyclohexanamine (78 mg, 0.50 mmol), THF (5 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (60 mg, 0.17 mmol, 33%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.23 (s, 1H), 10.06 (s, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.71 (m, 1H), 2.42 (m, 2H), 2.04 (s, 3H), 1.84 (d, <i>J</i> = 10.6 Hz, 1H), 1.64 (d, <i>J</i> = 9.9 Hz, 2H), 1.14–1.04 (m, 3H), 0.88 (s, 9H). LC–MS <i>m</i>/<i>z</i>: 356 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.4 min. <i>trans</i>-4-(<i>tert</i>-Butyl)cyclohexanamine was prepared from 4-(<i>tert</i>-butyl)cyclohexanone following General Procedure C and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.58 (m, 1H), 1.91 (m, 2H), 1.77 (m, 2H), 1.61 (s, 2H), 1.11–0.94 (m, 5H), 0.86 (s, 9H).</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N-</i>(2,4-Dioxo-1,4-dihydro-2<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)-acetamide (<b>20</b>)</h4><div class="NLM_p last">See General Procedure A.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 6-Amino-3-(2-cyclohexylethyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>30</b>)</h4><div class="NLM_p last">5-Acetylamino-2-amino-<i>N</i>-(2-cyclohexyl-ethyl)-benzamide (0.1 g, 0.33 mmol), was taken in ethyl chloroformate (0.4 mL) and heated to 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the crude was dissolved in EtOH (2 mL), followed by the addition of KOH (0.15 g, 2.6 mmol) and heating at 85 °C for 16 h. The solvent was removed under reduced pressure, followed by the addition of water (10 mL) and extraction with EtOAc (3 × 10 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash column chromatography on silica gel, which gave the title compound as a solid (0.035 g, 36%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>,): δ 10.98 (s, 1H), 7.08 (d, <i>J</i> = 2 Hz, 1H), 6.95–6.88 (m, 2H), 5.16 (s, 2H), 3.89–3.85 (m, 2H), 1.74–1.58 (m, 7H), 1.44–1.25 (m, 4H), 0.9–0.8 (m, 2H). MS: <i>m</i>/<i>z</i> 288 [M + 1]<sup>+</sup>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0038.gif" alt="" id="gr30" /></img></div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N-</i>(3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzamide (<b>31</b>)</h4><div id="sec4_2_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Step a: <i>N-</i>(2,4-Dioxo-1,4-dihydro-2<i>HH</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)benzamide</h5><div class="NLM_p last">HATU (0.93 g, 2.44 mmol) was added to a solution at 0 °C of benzoic acid (0.25 g, 2.04 mmol) in DMF (5 mL). The mixture was stirred for 10 min; then, 5-aminoisatoic anhydride (0.64 g, 2.04 mmol) and NMM (0.61 g, 6.12 mmol) were added, and the stirring was continued at room temperature for 16 h. The solvent was removed under reduced pressure, water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The afforded crude compound was used in the next step without further purification. MS: <i>m</i>/<i>z</i> 283 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Step b: 2-Amino-5-benzamido-<i>N-</i>(2-cyclohexylethyl)benzamide</h5><div class="NLM_p last">The crude material (0.18 g) from the previous step was added to a solution of cyclohexylethyl amine (0.12 g, 0.9 mmol) and DMAP (16 mg) in DMF (0.8 mL). The reaction mixture was stirred at room temperature for 3 h and then concentrated under reduced pressure. Water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The afforded crude compound was taken to the next step without further purification. MS: <i>m</i>/<i>z</i> 366 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_20_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Step c: <i>N-</i>(3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzamide (<b>31</b>)</h5><div class="NLM_p last">The crude material from the previous step (0.09 g) was taken in ethyl chloroformate (0.35 mL) and heated to 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the crude was dissolved in EtOH (3.36 mL), followed by the addition of KOH (0.06 g, 1.06 mmol) and heating at 85 °C for 5 h. The solvent was removed under reduced pressure, water (5 mL) was added, and the mixture was extracted with EtOAc (3 × 5 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash column chromatography on silica gel, which gave the title compound (0.055 g, 57%). MS: <i>m</i>/<i>z</i> 390 [M – 1]<sup>−</sup>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0039.gif" alt="" id="gr31" /></img></div></div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N-</i>(3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)pivalamide (<b>32</b>)</h4><div id="sec4_2_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step a: <i>N-</i>(2,4-Dioxo-1,4-dihydro-2<i>HH</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)-3,3-dimethylbutanamide</h5><div class="NLM_p last">EDC·HCl (0.8 g, 4.2 mmol) was added to a solution of <i>tert</i>-butyl acetic acid (0.97 g, 8.4 mmol) in DMF (11 mL). The mixture was stirred at room temperature for 30 min; then, 5-aminoisatoic anhydride (0.5 g, 2.8 mmol) was added, and the stirring was continued at room temperature. After 16 h, additional <i>tert</i>-butyl acetic acid (0.65 g, 5.6 mmol) and EDC × HCl (0.53 g, 2.8 mmol) were added, and the reaction mixture was stirred for an additional 4 h. The solvent was removed under reduced pressure, followed by the addition of water (10 mL) and extraction with EtOAc (3 × 10 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The afforded crude was used in the next step without further purification. MS: <i>m</i>/<i>z</i> 277 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step b: <i>N-</i>(3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)pivalamide (<b>32</b>)</h5><div class="NLM_p last">The crude compound from the previous step was reacted with cyclohexylethylamine followed by carbonylation and ring closure according to the method described in General Procedure A, steps b and c, which gave the title compound (0.075 g, 20%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 9.97 (s, 1H), 8.24 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 3.92–3.88 (m, 2H), 2.18 (s, 2H), 1.80–1.70 (m, 2H), 1.70–1.60 (m, 3H), 1.47–1.43 (m, 2H), 1.25–1.22 (m, 4H), 1.0 (m, 9H), 0.90–0.80 (m, 2H). MS: <i>m</i>/<i>z</i> 385 [M – 1]<sup>−</sup>.</div></div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 2-(3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetonitrile (<b>33</b>)</h4><div class="NLM_p last">Pd(PPh<sub>3</sub>)<sub>4</sub> (0.06 g, 0.005 mmol) was added under nitrogen to a degassed solution of iodo derivative <b>40</b> (0.1 g, 0.25 mmol) in 1,4-dioxane (1 mL), water (0.5 mL), Na<sub>2</sub>CO<sub>3</sub> (0.08 g, 0.7 mmol), and isoxazol-4-yl-boronic-acid (0.04 g, 0.4 mmol) in a screw-capped reaction vessel. The vessel was tightly sealed, and the reaction mixture was heated at 90 °C for 16 h. The vessel was opened at room temperature, then water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash column chromatography on silica gel, which gave the title compound (0.03 g, yield 42%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.46 (s, 1H), 7.91 (s, 1H), 7.60 (m, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 4.08 (s, 2H), 3.95–3.88 (m, 2H), 1.75–1.73 (m, 2H), 1.67–1.59 (m, 3H), 1.47–1.44 (m, 2H), 1.27–1.11 (m, 4H), 0.97–0.90 (m, 2H). MS: <i>m</i>/<i>z</i> 310 [M – 1]<sup>−</sup>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0040.gif" alt="" id="gr32" /></img></div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 3-(2-Cyclohexylethyl)-6-(3,5-dimethylisoxazol-4-yl)quinazoline-2,4(1<i>HH</i>,3<i>HH</i>)-dione (<b>34</b>)</h4><div id="sec4_2_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step a: 2-Amino-<i>N-</i>(2-cyclohexylethyl)-5-iodobenzamide</h5><div class="NLM_p last">HATU (6.84 g, 18 mmol) was added to a cold (0 °C) solution of 2-amino-5-iodo benzoic acid (4 g, 15 mmol) in DMF (80 mL). The solution was stirred for 5 min; then cyclohexyl ethylamine (1.93 g, 15 mmol) and NMM (4.5 g, 45 mmol) were added. The reaction mixture was stirred at room temperature for 16 h and concentrated under reduced pressure. Water (50 mL) was added, and the mixture was extracted with EtOAc (3 × 50 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The afforded crude was taken to the next step without further purification. MS: <i>m</i>/<i>z</i> 373 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step b: 3-(2-Cyclohexylethyl)-6-iodoquinazoline-2,4(1<i>HH</i>,3<i>HH</i>)-dione (<b>40</b>)</h5><div class="NLM_p last">The crude material from the previous step (2 g) was taken in ethyl chloroformate (7.6 mL) and heated to 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the crude was dissolved in EtOH (60 mL), followed by the addition of KOH (0.45 g, 8.06 mmol) and heating at 85 °C for 3 h. The solvent was removed under reduced pressure followed by the addition of water (100 mL). The solution was acidified with glacial acetic acid until pH 7 and extracted with EtOAc (3 × 50 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The obtained solid (2 g, 33% after two steps) was used in the next step. MS: <i>m</i>/<i>z</i> 397 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_23_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step c: 3-(2-Cyclohexylethyl)-6-(3,5-dimethylisoxazol-4-yl)quinazoline-2,4(1<i>HH</i>,3<i>HH</i>)-dione (<b>34</b>)</h5><div class="NLM_p last">Water (1 mL), Na<sub>2</sub>CO<sub>3</sub> (0.16 g, 1.5 mmol), and 3,5-dimethylisoxazol-4-yl-boronic-acid (0.14 g, 1 mmol) were added to a solution of iodo derivative <b>40</b> (0.2 g, 0.50 mmol) in 1,4-dioxane (2 mL). The solution was degasified, and then, PdP(Ph<sub>3</sub>)<sub>4</sub> (0.12 g, 0.01 mmol) was added under nitrogen. The reaction mixture was heated at 90 °C for 16 h, then water (20 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash column chromatography on silica gel, which gave the title compound (0.03 g, yield 32% based on the recovered starting material) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.53 (s, 1H,), 7.85 (d, <i>J</i> = 2 Hz, 1H), 7.68 (dd, <i>J</i> = 8.4, 2 Hz, 1H), 7.27 (d, <i>J</i> = 8.4 Hz, 1H), 3.94–3.90 (m, 2H), 2.49 (s, 3H), 2.39 (s, 3H), 1.80–1.70 (m, 2H), 1.70–1.59 (m, 3H), 1.55–1.40 (m, 2H), 1.29–1.11 (m, 4H), 0.90–0.70 (m, 2H). MS: <i>m</i>/<i>z</i> 366 [M – 1]<sup>−</sup>.</div></div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-(2-Cyclohexylethyl)-6-(pyridin-3-yl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>35</b>)</h4><div class="NLM_p last">Pyridine-3-boronic acid (0.04 g, 0.37 mmol) was reacted with the iodo derivative <b>40</b> (0.1 g, 0.25 mmol) according to the method described above for <b>34</b>, step c, but using Cs<sub>2</sub>CO<sub>3</sub> instead of Na<sub>2</sub>CO<sub>3</sub>, which gave the title compound (0.05 g, 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.56 (s, 1H), 8.90 (d, <i>J</i> = 2 Hz, 1H), 8.57 (dd, <i>J</i> = 8, 2 Hz, 1H), 8.19 (d, <i>J</i> = 2 Hz, 1H), 8.10 (d, <i>J</i> = 8 Hz, 1H), 8.05 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.62–7.48 (m, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 1H), 3.95–3.91 (m, 2H), 1.77–1.74 (m, 2H), 1.67–1.59 (m, 3H), 1.49–1.44 (m, 2H), 1.28–1.22 (m, 1H), 1.19–1.11 (m, 3H), 0.97–0.90 (m, 2H). MS: <i>m</i>/<i>z</i> 348 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 3-(2-Cyclohexylethyl)-6-(pyrimidin-5-yl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>36</b>)</h4><div class="NLM_p last">Pyrimidine-5-boronic acid (0.045 g, 0.37 mmol) was reacted with the iodo derivative <b>40</b> (0.1 g, 0.25 mmol) according to the method described above for <b>34</b>, step c, but using Cs<sub>2</sub>CO<sub>3</sub> instead of Na<sub>2</sub>CO<sub>3</sub>, which gave the title compound (0.035 g, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.60 (s, 1H), 9.18 (s, 1H), 9.16 (s, 2H), 8.29 (d, <i>J</i> = 2 Hz, 1H), 8.10 (dd, <i>J</i> = 8.4, 2 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 3.95–3.91 (m, 2H), 1.77–1.73 (m, 2H), 1.65–1.59 (m, 3H), 1.49–1.44 (m, 2H), 1.33–1.11 (m, 4H), 0.97–0.88 (m, 2H). MS: <i>m</i>/<i>z</i> 349 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 3-(2-Cyclohexylethyl)-6-(pyridin-4-yl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>37</b>)</h4><div class="NLM_p last">Pyridine-4-boronic acid (0.045 g, 0.37 mmol) was reacted with the iodo derivative <b>40</b> (0.1 g, 0.25 mmol) according to the method described above for <b>34</b>, step c, but using Cs<sub>2</sub>CO<sub>3</sub> instead of Na<sub>2</sub>CO<sub>3</sub>, which gave the title compound (0.055 g, 63%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.61 (s, 1H), 8.64 (d, <i>J</i> = 5.2 Hz, 2H), 8.28 (d, <i>J</i> = 2 Hz, 1H), 8.12 (dd, <i>J</i> = 8.4, 2 Hz, 1H), 7.73 (d, <i>J</i> = 5.2 Hz, 2H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 3.95–3.91 (m, 2H), 1.77–1.74 (m, 2H), 1.67–1.59 (m, 3H), 1.49–1.44 (m, 2H), 1.28–1.22 (m, 1H), 1.19–1.11 (m, 3H), 0.97–0.90 (m, 2H). MS: <i>m</i>/<i>z</i> 348 [M – 1]<sup>−</sup>.</div></div><div id="sec4_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 3-(2-Cyclohexylethyl)-6-iodoquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>40</b>)</h4><div class="NLM_p last">See the synthesis of compound <b>34</b>.</div></div><div id="sec4_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N-</i>(3-(<i>cis</i>-4-(<i>tert</i>-Butyl)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>42</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (110 mg, 0.50 mmol), <i>cis</i>-4-(<i>tert-</i>butyl)cyclohexanamine (78 mg, 0.50 mmol), THF (5 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (27.5 mg, 0.077 mmol, 15%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.21 (s, 1H), 10.06 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.92 (m, 1H), 2.33 (m, 2H), 2.05 (s, 3H), 1.73 (m, 2H), 1.50 (m, 4H), 1.33 (m, 1H), 0.92 (s, 9H). LC–MS <i>m</i>/<i>z</i>: 356 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.4 min. <i>cis</i>-4-(<i>tert</i>-Butyl)cyclohexanamine was prepared from 4-(<i>tert</i>-butyl)cyclohexanone following procedure C and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 3.08 (m, 1H), 1.87 (m, 1H), 1.69 (m, 2H), 1.55 (m, 6H), 1.30 (m, 1H), 1.00 (m, 1H), 0.88 (s, 9H).</div></div><div id="sec4_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>N</i>-(3-(<i>transtrans</i>-4-Isopropylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>43</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (1.167 g, 5.30 mmol), <i>trans</i>-4-isopropylcyclohexanamine (0.823 g, 5.83 mmol), THF (50 mL), and carbonyldiimidazole (1.3 g, 8 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (0.742 g, 2.11 mmol, 40%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.26 (s, 1H), 10.09 (s, 1H), 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.71 (m, 1H), 2.42 (m, 2H), 2.04 (s, 3H), 1.77 (m, 2H), 1.61 (d, <i>J</i> = 11.4 Hz, 2H), 1.46 (m, 1H), 1.08 (m, 4H), 0.89 (d, <i>J</i> = 6.8 Hz, 6H). LC–MS <i>m</i>/<i>z</i>: 344 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.2 min. <i>trans</i>-4-Isopropylcyclohexanamine was prepared from 4-isopropylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.82 (br s, 2H), 2.68 (m, 1H), 1.94 (m, 2H), 1.74 (m, 2H), 1.44–1.02 (m, 6H), 0.87 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec4_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>N</i>-(3-(<i>cis</i>-4-Isopropylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>44</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (110 mg, 0.50 mmol), <i>cis</i>-4-isopropylcyclohexanamine (71 mg, 0.50 mmol), THF (5 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (47 mg, 0.14 mmol, 27%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.76 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 4.77 (m, 1H), 2.53–2.46 (m, 2H), 2.04 (s, 3H), 1.97 (m, 1H), 1.90 (d, <i>J</i> = 13.6 Hz, 2H), 1.44–1.34 (m, 4H), 1.17 (m, 1H), 0.92 (d, <i>J</i> = 6.5 Hz, 6H). LC–MS <i>m</i>/<i>z</i>: 344 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.3 min. <i>cis</i>-4-Isopropylcyclohexanamine was prepared from 4-isopropylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 3.06 (m, 1H), 1.88 (br s, 2H), 1.57–1.38 (m, 9H), 1.06 (m, 1H), 0.87 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec4_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>N</i>-(3-(<i>trans</i>-4-Ethylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>45</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (220 mg, 1.00 mmol), <i>trans</i>-4-ethylcyclohexanamine (140 mg, 1.00 mmol), THF (8 mL), and carbonyldiimidazole (243 mg, 1.50 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (51.8 mg, 0.157 mmol, 16%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.26 (s, 1H), 10.09 (s, 1H), 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.73 (m, 1H), 2.42 (qd, <i>J</i> = 12.6 and 3.2 Hz, 2H), 2.04 (s, 3H), 1.83 (d, <i>J</i> = 12.0 Hz, 2H), 1.58 (d, <i>J</i> = 9.6 Hz, 2H) 1.23 (m, 2H), 1.16 (m, 1H), 0.98 (qd, <i>J</i> = 12.8, 3.1 Hz, 2H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H). LC–MS <i>m</i>/<i>z</i>: 330 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.1 min. <i>trans</i>-Ethylcyclohexanamine was prepared from 4-ethylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.58 (m, 1H), 1.84 (m, 2H), 1.74 (m, 2H), 1.33 (br s, 2H), 1.27–1.17 (m, 3H), 1.05 (m, 2H), 0.91 (m, 2H), 0.86 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>N</i>-(3-(<i>cis</i>-4-Ethylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>46</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (132 mg, 0.60 mmol), <i>cis</i>-4-ethylcyclohexanamine (84 mg, 0.60 mmol), THF (5 mL), and carbonyldiimidazole (146 mg, 0.90 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (34.7 mg, 0.088 mmol, 18%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.24 (s, 1H), 10.09 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.72 (m, 1H), 2.53 (m, 2H), 2.05 (s, 3H), 1.70 (d, <i>J</i> = 12.6 Hz), 1.50 (m, 5H), 1.33 (d, <i>J</i> = 9.7 Hz, 2H), 0.89 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS <i>m</i>/<i>z</i>: 330 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min. <i>cis</i>-4-Ethylcyclohexanamine was prepared from 4-ethylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.99 (m, 1H), 1.61–1.25 (m, 13H), 0.90 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>N</i>-(2,4-Dioxo-3-(<i>trans</i>-4-propylcyclohexyl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>47</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (220 mg, 1.00 mmol), <i>trans</i>-4-propylcyclohexanamine (155 mg, 1.00 mmol), THF (8 mL), and carbonyldiimidazole (243 mg, 1.50 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (64.1 mg, 0.187 mmol, 19%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.26 (s, 1H), 10.09 (s, 1H), 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.72 (m, 1H), 2.42 (qd, <i>J</i> = 8.5, 3.0 Hz, 2H), 2.04 (s, 3H), 1.81 (d, <i>J</i> = 12.0 Hz, 2H), 1.58 (d, <i>J</i> = 9.8 Hz), 1.36–1.16 (m, 5H), 0.99 (qd, <i>J</i> = 12.5, 3.0 Hz, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS <i>m</i>/<i>z</i>: 344 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.1 min. <i>trans</i>-4-Propylcyclohexanamine was prepared from 4-propylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.60 (m, 1H), 1.85 (m, 2H), 1.74 (m, 2H), 1.38 (br s, 2H), 1.31 (m, 2H), 1.17 (m, 3H), 1.07 (m, 2H), 0.94 (m, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>N</i>-(2,4-Dioxo-3-(<i>cis</i>-4-propylcyclohexyl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>48</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (220 mg, 1.00 mmol), <i>cis</i>-4-propylcyclohexanamine (155 mg, 1.00 mmol), THF (8 mL), and carbonyldiimidazole (243 mg, 1.50 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (51.3 mg, 0.149 mmol, 15%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.23 (s, 1H), 10.09 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.76 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 4.73 (m, 1H), 2.53 (m, 2H), 2.05 (s, 3H), 1.67 (m, 3H), 1.55–1.42 (m, 4H), 1.30 (m, 4H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS <i>m</i>/<i>z</i>: 344 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.2 min. <i>cis</i>-4-Propylcyclohexanamine was prepared from 4-propylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.94 (m, 1H), 1.55 (m, 2H), 1.50–1.21 (m, 13H), 0.88 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(3-(4-Methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>49</b>)</h4><div class="NLM_p last">The compound was prepared per General Procedure B, using methylcyclohexyl amine (112.1 mg, 0.990 mmol). Purification by flash chromatography (0–80% EtOAc/hexane) gave the title compound as a white/pale pink powder (189 mg, 0.599 mmol, 88%) as a mixture of isomers. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.23 (s, 1H), 10.07 (s, 1H), 8.26–8.24(m, 1H), 8.20 (dd, <i>J</i> = 11.7, 2.4 Hz, 1H), 7.80–7.76 (m, 1H), 7.71–7.68 (m, 1H), 7.10 (dd, <i>J</i> = 8.8, 5.2 Hz, 1H), 7.04–7.01 (m, 1H), 4.74–4.69 (m, 1H), 2.66–2.58 (m, 1H), 2.46 (dd, <i>J</i> = 12.6, 3.1 Hz, 1H), 2.05 (s, 3H), 1.95–1.87 (m, 1H), 1.77–1.66 (m, 2H), 1.63–1.48 (m, 4H), 1.45–1.33 (m, 3H), 1.08–1.00 (m, 3H), 0.98–0.91 (d, <i>J</i> = 6.9 Hz, 1H), 0.90–0.87 (m, 2H). LC–MS <i>m</i>/<i>z</i>: 316 [M + H]<sup>+</sup>, 631 [2M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 5.0 min.</div></div><div id="sec4_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>N</i>-(3-(4,4-Dimethylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>50</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (110 mg, 0.50 mmol), 4,4-dimethylcyclohexanamine (64 mg, 0.50 mmol), THF (5 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (16.3 mg, 0.050 mmol, 10%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.09 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.69 (m, 1H), 2.60 (qd, <i>J</i> = 13.0, 3.2 Hz, 2H), 2.05 (s, 3H), 1.44 (d, <i>J</i> = 12.4 Hz, 2H), 1.38 (m, 2H), 1.28 (td, <i>J</i> = 13.3, 3.6 Hz, 2H), 1.01 (s, 3H), 0.94 (s, 9H). LC–MS <i>m</i>/<i>z</i>: 328 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.1 min. 4,4-Dimethylcyclohexanamine was prepared from 4,4-dimethylcyclohexanone, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.58 (m, 1H), 1.64 (m, 2H), 1.39–1.18 (m, 8H), 0.90 (s, 6H).</div></div><div id="sec4_2_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>N</i>-(3-(3-(<i>tert</i>-Butyl)cyclopentyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>51</b>)</h4><div class="NLM_p">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (165 mg, 0.75 mmol), 3-(<i>tert</i>-butyl)cyclopentanamine (117 mg, 0.83 mmol), THF (6 mL), and carbonyldiimidazole (182 mg, 1.12 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound, a mixture of diastereomers, as a white powder (139.8 mg, 0.407 mmol, 54%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.26 (s, 1H), 10.09 and 10.08 (2<i>s</i>, 1H), 8.23 (m, 1H), 7.76 (m, 1H), 7.10 (m, 1H), 5.25 (m, 1H), 2.36–1.23 (m, 7H), 2.05 (s, 3H), 0.89 and 0.86 (2s, 9H). LC–MS <i>m</i>/<i>z</i>: 342 [M – H]<sup>−</sup>, <i>t</i><sub>R</sub> = 4.6 min.</div><div class="NLM_p last">3-(<i>tert</i>-Butyl)cyclopentanamine was made as follows:<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0041.gif" alt="" id="gr33" /></img></div></div><div id="sec4_2_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 3-(<i>tert</i>-Butyl)cyclopentanamine</h4><div id="sec4_2_38_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Step 1</h5><div class="NLM_p last">The procedure of Matsumura and Yoshihiro et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> was used. A solution of 4-<i>tert</i>-butylcyclohexanol (10.0 g, 64 mmol, a mixture of <i>cis</i>- and <i>trans</i>-isomers) in trifluoroacetic acid (100 mL) at 0 °C was treated with sodium nitrite (17.0 g, 250 mmol) in small portions over 90 min. The thick suspension was stirred at room temperature overnight and then concentrated. The residue was poured onto ice, treated with aqueous NaHCO<sub>3</sub> (500 mL), and then made basic by the addition of solid NaOH. The aqueous solution was washed with dichloromethane (3 × 200 mL) and then acidified to pH < 1 with concentrated hydrochloric acid, extracted with ethyl acetate (3 × 300 mL), dried (MgSO<sub>4</sub>), and concentrated to give crude 3-(<i>tert</i>-butyl)hexanedioic acid as a brown oil (13.05 g, ca. 100%), which was used without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.63 (br s, 2H), 2.56 (dd, <i>J</i> = 16.3 and 3.9 Hz, 1H), 2.50–2.39 (m, 2H), 2.12 (dd, <i>J</i> = 16.3 and 8.0 Hz, 1H), 1.98 (m, 1H), 1.74 (m, 1H), 1.44 (m, 1H), 0.93 (s, 9H).</div></div><div id="sec4_2_38_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Step 2</h5><div class="NLM_p">Crude 3-(<i>tert</i>-butyl)hexanedioic acid (8.33 g, 41 mmol) and solid sodium carbonate (0.216 g, 2 mmol) were heated together to 240 °C in a Kugelrohr distillation apparatus for 1 h. 3-(<i>tert</i>-Butyl)cyclopentanone was distilled from the reaction mixture and was collected as a green oil (1.983 g, 14 mmol, 34%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.38 (dd, <i>J</i> = 8.1, 1.1 Hz), 2.29–2.17 (m, 2H), 2.07–1.94 (m, 2H), 1.61 (m, 1H), 0.93 (s, 9H).</div><div class="NLM_p last">3-(<i>tert</i>-Butyl)cyclopentanone was converted into 3-(<i>tert</i>-butyl)cyclopentanamine as a mixture of <i>cis</i>- and <i>trans</i>-isomers following General Procedure B, which was used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 3.56–3.24 (m, 1H), 2.00–1.84 (m, 2H), 1.73 (m, 1H), 1.59 (m, 1H), 1.51–1.44 (m, 3H), 1.37–1.22 (m, 2H), 0.86 (s, 5.5H), 0.85 (s, 3.5H).</div></div></div><div id="sec4_2_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>N</i>-(3-(4-(<i>tert</i>-Butyl)phenyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>52</b>)</h4><div class="NLM_p last">Following General Procedure D, 5-acetamido-2-aminobenzoic acid (200 mg, 1.03 mmol) and <i>tert</i>-butylaniline (152.2 mg, 1.02 mmol) were combined in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at room temperature, followed by the addition of DIPEA (15.79 mg, 0.156 mmol), and the mixture was stirred. A 50% solution of propylphosphonic anhydride in EtOAc (399.1 mg, 1.25 mmol) was added dropwise, and the reaction was stirred at room temperature overnight. The resultant mixture was washed with aq NaHCO<sub>3</sub> and water, dried (MgSO<sub>4</sub>), and concentrated. Purification by flash chromatography (0–100% EtOAc/hexane) gave the intermediate amide (147 mg, 0.452 mmol). This was suspended in THF (15 mL), CDI (251 mg, 1.55 mmol) was added, and the reaction was heated to 100 °C overnight. Upon cooling, the mixture was concentrated and purified by flash chromatography (0–100% EtOAc/hexane) to the title compound as a pale orange powder (81 mg, 0.231 mmol, 22%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.48 (s, 1H), 10.11 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 8.89 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.50 (d, <i>J</i> = 8.6 Hz, 2H), 7.23 (d, <i>J</i> = 8.5, 2H), 7.18 (d, <i>J</i> = 8.8 Hz, 2H), 2.05 (s, 3H), 1.35 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.2, 162.1, 150.3, 150.0, 135.3, 134.3, 133.1, 128.4, 126.7, 125.5, 116.7, 115.5, 114.2, 34.3, 31.1, 23.8. LC–MS <i>m</i>/<i>z</i>: 352 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.9 min.</div></div><div id="sec4_2_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> <i>N</i>-(2,4-Dioxo-3-(<i>trans</i>-4-(trifluoromethyl)cyclohexyl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>57</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (165 mg, 0.75 mmol), <i>trans</i>-4-(trifluoromethyl)cyclohexanamine (125 mg, 0.75 mmol), THF (6 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (59.6 mg, 0.16 mmol, 22%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.30 (s, 1H), 10.10 (s, 1H), 8.20 (d, <i>J</i> = 2.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.76 (m, 1H), 2.49 (m, 2H), 2.30 (m, 1H), 2.04 (s, 3H), 1.98 (d, <i>J</i> = 11.8 Hz, 2H), 1.71 (d, <i>J</i> = 10.2 Hz, 2H), 1.39 (qd, <i>J</i> = 12.8, 3.4 Hz, 2H). LC–MS <i>m</i>/<i>z</i>: 368 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.0 min. <i>trans-4</i>-(Trifluoromethyl)cyclohexanamine was prepared from 4-(trifluoromethyl)cyclohexan-1-one, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.65 (m, 1H), 1.94 (m, 5H), 1.40 (br s, 2H), 1.36 (m, 2H), 1.09 (m, 2H).</div></div><div id="sec4_2_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>N</i>-(2,4-Dioxo-3-(<i>cis</i>-4-(trifluoromethyl)cyclohexyl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>58</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (165 mg, 0.75 mmol), <i>cis</i>-4-(trifluoromethyl)cyclohexanamine (125 mg, 0.75 mmol), THF (6 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (40.2 mg, 0.11 mmol, 15%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.25 (s, 1H), 10.09 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.80 (m, 1H), 2.53 (m, 3H), 2.05 (m, 5H), 1.73 (m, 2H), 1.50 (m, 2H). LC–MS <i>m</i>/<i>z</i>: 368 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min. <i>cis</i>-4-(Trifluoromethyl)cyclohexanamine was prepared from 4-(trifluoromethyl)cyclohexan-1-one, following procedure C, and used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 3.18 (m, 1H), 2.05 (m, 1H), 1.68 (m, 8H), 1.34 (br s, 2H).</div></div><div id="sec4_2_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-(3-(<i>trans</i>-4-(2-Fluoropropan-2-yl)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>59</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (165 mg, 0.75 mmol), <i>trans</i>-4-(2-fluoropropan-2-yl)cyclohexanamine (119 mg, 0.75 mmol), THF (6 mL), and carbonyldiimidazole (182 mg, 1.12 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a brown solid (145 mg, 0.40 mmol, 54%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.24 (s, 1H), 10.06 (s, 1H), 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.73 (m, 1H), 2.45 (qd, <i>J</i> = 2.9, 12.4 Hz, 2H), 2.05 (s, 3H), 1.86 (d, <i>J</i> = 12.1 Hz, 2H) 1.66 (d, <i>J</i> = 10.1 Hz, 2H), 1.54 (q, <i>J</i> = 12.0 Hz, 1H), 1.30 (d, <i>J</i> = 22.2 Hz, 6H), 1.19 (qd, <i>J</i> = 2.9, 12.6 Hz, 2H). LC–MS <i>m</i>/<i>z</i>: 362 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.9 min.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0042.gif" alt="" id="gr34" /></img></div></div><div id="sec4_2_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>trans</i>-4-(2-Fluoropropan-2-yl)cyclohexanamine</h4><div id="sec4_2_43_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Step 1</h5><div class="NLM_p last">A suspension of <i>trans</i>-4-(carbobenzoxyamino)cyclohexanecarboxylic acid (8.093 g, 29.2 mmol) and freshly ground potassium carbonate (4.24 g, 30.7 mmol) in DMF (140 mL) was stirred at room temperature for 40 min then cooled to 0 °C. Iodomethane (1.90 mL, 30.5 mmol) was added dropwise. The mixture was stirred at room temperature overnight and then concentrated and partitioned between water (100 mL) and EtOAc (3 × 100 mL). The combined organic phases were dried (MgSO<sub>4</sub>) and concentrated to give methyl <i>trans</i>-4-(carbobenzoxyamino)cyclohexanecarboxylate as an off-white solid (7.722 g, 26.5 mmol, 91%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.35 (m, 5H), 5.11 (s, 2H), 4.64 (br s, 1H), 3.69 (s, 3H), 3.52 (m, 1H), 2.25 (tt, <i>J</i> = 12.2, 3.6 Hz, 1H), 2.11 (br d, <i>J</i> = 10.8 Hz, 2H), 2.04 (br d, <i>J</i> = 13.2 Hz, 2H), 1.56 (br q, <i>J</i> = 12.1 Hz, 2H), 1.16 (qd, <i>J</i> = 12.8, 3.4 Hz, 2H).</div></div><div id="sec4_2_43_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> Step 2</h5><div class="NLM_p last">A solution of methyl <i>trans</i>-4-(carbobenzoxyamino)cyclohexanecarboxylate (3.00 g, 10.3 mmol) in Et<sub>2</sub>O (180 mL) at 0 °C was treated dropwise with MeMgBr, 3 M in Et<sub>2</sub>O (10.5 mL, 31.5 mmol). The white suspension was stirred at 0 °C for 90 min and then at room temperature for 21 h. The reaction mixture was treated with saturated aqueous NH<sub>4</sub>Cl (100 mL), and the phases were separated. The aqueous phase was extracted with Et<sub>2</sub>O (2 × 100 mL), and the combined organic phases were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. Purification by flash chromatography (0–100% EtOAc/hexane) gave benzyl ((1<i>R</i>,4<i>R</i>)-4-(2-hydroxypropan-2-yl)cyclohexyl)carbamate as a white solid (1.599 g, 5.49 mmol, 53%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.35 (m, 5H), 5.11 (s, 2H), 4.62 (br s, 1H), 3.46 (m, 1H), 2.12 (br d, <i>J</i> = 11.0 Hz, 2H), 1.89 (br d, <i>J</i> = 12.0 Hz, 2H), 1.31–1.09 (m, 11H).</div></div><div id="sec4_2_43_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> Step 3</h5><div class="NLM_p last">A suspension of benzyl (<i>trans</i>-4-(2-hydroxypropan-2-yl)cyclohexyl)carbamate (0.585 g, 2.01 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at −78 °C was treated with DBU (0.45 mL, 3.0 mmol) and XtalFluor-E (0.684 g, 2.99 mmol). The resulting pale yellow solution was stirred at −78 °C for 1 h and then at room temperature overnight. The resulting brown solution was treated with saturated aqueous NaHCO<sub>3</sub> (12 mL) and vigorously stirred for 15 min. The phases were separated, the aqueous phase was further extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic phases were filtered through plugs of MgSO<sub>4</sub> and silica and concentrated. Purification by flash chromatography (0–100% EtOAc/petroleum ether 40–60) gave benzyl ((1<i>R</i>,4<i>R</i>)-4-(2-fluoropropan-2-yl)cyclohexyl)carbamate as a yellow solid (0.486 g, 1.66 mmol, 82%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.35 (m, 5H), 5.11 (s, 2H), 4.61 (br s, 1H), 3.47 (m, 1H), 2.12 (br d, <i>J</i> = 11.5 Hz, 2H), 1.87 (br d, <i>J</i> = 12.7 Hz, 2H), 1.51 (m, 1H), 1.32 (d, <i>J</i> = 22.1 Hz, 6H), 1.28–1.09 (m, 4H).</div></div><div id="sec4_2_43_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Step 4</h5><div class="NLM_p last">A vessel containing a solution of (<i>trans</i>-4-(2-fluoropropan-2-yl)cyclohexyl)carbamate (0.360 g, 1.23 mmol) in ethanol (5 mL) was purged with three vacuum/argon cycles. Palladium on carbon (60 mg) was added, and the vessel was purged three times with vacuum/argon cycles and then three times with vacuum/hydrogen cycles. The mixture was stirred at room temperature for 3 days, then filtered through a plug of Celite, and concentrated to give (1<i>R</i>,4<i>R</i>)-4-(2-fluoropropan-2-yl)cyclohexanamine as a cloudy oil (0.180 g, 1.13 mmol, 92%), which was used without purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 2.54 (m, 1H), 1.85 (m, 2H), 1.74 (m, 2H), 1.43 (m, 3H), 1.22 (d, <i>J</i> = 22.1 Hz, 6H), 1.10–0.98 (m, 4H).</div></div></div><div id="sec4_2_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> <i>N</i>-(3-(<i>trans</i>-4-(2-Hydroxypropan-2-yl)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>60</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (165 mg, 0.75 mmol), 2-(<i>trans</i>-4-aminocyclohexyl)propan-2-ol (130 mg, 0.83 mmol), THF (6 mL), and carbonyldiimidazole (182 mg, 1.12 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as an off-white solid (54.9 mg, 0.153 mmol, 20%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.18 (s, 1H), 10.06 (s, 1H), 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.71 (m, 1H), 4.03 (s, 1H), 2.41 (qd, <i>J</i> = 12.4, 3.0 Hz, 2H), 2.04 (s, 3H), 1.90 (d, <i>J</i> = 13.1 Hz, 2H) 1.63 (d, <i>J</i> = 9.5 Hz, 2H), 1.25 (m, 2H), 1.15–1.01 (m, 9H). LC–MS <i>m</i>/<i>z</i>: 358 [M – H]<sup>−</sup>, <i>t</i><sub>R</sub> = 3.4 min.</div></div><div id="sec4_2_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>N</i>-(3-(<i>trans</i>-2-(<i>tert</i>-Butyl)-1,3-dioxan-5-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>61</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (110 mg, 0.50 mmol), <i>trans</i>-2-(<i>tert</i>-butyl)-1,3-dioxan-5-amine (see below) (80 mg, 0.50 mmol), THF (4 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as an off-white powder (96 mg, 0.29 mmol, 57%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.39 (s, 1H), 10.11 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 5.01 (m, 1H), 4.52 (dd appearing as t, <i>J</i> = 10.7 Hz, 2H), 4.22 (s, 1H), 4.12 (dd appearing as q, <i>J</i> = 5.3 Hz, 2H), 2.05 (s, 3H), 0.91 (s, 9H). LC–MS <i>m</i>/<i>z</i>: 276 [M – C<sub>5</sub>H<sub>11</sub>O + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.0 min.</div></div><div id="sec4_2_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>N</i>-(3-(<i>cis</i>-2-(<i>tert</i>-Butyl)-1,3-dioxan-5-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>62</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (110 mg, 0.50 mmol), <i>cis</i>-2-(<i>tert</i>-butyl)-1,3-dioxan-5-amine (see below) (80 mg, 0.50 mmol), THF (4 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (53.4 mg, 0.15 mmol, 36%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.29 (s, 1H), 10.09 (s, 1H), 8.21 (s, 1H), 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 5.09 (m, 1H), 4.32 (m, 3H), 4.12 (m, 2H), 2.04 (s, 3H), 0.88 (s, 9H). LC–MS <i>m</i>/<i>z</i>: 276 [M – C<sub>5</sub>H<sub>11</sub>O + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.7 min.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0043.gif" alt="" id="gr35" /></img></div></div><div id="sec4_2_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> <i>trans</i>-2-(<i>tert</i>-Butyl)-1,3-dioxan-5-amine and <i>cis</i>-2-(<i>tert</i>-Butyl)-1,3-dioxan-5-amine</h4><div id="sec4_2_47_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> Step 1</h5><div class="NLM_p last">A mixture of benzyl (1,3-dihydroxypropan-2-yl)carbamate (1.122 g, 4.98 mmol), trimethylacetaldehyde (1.03 mL, 9.48 mmol), toluenesulfonic acid monohydrate (52 mg, 0.27 mmol), and anhydrous magnesium sulfate (2.4 g, 20 mmol) in anhydrous THF (15 mL) was heated under reflux overnight. The mixture was cooled, treated with aqueous NaHCO<sub>3</sub> (20 mL), and stirred until effervescence ceased. The phases were separated, and the aqueous phase was extracted with diethyl ether (3 × 20 mL). The combined organic phases were washed with water and brine, dried (MgSO<sub>4</sub>), and concentrated to give a colorless oil. The oil was triturated with petroleum ether 40–60, and the resulting suspension was extracted with petroleum ether (3 × 50 mL) and filtered to remove the solid. The filtrate was concentrated to give a colorless waxy solid, benzyl (2-(<i>tert</i>-butyl)-1,3-dioxan-5-yl)carbamate (1.068 g, 3.64 mmol, 73%), as a ca. 1:1 mixture of <i>cis</i>- and <i>trans</i>-isomers, which was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 5H), 5.66 (d, <i>J</i> = 9.2 Hz, 0.5H), 5.17–5.10 (m, 2.5H), 4.56 (m, 0.5H), 4.22 (m, 1H), 4.16 (s, 0.5H), 4.00 (m, 1.5H), 3.89 (m, 1H), 3.64 (m, 0.5H), 3.30 (m, 1H), 0.93 (s, 9H).</div></div><div id="sec4_2_47_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> Step 2</h5><div class="NLM_p last">A vessel containing a solution of benzyl (2-(<i>tert</i>-butyl)-1,3-dioxan-5-yl)carbamate (1.027 g, 3.50 mmol, a mixture of diastereomers) in methanol (10 mL) was purged with three vacuum/argon cycles. Palladium on carbon (0.120 g) was added, and the vessel was purged three times with vacuum/argon cycles and then three times with vacuum/hydrogen cycles. The mixture was stirred at room temperature overnight, then filtered through a plug of Celite, and concentrated. The diastereomers were separated by flash chromatography on silica using a gradient elution of 0–10% methanol/ammonia in dichloromethane to give first the <i>trans</i>-product, <i>trans</i>-2-(<i>tert</i>-butyl)-1,3-dioxan-5-amine (0.218 g, 1.37 mmol, 39%) and then the <i>cis</i>-product, <i>cis</i>-2-(<i>tert</i>-butyl)-1,3-dioxan-5-amine (0.211 g, 1.33 mmol, 38%). <i>trans</i>-2-(<i>tert</i>-Butyl)-1,3-dioxan-5-amine <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 4.13 (ddd, <i>J</i> = 9.8, 4.9, 1.4 Hz, 2H), 3.99 (s, 1H), 3.19 (ddd appearing as td, <i>J</i> = 10.3, 1.3 Hz), 3.01 (m, 1H), 1.00 (br s, 2H), 0.91 (s, 9H). <i>cis</i>-2-(<i>tert</i>-Butyl)-1,3-dioxan-5-amine <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 4.12 (s, 1H), 3.90 (dd, <i>J</i> = 10.5, 1.7 Hz, 2H), 3.87 (dd, <i>J</i> = 10.5, 1.7 Hz, 2H), 2.65 (m, 1H), 1.83 (br s, 2H), 0.92 (s, 9H).</div></div></div><div id="sec4_2_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>N</i>-(3-(<i>trans</i>-4-(<i>tert</i>-Butoxy)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>63</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (165 mg, 0.75 mmol), <i>trans</i>-4-(<i>tert</i>-butoxy)cyclohexanamine (129 mg, 0.75 mmol), THF (6 mL), and carbonyldiimidazole (122 mg, 0.75 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the title compound as a white powder (76.2 mg, 0.20 mmol, 27%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.22 (s, 1H), 10.09 (s, 1H), 8.17 (d, <i>J</i> = 2.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.71 (m, 1H), 3.43 (m, 1H), 2.08 (s, 3H), 1.82 (d, <i>J</i> = 10.5 Hz, 1H), 1.56 (d, <i>J</i> = 11.2 Hz, 2H), 1.28 (m, 2H), 1.15 (m, 11H). LC–MS <i>m</i>/<i>z</i>: 372 [M – H]<sup>−</sup>, <i>t</i><sub>R</sub> = 3.8 min.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0044.gif" alt="" id="gr36" /></img></div></div><div id="sec4_2_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> <i>trans</i>-4-(<i>tert</i>-Butoxy)cyclohexanamine</h4><div id="sec4_2_49_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> Step 1</h5><div class="NLM_p last">A suspension of <i>trans</i>-4-(benzyloxycarbonylamino)cyclohexan-1-ol (2.50 g, 10.0 mmol) and zinc perchlorate hexahydrate (0.50 g, 1.34 mmol) in 1,2-dichloroethane (24 mL) was heated to 80 °C. A solution of Boc<sub>2</sub>O (6.0 g, 27.5 mmol) in 1,2-dichloroethane (6 mL) was added dropwise. The mixture was heated at 80 °C for 5.5 h and then cooled and treated with water (40 mL) and brine (20 mL). The mixture was extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated to give a white solid. The solid residue was extracted with petroleum ether 40–60 (100 mL), and this extract was concentrated to give benzyl ((1<i>R</i>,4<i>R</i>)-4-(<i>tert</i>-butoxy)cyclohexyl)carbamate as a white solid (1.465 g, 4.80 mmol, 48%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.35 (m, 5H), 5.11 (s, 2H), 3.48 (m, 1H), 3.37 (m, 1H), 2.04 (m, 2H), 1.83 (m, 2H), 1.43 (m, 2H), 1.22 (m, 2H), 1.20 (s, 9H).</div></div><div id="sec4_2_49_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> Step 2</h5><div class="NLM_p last">A vessel containing a solution of the benzyl ((<i>trans</i>-4-(<i>tert</i>-butoxy)cyclohexyl)carbamate (0.506 g, 1.66 mmol) in methanol (5 mL) was purged with three vacuum/argon cycles. Palladium on carbon (70 mg) was added, and the vessel was purged three times with vacuum/argon cycles and then three times with vacuum/hydrogen cycles. The mixture was stirred at room temperature for 3 days, then filtered through a plug of Celite, and concentrated to give (1<i>R</i>,4<i>R</i>)-4-(<i>tert</i>-butoxy)cyclohexanamine as a waxy white solid (0.152 g, 0.887 mmol, 53%), which was used without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 3.36 (m, 1H), 2.70 (m, 1H), 1.99 (s, 2H), 1.87 (m, 2H), 1.81 (m, 2H), 1.35 (m, 2H), 1.21 (m, 2H), 1.20 (s, 9H).</div></div></div><div id="sec4_2_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> <i>N</i>-(3-(<i>trans</i>-4-Isopropoxycyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>64</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (154 mg, 0.70 mmol), (1<i>R</i>,4<i>R</i>)-4-isopropoxycyclohexanamine (110 mg, 0.70 mmol), THF (5.6 mL), and carbonyldiimidazole (170 mg, 1.05 mmol) to give the title compound as a brown powder (39.3 mg, 0.11 mmol, 16%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.28 (s, 1H), 10.10 (s, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.73 (m, 1H), 3.71 (septet, <i>J</i> = 6.0 Hz, 1H), 3.32 (m, 1H), 2.49 (m, 2H), 2.04 (s, 3H), 1.98 (d, <i>J</i> = 11.2 Hz, 2H), 1.58 (d, <i>J</i> = 10.6 Hz, 2H), 1.22 (m, 2H), 1.08 (d, <i>J</i> = 6.0 Hz, 9H). LC–MS <i>m</i>/<i>z</i>: 358 [M – H]<sup>−</sup>, <i>t</i><sub>R</sub> = 4.0 min.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0045.gif" alt="" id="gr37" /></img></div></div><div id="sec4_2_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>trans</i>-4-Isopropoxycyclohexanamine</h4><div id="sec4_2_51_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> Step 1</h5><div class="NLM_p last">A suspension of <i>trans</i>-4-(benzyloxycarbonylamino)cyclohexan-1-ol (1.91 g, 7.66 mmol) and isopropyl trichloroacetimidate (3.22 g, 15.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was treated with trifluoroacetic acid (0.090 mL, 1 mmol) and stirred at room temperature for 3 days. Further isopropyl trichloroacetimidate (1 g, 5 mmol) and trifluoroacetic acid (8 drops) were added, and the reaction was stirred for a further day and then treated with aqueous NaHCO<sub>3</sub> (50 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The organic phases were concentrated to give a yellow solid, which was extracted with Et<sub>2</sub>O (3 × 50 mL). The combined ethereal extracts were concentrated and purified by flash chromatography (0–20% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) to give benzyl (<i>trans</i>-4-isopropoxycyclohexyl)carbamate as a yellow solid (0.206 g, 0.71 mmol, 9%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.34 (m, 5H), 5.11 (s, 2H), 3.70 (septet, <i>J</i> = 6.1 Hz, 1H), 3.52 (m, 1H), 3.29 (m, 1H), 2.06 (m, 2H), 1.97 (m, 2H), 1.39 (m, 2H), 1.19 (m, 2H), 1.15 (d, <i>J</i> = 6.1 Hz, 6H).</div></div><div id="sec4_2_51_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> Step 2</h5><div class="NLM_p last">A vessel containing a solution of the benzyl (<i>trans</i>-4-isopropoxycyclohexyl)carbamate (0.186 g, 0.64 mmol) in ethanol (2 mL) was purged with three vacuum/argon cycles. Palladium on carbon (32 mg) was added, and the vessel was purged three times with vacuum/argon cycles and then three times with vacuum/hydrogen cycles. The mixture was stirred at room temperature overnight, then filtered through a plug of Celite, and concentrated to give <i>trans</i>-4-isopropoxycyclohexanamine as a waxy solid (0.124 g, 0.79 mmol, >100% crude yield), which was used without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 3.61 (septet, <i>J</i> = 6.1 Hz, 1H), 3.22 (m, 1H), 2.81 (m, 1H), 1.91 (m, 4H), 1.24 (m, 4H), 1.06 (d, <i>J</i> = 6.1 Hz, 6H).</div></div></div><div id="sec4_2_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (<i>±</i>)<i>N</i>-(3-(<i>cis</i>-2-(<i>tert</i>-Butyl)tetrahydro-2<i>H</i>-pyran-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>65</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>N</i>-(2,4-dioxo-2,4-dihydro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (166 mg, 0.75 mmol), (±)<i>cis</i>-2-(<i>tert</i>-butyl)tetrahydro-2<i>H</i>-pyran-4-amine (117 mg, 0.74 mmol), THF (6 mL), and carbonyldiimidazole (183 mg, 1.13 mmol). Purification by flash chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave the racemic title compound as a yellow solid (143 mg, 0.40 mmol, 53%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.30 (s, 1H), 10.10 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 5.00 (m, 1H), 4.04 (dd, <i>J</i> = 11.3, 3.8 Hz, 1H), 3.40 (m, 1H), 2.96 (dd, <i>J</i> = 11.2, 1.4 Hz, 1H), 2.59 (dq, <i>J</i> = 4.8, 12.2 Hz, 1H), 2.36 (q, <i>J</i> = 12.2 Hz, 1H), 2.04 (s, 3H), 1.57 (m, 1H), 1.48 (m, 1H), 0.88 (s, 9H). LC–MS <i>m</i>/<i>z</i>: 360 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0046.gif" alt="" id="gr38" /></img></div></div><div id="sec4_2_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> (<i>±</i>)<i>cis</i>-2-(<i>tert</i>-Butyl)tetrahydro-2<i>H</i>-pyran-4-amine</h4><div id="sec4_2_53_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> Step 1</h5><div class="NLM_p last">A solution of trimethylacetaldehyde (2.2 mL, 20 mmol) and 3-buten-1-ol (1.7 mL, 20 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was cooled to 0 °C and treated with trifluoroacetic acid (5 mL). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was concentrated, redissolved in MeOH (20 mL), and cooled to 0 °C. Solid potassium carbonate (3.6 g) was added portionwise, and the mixture was stirred at room temperature for 5 h before being concentrated. The residue was extracted with Et<sub>2</sub>O (100 mL) and concentrated to give 2-(<i>tert</i>-butyl)tetrahydro-2<i>H</i>-pyran-4-ol as a colorless oil, which was used without further purification (2.868 g, 18.1 mmol, 91%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 4.04 (ddd, <i>J</i> = 11.7, 5.0, 1.6 Hz, 1H), 3.77 (m, 1H), 3.36 (td, <i>J</i> = 12.2, 2.1 Hz, 1H), 2.88 (dd, <i>J</i> = 11.4, 1.7 Hz, 1H), 1.97 (m, 1H), 1.88 (m, 1H), 1.76 (br s, 1H), 1.48 (m, 1H), 1.22 (m, 1H), 0.92 (s, 9H).</div></div><div id="sec4_2_53_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> Step 2</h5><div class="NLM_p">A solution of 2-(<i>tert</i>-butyl)tetrahydro-2<i>H</i>-pyran-4-ol (1.007 g, 6.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (125 mL) was treated with Dess–Martin Periodinane (4.04 g, 9.53 mmol) and stirred at room temperature for 3 days. Saturated aqueous NaHCO<sub>3</sub> (100 mL) and 20% aqueous sodium thiosulfate (100 mL) were then added, and the mixture was vigorously stirred for 1 h. The phases were separated, and the aqueous phase was extracted with further CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic extracts were concentrated to give a yellow oil, which was purified by flash chromatography (0–100% Et<sub>2</sub>O/hexane) to give 2-(<i>tert</i>-butyl)dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one as a colorless oil (0.648 g, 4.15 mmol, 65%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 4.32 (ddd, <i>J</i> = 11.4, 7.6, 1.0 Hz, 1H), 3.61 (ddd, <i>J</i> = 14.1, 11.4, 2.7 Hz, 1H), 3.20 (dd, <i>J</i> = 11.5, 2.7 Hz, 1H), 2.58 (m, 1H), 2.42–2.29 (m, 3H), 0.95 (s, 9H).</div><div class="NLM_p last">2-(<i>tert</i>-Butyl)dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one was converted into (±)<i>cis</i>-2-(<i>tert</i>-butyl)tetrahydro-2<i>H</i>-pyran-4-amine and (<i>±</i>)<i>trans</i>-2-(<i>tert</i>-butyl)tetrahydro-2<i>H</i>-pyran-4-amine, following General Procedure C, which were used without purification. (<i>±</i>)<i>cis-</i>2<i>-</i>(<i>tert</i>-Butyl)tetrahydro-2<i>H</i>-pyran-4-amine <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 4.04 (m, 1H), 3.39 (t, <i>J</i> = 12.0 Hz, 1H), 2.89 (m, 1H), 1.84 (d, <i>J</i> = 12.4 Hz, 1H), 1.75 (d, <i>J</i> = 12.7 Hz, 1H), 1.49 (br s, 2H), 1.21 (m, 1H), 0.96 (m, 1H), 0.83 (s, 9H).</div></div></div><div id="sec4_2_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> <i>N</i>-(3-(1-<i>tert</i>-Butyl)piperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>66</b>)</h4><div class="NLM_p last">The compound was prepared using General Procedure B, using (1-<i>tert</i>-butyl)piperidin-4-amine (104.8 mg). Upon reaction completion, the mixture was diluted with water and extracted with EtOAc. The desired product remained in the aqueous layer, which was concentrated. Upon the addition of MeOH, the title compound precipitated as a white powder (10 mg, 0.028 mmol, 4%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.41 (s, 1H), 10.21 (s, 1H), 8.26 (s, 1H), 7.80 (d, <i>J</i> = 8.2 Hz, 1H), 7.14 (d, <i>J</i> = 8.5 Hz, 1H), 5.10 (bs, 1H), 3.58 (bs, 2H), 3.11 (bs, 2H), 2.97–2.94 (m, 2H), 2.05 (s, 3H), 1.87 (d, <i>J</i> = 11.3 Hz, 2H), 1.38 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.3, 149.9, 116.7, 115.2, 62.8, 48.2, 46.3, 25.4, 24.1, 23.8; LC–MS <i>m</i>/<i>z</i>: 359 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.3 min</div></div><div id="sec4_2_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> <i>tert</i>-Butyl 4-(6-Acetamido-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)piperidine-1-carboxylate (<b>67</b>)</h4><div class="NLM_p last">The compound was prepared using General Procedure B; <i>tert</i>-butyl-4-aminopiperidine-1-carboxylate (1.80 g, 8.99 mmol) gave the title compound as an off-white powder (2.90 g, 7.21 mmol, 79%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.32 (s, 1H), 10.10 (s, 1H), 8.20 (d, <i>J</i> = 2.1 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 4.39 (t, <i>J</i> = 11.9 Hz, 1H), 4.06 (bs, 2H), 2.80 (m, 2H), 2.46 (m, 2H), 2.04 (s, 3H), 1.57 (d, <i>J</i> = 10.4 Hz, 2H), 1.43 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 162.1, 153.7, 149.7, 135.0, 134.2, 126.6, 116.6, 115.2, 114.0, 78.7, 50.8, 28.0, 27.4, 23.8. LC–MS <i>m</i>/<i>z</i>: 292 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 0.6 min.</div></div><div id="sec4_2_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> <i>N</i>-(2,4-Dioxo-3-(piperidin-4-yl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide, TFA Salt (<b>114</b>)</h4><div class="NLM_p last">Carbamate <b>67</b> (2.87 g, 7.13 mmol) was suspended in 20% TFA/CH<sub>2</sub>Cl<sub>2</sub> (60 mL) and stirred at room temperature overnight. The solvent was then removed <i>in vacuo</i>. The salt was resuspended in CH<sub>2</sub>Cl<sub>2</sub>/MeOH and reconcentrated. Finally CH<sub>2</sub>Cl<sub>2</sub> was added, and the precipitate was filtered and dried to give the title compound as a white powder (2.56 g, 6.15 mmol, 86%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.40 (bs, 1H), 10.14 (s, 1H), 8.54 (bs, 1H), 8.25 (d, <i>J</i> = 2.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 5.06 (m, 1H), 3.39–3.35 (m, 1H), 3.17 (s, 1H), 3.06 (m, 2H), 2.80 (dq, <i>J</i> = 16.8, 3.8 Hz, 2H), 2.05 (s, 3H), 1.80 (d, <i>J</i> = 12.3 Hz, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 162.2, 149.9, 135.0, 134.3, 126.6, 116.6, 115.2, 114.0, 48.5, 48.1, 43.4, 24.8, 23.8. <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.5. LC–MS <i>m</i>/<i>z</i>: 303 [M + H]<sup>+</sup>, 605 [2M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.4 min; HRMS (ES<sup>+</sup>): found 303.1442 [M + H]<sup>+</sup>; C<sub>15</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, requires 303.1452.</div></div><div id="sec4_2_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> <i>N</i>-(3-(1-Benzoylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>68</b>)</h4><div class="NLM_p last">TFA salt <b>114</b> (0.150 mg, 0.361 mmol) was suspended in pyridine (2 mL), followed by the addition of benzoyl chloride (60.87 mg, 0.433 mmol), and the mixture was stirred at room temperature overnight. Purification was carried out by semipreparative HPLC (Waters, basic mode, 5:95 MeCN/water + 0.1% NH<sub>3</sub>) to give the title compound as an off-white powder (26 mg, 0.064 mmol, 18%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.30 (s, 1H), 10.08 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.50–7.47 (m, 3H), 7.41–7.39 (m, 2H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 5.06 (m, 1H), 4.63 (bs, 1H), 3.67 (bs, 1H), 3.19–3.17 (m, 1H), 2.85–2.80 (m, 1H), 2.05 (s, 3H), 1.71–1.59 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.9, 168.2, 162.1, 155.3, 149.9, 136.1, 134.2, 132.8, 128.4, 126.5, 117.9, 116.6, 115.2, 114.3, 114.0, 50.63, 41.4, 27.3, 23.8. LC–MS <i>m</i>/<i>z</i>: 407 [M + H]<sup>+</sup>, 813 [2M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.4 min.</div></div><div id="sec4_2_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> <i>N</i>-(2,4-Dioxo-3-(1-(phenylsulphonyl)piperidin-4-yl)-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide (<b>69</b>)</h4><div class="NLM_p last">TFA salt <b>114</b> (0.150 mg, 0.361 mmol) was suspended in pyridine (2 mL), followed by the addition of benzene sulphonyl chloride (76.48 mg, 0.433 mmol), and the mixture was stirred at room temperature overnight. Purification was carried out by semipreparative HPLC (Waters, basic mode, 5:95 MeCN/water + 0.1% NH<sub>3</sub>) to give the title compound as a white powder (6 mg, 0.014 mmol, 4%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.29 (s, 1H), 10.06 (s, 1H), 8.17(d, <i>J</i> = 2.4 Hz, 1H), 7.81–7.74 (m, 4H), 7.69–7.66 (m, 2H), 7.08 (d, <i>J</i> = 8.8, 1H), 4.73–4.68 (m, 1H), 3.81–3.79 (m, 2H), 2.67 (dd, <i>J</i> = 12.6, 4.4 Hz, 1H), 2.63 (dd, <i>J</i> = 12.4, 4.0 Hz, 1H), 2.37–2.32 (m, 2H), 2.04 (s, 3H), 1.66–1.64 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.1, 162.1, 149.9, 135.7, 135.1, 134.2, 133.0, 129.3, 127.3, 126.5, 116.6, 115.3, 114.0, 49.8, 46.2, 26.8, 23.8. LC–MS <i>m</i>/<i>z</i>: 443 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.8 min.</div></div><div id="sec4_2_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> <i>tert</i>-Butyl(<i>cis</i>-4-(6-acetamido-2,4-dihydroquinazolin-3(4<i>H</i>)-yl)cyclohexyl)carbamate (<b>70</b>)</h4><div class="NLM_p last">The compound was prepared following General Procedure B, using <i>cis</i>-<i>tert</i>-butyl-4-aminocyclohexyl)carbamate (144.5 mg). Purification by flash chromatography (0–80% EtOAc/hexane) gave the title compound as a white/pale pink powder (176 mg, 0.423 mmol, 62%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.24 (s, 1H), 10.07 (s, 1H), 8.21 (d, <i>J</i> = 2.1 Hz, 1H), 7.78 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.10 (d, <i>J</i> = 8.7, 1H), 6.50 (bs, 1H), 4.73 (tt, <i>J</i> = 12.2, 3.4 Hz, 1H), 3.58 (bs, 1H), 2.65–2.58 (m, 2H), 2.05 (s, 3H), 1.90 (d, <i>J</i> = 13.2 Hz, 2H), 1.55–1.47 (m, 2H), 1.43 (s, 9H), 1.39–1.35 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.1, 162.1, 155.0, 149.9, 135.0, 134.1, 126.5, 116.5, 115.1, 114.1, 77.5, 52.3, 44.3, 29.4, 28.2, 23.8, 22.9.</div></div><div id="sec4_2_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> <i>tert</i>-Butyl 3-(6-Acetamido-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)pyrrolidine-1-carboxylate (<b>71</b>)</h4><div class="NLM_p">Following General Procedure D, 5-acetamido-2-aminobenzoic acid (200 mg, 1.03 mmol), (<i>S</i>)-1-boc-3-aminopyrrolidine (59.00 μL, 0.338 mmol), and (<i>R</i>)-1-Boc-3-aminopyrrolidine (57.33 μL, 0.338 mmol) were combined in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at room temperature, followed by the addition of DIPEA (15.79 mg, 0.156 mmol); the mixture was stirred. A 50% solution of propylphosphonic anhydride in EtOAc (399.1 mg, 1.25 mmol) was added dropwise, and the reaction was stirred at room temperature overnight. The resultant mixture was washed with aq NaHCO<sub>3</sub>, water, dried (MgSO<sub>4</sub>), and concentrated. This was suspended in THF (15 mL); CDI (251 mg, 1.55 mmol) was added, and the reaction was heated to 100 °C overnight. Upon cooling, the mixture was concentrated and purified by flash chromatography (0–5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give the racemic title compound as a light brown powder (16 mg, 0.041 mmol, 6%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.09 (s, 1H), 10.11 (s, 1H), 8.23 (d, <i>J</i> = 2.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.64 (s, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 5.56 (quintet, <i>J</i> = 8.3 Hz, 1H), 3.66–3.62 (m, 2H), 3.60–3.33 (m, 2H + MeOD), 2.05 (s, 3H), 1.43–1.40 (m, 11H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 162.2, 153.4, 149.8, 134.9, 134.2, 126.6, 116.6, 115.3, 114.0, 78.25, 77.91, 49.9, 49.2, 46.3, 45.0, 44.6, 44.1, 43.9, 28.1, 27.5, 26.5, 23.8. LC–MS <i>m</i>/<i>z</i>: 378 [M-boc + H]<sup>+</sup>, 755 [2M-boc + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.2 min.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0047.gif" alt="" id="gr39" /></img></div><div id="sec4_2_60_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> Step a: 2,5-Diamino-<i>N</i>-(4-<i>tert</i>-butyl-cyclohexyl)-benzamide</h5><div class="NLM_p last">DMAP (0.04 g, 0.3 mmol) was added to a cooled (0 °C) solution of a <i>cis</i>/<i>trans</i>-mix of 4-<i>tert</i>-butylcyclohexyl amine (1.2 g, 8.5 mmol) in DMF (10 mL), followed by the addition of 5-aminoisatoic anhydride (1g, 5.6 mmol). The solution was stirred for 3 h at room temperature and then concentrated under reduced pressure. Water (10 mL) was added, and the mixture was stirred and extracted with EtOAc (3 × 20 mL). The combined organics were concentrated under reduced pressure, and the afforded crude was taken to the next step without further purification. MS: <i>m</i>/<i>z</i> 288 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_60_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> Step b: 6-Amino-3-(4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (A Mixture of Diastereomers)</h5><div class="NLM_p last">The crudeamine from step a (0.9 g, 3.13 mmol) and ethyl chloroformate (3.4 mL) was heated at 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the crude was dissolved in EtOH (33 mL). KOH (0.36 g, 6.26 mmol) was added, and the mixture was heated at 85 °C overnight. The solvent was removed under reduced pressure; water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The afforded crude was purified by flash column chromatography on silica gel, which gave the title compound as a mixture of <i>cis</i>- and <i>trans</i>-isomers (0.3 g, 30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.90 + 10.88 (s, 1H, each), 7.08 (d, <i>J</i> = 2 Hz, 1H), 6.92–6.85 (m, 2H), 5.15 (br s, 2H), 4.91 + 4.69 (m, 1H, each), 2.55–2.32 (m, 2H), 1.84–1.81 (m, 1H), 1.71–1.68 (m, 1H), 1.61–1.58 (m, 1H), 1.49–1.42 (m, 2H), 1.35–1.2 (m, 1H), 1.14–1.05 (m, 1H), 0.90 + 0.86 (s, 9H, each). MS: <i>m</i>/<i>z</i> 316 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_60_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> Separation of Diastereomers</h5><div class="NLM_p last">The two diastereomers were separated by chiral prep. HPLC using a CHIRAL Phenomenox Lux Cellulose-4 (250 × 4.6) mm, 5 μm, flow = 1.0 mL/min, mobile phase A = hexanes/EtOH (70:30);</div></div></div><div id="sec4_2_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> 6-Amino-3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (<b>89</b>)</h4><div class="NLM_p last">Chiral HPLC: <i>t</i><sub>R</sub> = 10.41 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.90 (s, 1H), 7.08 (s, 1H), 6.93–6.85 (m, 2H), 5.17 (br s, 2H), 4.73–4.65 (m, 1H), 2.50–2.40 (m, 2H), 1.84–1.80 (m, 2H), 1.62–1.58 (m, 2H), 1.10–1.04 (m, 3H), 0.86 (s, 9H).</div></div><div id="sec4_2_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> 6-Amino-3-(<i>cis</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (<b>90</b>)</h4><div class="NLM_p last">Chiral HPLC: <i>t</i><sub>R</sub> = 8.19 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.88 (s, 1H), 7.08 (s, 1H), 6.93–6.85 (m, 2H), 5.14 (br s, 2H), 4.92–4.85 (m, 1H), 2.40–2.25 (m, 2H), 1.75–1.65 (m, 2H), 1.55–1.40 (m, 4H), 1.35–1.25 (m, 1H), 0.90 (s, 9H).</div></div><div id="sec4_2_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Alternative Route for the Synthesis of 6-Amino-3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (<b>89</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0048.gif" alt="" id="gr40" /></img><div id="sec4_2_63_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> Step a: 5-Acetylamino-2-amino-<i>N</i>-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-benzamide</h5><div class="NLM_p last">Et<sub>3</sub>N (3.57 mL, 26 mmol) and <i>N</i>-(2,4-dioxo-1,4-dihydro-2<i>H</i>-benzo[<i>d</i>][1,3]oxazin-6-yl)acetamide (5 g, 22 mmol) were added to a solution of <i>trans</i>-4-<i>tert</i>-butyl-cyclohexylamine hydrochloride (6.5 g, 34 mmol) in DMF (40 mL) at 0 °C. The solution was stirred at room temperature for 3 h and then concentrated under reduced pressure, followed by addition of water and extraction with EtOAc (3 × 100 mL). The combined organics were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The afforded crude was purified by flash column chromatography on silica gel, which gave the title compound (3.6 g, 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.57 (s, 1H), 7.93 (d, <i>J</i> = 2.4 Hz, 1H), 7.39 (d, <i>J</i> = 2.4 Hz, 1H), 7.33 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.60 (d, <i>J</i> = 8.4 Hz, 1H), 5.91 (s, 2H), 3.64–3.60 (m, 1H), 1.95 (s, 3H), 1.86–1.84 (m, 2H), 1.76–1.73 (m, 2H), 1.32–1.21 (m, 2H), 1.09–0.9 (m, 3H), 0.84 (s, 9H). MS: <i>m</i>/<i>z</i> 332 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_63_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> Step b: 6-Amino-3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (<b>89</b>)</h5><div class="NLM_p last">The intermediate above (3.2 g, 9.6 mmol) was taken up in ethyl chloroformate (11.84 mL) and heated to 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the crude was dissolved in EtOH (64 mL), followed by the addition of KOH (4.4 g, 77 mmol) and heating at 85 °C for 16 h. The solvent was removed under reduced pressure, followed by the addition of water (100 mL) and extraction with EtOAc (3 × 100 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash column chromatography on silica gel, which gave the title compound (1.4 g, 46%) as a brown colored solid.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0049.gif" alt="" id="gr41" /></img></div></div></div><div id="sec4_2_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> 6-Amino-3-(4-isopropylcyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (Mixture of Diastereomers)</h4><div class="NLM_p last">The title compound was prepared from 5-aminoisatoic anhydride (1 g, 5.6 mmol) and 4-isopropylcyclohexyl amine (<i>cis</i>/<i>trans</i> mixture, 1.18 g, 8.5 mmol) according to the procedure described for <b>89</b> and <b>90</b> in the above steps a and b (0.4 g, 53%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.89 and 10.86 (s, 1H, each), 7.08 (s, 1H), 6.93–6.85 (m, 2H), 5.15 (s, 2H), 4.76–4.69 (m, 1H), 2.50–2.41 (m, 2H), 2.0–1.60 (m, 2H), 1.59–1.56 (m, 2H), 1.50–1.25 (m, 1H), 1.07–1.03 (m, 3H), 0.90 and 0.86 (d each, <i>J</i> = 6.8 Hz, 6H). MS: <i>m</i>/<i>z</i> 302 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> 6-Amino-3-(<i>trans</i>-4-isopropylcyclohexyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>91</b>)</h4><div class="NLM_p last">The <i>trans</i>-isomer was isolated by chiral prep HPLC using a CHIRAL PAK IC (250 × 4.6) mm, 5 μ, flow = 1.0 mL/min, mobile phase A = hexanes/IPA (90:10), <i>t</i><sub>R</sub> = 13.72 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.89 (s, 1H), 7.08 (d, <i>J</i> = 2.4 Hz, 1H), 6.93–6.8 (m, 2H), 5.15 (m, 2H), 4.73–4.65 (m, 1H), 2.50–2.40 (m, 2H), 1.77–1.75 (m, 2H), 1.59–1.56 (m, 2H), 1.45 (br m, 1H), 1.07–1.03 (m, 3H), 0.86 (d, <i>J</i> = 6.8 Hz, 6H). MS: <i>m</i>/<i>z</i> 302 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> 6-Amino-3-(4-ethyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione, <i>cis</i>/<i>trans</i> Mixture (Mixture of Diastereomers) (<b>92</b> and <b>93</b>)</h4><div class="NLM_p">The title compound was prepared from 5-aminoisatoic anhydride (1 g, 5.6 mmol) and 4-ethylcyclohexyl amine (<i>cis</i>, <i>trans</i> mix, 1.17 g, 8.5 mmol) according to the procedure described for <b>89</b> and <b>90</b> in the above steps a and b. Yield: 0.4 g, 51%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.89 and 10.88 (s, 1H, each), 7.08 (d, <i>J</i> = 2 Hz, 1H), 6.93–6.85 (m, 2H), 5.15 (s, 2H), 4.75–4.68 (m, 1H), 2.45–2.39 (m, 2H), 1.83–1.80 and 1.70–1.67 (m, 2H, each), 1.56–1.46 (m, 3H), 1.41–1.31 (m, 2H), 1.31–1.28 and 1.20 and 1.14 (m, 3H, each), 1.02–0.95 (m, 1H), 0.90–0.88 (m, 3H). MS: <i>m</i>/<i>z</i> 288 [M + 1]<sup>+</sup>.</div><div class="NLM_p last">The two diastereomers were separated by chiral prep. HPLC using a CHIRAL Phenomenox Lux Cellulose-4 (250 × 4.6) mm, 5 μm, flow = 1.0 mL/min, mobile phase A = hexanes/EtOH (70:30).</div></div><div id="sec4_2_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> 6-Amino-3-(<i>trans</i>-4-ethyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (<b>92</b>)</h4><div class="NLM_p last">Chiral HPLC: <i>t</i><sub>R</sub> = 8.32 min. <sup>1</sup>H NMR (400 MHz, MeOD,): δ 7.30 (d, <i>J</i> = 2.8 Hz, 1H), 7.07 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 6.94 (d, <i>J</i> = 8.8 Hz, 1H), 4.85–4.81 (m, 1H), 2.60–2.50 (m, 2H), 1.93–1.90 (m, 2H), 1.67–1.64 (m, 2H), 1.32–1.26 (m, 3H), 1.12–1.04 (m, 2H), 0.94 (t, <i>J</i> = 8 Hz, 3H).</div></div><div id="sec4_2_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> 6-Amino-3-(<i>cis</i>-4-ethyl-cyclohexyl)-1<i>H</i>-quinazoline-2,4-dione (<b>93</b>)</h4><div class="NLM_p last">Chiral HPLC: <i>t</i><sub>R</sub> = 7.32 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.87 (s, 1H), 7.07 (d, <i>J</i> = 2 Hz, 1H), 6.94–6.85 (m, 2H), 5.15 (s, 2H), 4.76–4.69 (m, 1H), 2.60–2.50 (m, 2H), 1.71–1.67 (m, 2H), 1.53–1.45 (m, 5H), 1.32–1.25 (m, 2H), 0.88 (t, <i>J</i> = 7 Hz, 3H).</div></div><div id="sec4_2_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> <i>N</i>-[3-(<i>trans</i>-4-<i>tert</i>-Butyl-cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrido[2,3-<i>d</i>]pyrimidin-6-yl]-acetamide (<b>94</b>)</h4><div class="NLM_p last">See General Procedure F.</div></div><div id="sec4_2_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> <i>N</i>-(3-(<i>cis</i>-4-(<i>tert</i>-Butyl)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (<b>95</b>)</h4><div class="NLM_p last">The compound was prepared from <b>108</b> according to General Procedure F. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.79 (s, 1H), 10.29 (s, 1H), 8.67 (d, <i>J</i> = 2.4 Hz, 1H), 8.55 (d, <i>J</i> = 2.4 Hz, 1H), 4.89–4.86 (m, 1H), 2.20–2.32 (m, 2H), 2.08 (s, 3H), 1.76–1.70 (m, 2H), 1.52–1.46 (m, 4H), 1.33–1.30 (m, 1H), 0.86 (s, 9H). MS: <i>m</i>/<i>z</i> 359 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> <i>N</i>-(3-(<i>trans</i>-4-Isopropylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (<b>96</b>)</h4><div class="NLM_p last">The compound was prepared from <b>109</b> according to General Procedure F. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.79 (s, 1H), 10.29 (s, 1H), 8.68 (d, <i>J</i> = 2.4 Hz, 1H), 8.54 (d, <i>J</i> = 2.4 Hz, 1H), 4.75–4.60 (m, 1H), 2.41–2.37 (m, 2H), 2.07 (s, 3H), 1.77 (m, 2H), 1.65–1.61 (m, 2H), 1.44 (m, 1H), 1.17–1.08 (m, 3H), 0.86 (d, <i>J</i> = 8 Hz, 6H). MS: <i>m</i>/<i>z</i> 345 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> <i>N</i>-(3-(<i>cis</i>-4-Isopropylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (<b>97</b>)</h4><div class="NLM_p last">The compound was prepared from <b>110</b> according to General Procedure F. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.80 (s, 1H), 10.29 (s, 1H), 8.66 (d, <i>J</i> = 2.4 Hz, 1H), 8.54 (d, <i>J</i> = 2.4 Hz, 1H), 4.76–4.72 (m, 1H), 2.49–2.40 (m, 2H), 2.07 (s, 3H), 1.98–1.86 (m, 3H), 1.42–1.30 (m, 4H), 1.17–1.14 (m, 1H), 0.89 (d, <i>J</i> = 8 Hz, 6H). MS: <i>m</i>/<i>z</i> 345 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> <i>N</i>-(3-(<i>trans</i>-4-Ethylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (<b>98</b>)</h4><div class="NLM_p last">The compound was prepared from <b>111</b> according to General Procedure F. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.79 (s, 1H), 10.30 (s, 1H), 8.68 (d, <i>J</i> = 2 Hz, 1H), 8.54 (d, <i>J</i> = 2 Hz, 1H), 4.72–4.65 (m, 1H), 2.41–2.37 (m, 2H), 2.08 (s, 3H), 1.83–1.80 (m, 2H), 1.58–1.55 (m, 2H), 1.25–1.10 (m, 3H), 1.0–0.9 (m, 2H), 0.87 (t, <i>J</i> = 7.2 Hz, 3H). MS: <i>m</i>/<i>z</i> 331 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> <i>N</i>-(3-(<i>cis</i>-4-Ethylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (<b>99</b>)</h4><div class="NLM_p last">The compound was prepared from <b>112</b> according to General Procedure F. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.80 (s, 1H), 10.29 (s, 1H), 8.68 (s, 1H), 8.55 (s, 1H), 4.67–4.70 (m, 1H), 2.51–2.49 (m, 2H), 2.08 (s, 3H), 1.71–1.67 (m, 2H), 1.54–1.48 (m, 5H), 1.37–1.30 (m, 2H), 0.88 (t, <i>J</i> = 6.8 Hz, 3H). MS: <i>m</i>/<i>z</i> 331 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> <i>N</i>-(3-(2-Cyclohexylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (<b>100</b>)</h4><div class="NLM_p last">This compound was prepared according to General Procedures E and F from cyclohexylethylamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.88 (s, 1H), 10.30 (s, 1H), 8.69 (d, <i>J</i> = 2.4 Hz, 1H), 8.57 (d, <i>J</i> = 2.4 Hz, 1H), 3.90–3.87 (m, 2H), 2.08 (s, 3H), 1.76–1.64 (m, 5H), 1.47–1.44 (m, 2H), 1.22–1.11 (m, 4H), 0.95–0.87 (m, 2H). MS: <i>m</i>/<i>z</i> 331 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> 2-Amino-5-nitronicotinic Acid Methyl Ester (<b>102</b>)</h4><div class="NLM_p last">See General Procedure E.</div></div><div id="sec4_2_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> 2-Amino-<i>N</i>-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-5-nitro-nicotinamide (<b>103</b>)</h4><div class="NLM_p last">See General Procedure E.</div></div><div id="sec4_2_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> 3-(<i>trans</i>-4-<i>tert</i>-Butyl-cyclohexyl)-6-nitro-1<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-2,4-dione (<b>104</b>)</h4><div class="NLM_p last">See General Procedure E.</div></div><div id="sec4_2_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> 6-Amino-3-(<i>trans</i>-4-<i>tert</i>-butyl-cyclohexyl)-1<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-2,4-dione (<b>107</b>)</h4><div class="NLM_p last">See General Procedure E.</div></div><div id="sec4_2_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> 6-Amino-3-(<i>cis</i>-4-(<i>tert</i>-butyl)-cyclohexyl)pyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>108</b>)</h4><div class="NLM_p last">This compound was prepared according to General Procedure E using <i>cis</i>-4-(<i>tert</i>-butyl)-cyclohexanamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.37 (s, 1H), 8.01 (d, <i>J</i> = 2.8 Hz, 1H), 7.44 (d, <i>J</i> = 2.8 Hz, 1H), 5.37 (s, 2H), 4.92–4.84 (m, 1H), 2.33–2.30 (m, 2H), 1.72–1.68 (m, 4H), 1.32–1.31 (m, 1H), 1.33–1.30 (m, 1H), 0.90 (s, 9H). MS: <i>m</i>/<i>z</i> 317 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> 6-Amino-3-(<i>trans</i>-4-isopropylcyclohexyl)pyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>109</b>)</h4><div class="NLM_p last">This compound was prepared according to General Procedure E using <i>trans</i>-4-isopropyl-cyclohexanamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.37 (s, 1H), 8.01 (d, <i>J</i> = 2.8 Hz, 1H), 7.44 (d, <i>J</i> = 2.8 Hz, 1H), 5.37 (s, 2H), 4.70–4.63 (m, 1H), 2.45–2.34 (m, 2H), 1.78–1.74 (m, 2H), 1.62–1.50 (m, 2H), 1.45–1.43 (m, 1H), 1.08–1.04 (m, 3H), 0.86 (d, <i>J</i> = 8 Hz, 6H). MS: <i>m</i>/<i>z</i> 303 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> 6-Amino-3-(<i>cis</i>-4-isopropylcyclohexyl)pyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>110</b>)</h4><div class="NLM_p last">This compound was prepared according to General Procedure E using <i>cis</i>-4-isopropyl-cyclohexanamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.37 (s, 1H) 8.01 (d, <i>J</i> = 2.8 Hz, 1H), 7.42 (d, <i>J</i> = 2.8 Hz, 1H), 5.37 (s, 2H), 4.75–4.69 (m, 1H), 2.49–2.40 (m, 2H), 1.97–1.85 (m, 3H), 1.42–1.30 (m, 4H), 1.15–1.13 (m, 1H), 0.86 (d, <i>J</i> = 8 Hz, 6H). MS: <i>m</i>/<i>z</i> 303 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> 6-Amino-3-(<i>trans</i>-4-ethylcyclohexyl)pyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>111</b>)</h4><div class="NLM_p last">This compound was prepared according to General Procedure E using <i>trans</i>-4-ethyl-cyclohexanamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.38 (s, 1H), 8.02 (d, <i>J</i> = 2.8 Hz, 1H), 7.44 (d, <i>J</i> = 2.8 Hz, 1H), 5.37 (s, 2H), 4.72–4.65 (m, 1H), 2.41–2.37 (m, 2H), 1.83–1.80 (m, 2H), 1.58–1.55 (m, 2H), 1.25–1.10 (m, 3H), 1.0–0.9 (m, 2H), 0.87 (t, <i>J</i> = 7.2 Hz, 3H). MS: <i>m</i>/<i>z</i> 289 [M + 1]<sup>+</sup>.</div></div><div id="sec4_2_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> 6-Amino-3-(<i>cis</i>-4-ethylcyclohexyl)pyrido[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>112</b>)</h4><div class="NLM_p last">This compound was prepared according to General Procedure E using <i>cis</i>-4-ethyl-cyclohexanamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.38 (s, 1H), 8.02 (d, <i>J</i> = 2.8 Hz, 1H), 7.44 (d, <i>J</i> = 2.8 Hz, 1H), 5.37 (s, 2H), 4.72–4.65 (m, 1H), 2.41–2.37 (m, 2H), 1.83–1.80 (m, 2H), 1.58–1.55 (m, 2H), 1.25–1.10 (m, 3H), 1.0–0.9 (m, 2H), 0.87 (t, <i>J</i> = 7.2 Hz, 3H). MS: <i>m</i>/<i>z</i> 289 [M + 1]<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i159" class="anchor-spacer"></div><h3 class="article-section__title" id="_i159"> Activity against <i>T</i>. <i>cruzi</i></h3><div class="NLM_p last">Rat skeletal myoblasts (L-6 cells, ATCC CRL1458) were seeded in 96-well microtiter plates at 2000 cells/well in 100 μL of the RPMI 1640 medium with 10% FBS and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. After 24 h, the medium was removed and replaced by 100 μL per well containing 5000 trypomastigote forms of the <i>T. cruzi</i> Tulahuen strain C2C4 containing the β-galactosidase (Lac Z) gene (Buckner et al. 1996). After 48 h, the medium was removed from the wells and replaced by 100 μL of fresh medium with or without a serial drug dilution of 11 3-fold dilution steps covering a range from 100 to 0.002 μg/mL. After 96 h of incubation, the plates were inspected under an inverted microscope to ensure the growth of the controls and sterility. Then, the substrate CPRG/Nonidet (50 μL) was added to all wells. A color reaction developed within 2–6 h and could be read photometrically at 540 nm. Data were analyzed with the graphic program Softmax Pro (Molecular Devices), which calculated EC<sub>50</sub> values by linear regression and 4-parameter logistic regression from the sigmoidal dose inhibition curves. Benznidazole is used as a control.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i160" class="anchor-spacer"></div><h3 class="article-section__title" id="_i160"> <i>In Vitro</i> Cytotoxicity with L-6 Cells</h3><div class="NLM_p last">Assays were performed in 96-well microtiter plates, each well containing 100 μL of RPMI 1640 medium supplemented with 1% <span class="smallcaps smallerCapital">l</span>-glutamine (200 mM) and 10% fetal bovine serum, and 4000 L-6 cells (rat skeletal muscle myoblasts; ATCC CRL1458) were seeded in 96-well plates. Serial drug dilutions of 11 3-fold dilution steps covering a range from 100 to 0.002 μg/mL were prepared. After 70 h of incubation, the plates were inspected under an inverted microscope to ensure the growth of the controls and sterile conditions. Ten μL of resazurin solution (12.5 mg of resazurin dissolved in 100 mL of distilled water) was then added to each well, and the plates were incubated for another 2 h. Then the plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. The IC<sub>50</sub> values were calculated by linear regression and 4-parameter logistic regression from the sigmoidal dose inhibition curves using SoftmaxPro software (Molecular Devices Cooperation, Sunnyvale, CA, USA). Podophyllotoxin (Sigma P4405) was used as a control.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161"> Aqueous Solubility by Nephelometry</h3><div class="NLM_p">The kinetic aqueous solubility of the test compounds was measured using laser nephelometry. Compounds were subject to serial dilution from 10 mg/mL to 0.5 mg/mL in DMSO. An aliquot was then mixed with Milli-Q water to obtain an aqueous dilution plate with a final concentration range of 100–5 ug/mL, with a final DMSO concentration of 1.0%. Triplicate aliquots were transferred to a flat-bottomed polystyrene plate, which was immediately read on the NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates (relative nephelometry units, RNU) was plotted against the compound concentration using a segmental regression fit, with the point of inflection being quoted as the compounds aqueous solubility (μg/mL).</div><div class="NLM_p last">The aqueous solubility of the test compounds was measured using laser nephelometry. Compounds were subject to serial dilution from 10 mM to 0.5 mM in DMSO. An aliquot was then mixed with Milli-Q water to obtain an aqueous dilution plate with a final concentration range of 250–12 uM, with a final DMSO concentration of 2.5%. Triplicate aliquots were transferred to a flat bottomed polystyrene plate, which was immediately read on the NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates (relative nephelometry units, RNU) was plotted against compound concentration using a segmental regression fit, with the point of inflection being quoted as the compound aqueous solubility (μM).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i162" class="anchor-spacer"></div><h3 class="article-section__title" id="_i162"> Intrinsic Clearance (Cli) Experiments</h3><div class="NLM_p">The test compound (0.5 μM) was incubated with female CD1 mouse liver microsomes (Xenotech LLC; 0.5 mg/mL 50 mM potassium phosphate buffer, pH 7.4), and the reaction was started with the addition of excess NADPH (8 mg/mL 50 mM potassium phosphate buffer, pH 7.4). Immediately, at time zero, then at 3, 6, 9, 15, and 30 min, an aliquot (50 μL) of the incubation mixture was removed and mixed with acetonitrile (100 μL) to stop the reaction. The internal standard was added to all samples, the samples centrifuged to sediment precipitated protein, and the plates were then sealed prior to UPLCMSMS analysis using a Quattro Premier XE (Waters Corporation, USA).</div><div class="NLM_p last">XLfit (IDBS, U.K.) was used to calculate the exponential decay and, consequently, the rate constant (<i>k</i>) from the ratio of peak area of the test compound to the internal standard at each time point. The rate of intrinsic clearance (CLi) of each test compound was then calculated using the following calculation:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_m001.gif" alt="" id="_i163" /></img></span>where <i>V</i> (mL/mg protein) is the incubation volume/mg protein added, and the microsomal protein yield is taken as 52.5 mg protein/g liver. Verapamil (0.5 μM) was used as a positive control to confirm acceptable assay performance.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i164" class="anchor-spacer"></div><h3 class="article-section__title" id="_i164"> <i>In Vivo</i> Pharmacokinetics</h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> Female NMR1 Mouse</h4><div class="NLM_p last">Test compound <b>43</b> was dosed intraperitoneally or orally by gavage as a solution at 10 mg free base/kg (dose volume 10 mL/kg; dose vehicle, 10% (v/v) dimethyl sulfoxide (DMSO), 60% polyethylene glycol 400, and 30% deionized water); alternatively, compound <b>89</b> was dosed intraperitoneally as a solution or suspension at 10 mg free base/kg, respectively, or orally by gavage as a suspension at 10 mg free base/kg (dose volume 10 mL/kg; dose vehicle 10% (v/v) dimethyl sulfoxide (DMSO), 60% polyethylene glycol 400, and 30% deionized water or 0.5% w/v hydroxypropylmethylcellulose (HPMC) with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol) to female Balb/c mice (<i>n</i> = 3). Blood samples (10 μL) were taken from each mouse at 0.08, 0.25, 0.5, 1, 2, 4, 6, and 8 h post dose and mixed with two volumes of distilled water (20 μL). After suitable sample preparation, the concentration of test compounds in blood was determined by UPLC–MS/MS using a Quattro Premier XE (Waters, USA). Pharmacokinetic parameters were derived from the mean blood concentration–time curve using PK solutions software v 2.0 (Summit Research Services, USA).</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i166" class="anchor-spacer"></div><h3 class="article-section__title" id="_i166"> <i>In Vivo</i> Efficacy</h3><div class="NLM_p last">Trypomastigote forms from transgenic <i>T. cruzi</i> Brazil strain expressing firefly Luciferase were diluted in PBS and injected IP in Balb/c mice (10<sup>5</sup> trypomastigotes per mouse). Three days after infection, the mice were anesthetized by either IP injection of 300 mg/kg of xylazine and 3500 mg/kg of ketamine or by inhalation of isofluorane (controlled flow of 1.5% isofluorane in the air was administered through a nose cone via a gas anesthesia system). Mice were injected with 150 mg/kg of <span class="smallcaps smallerCapital">d</span>-luciferin potassium-salt (Goldbio) dissolved in PBS. Mice were imaged 5–10 min after injection of luciferin with an IVIS 100 (Xenogen, Alameda, CA), and the data acquisition and analysis were performed with the software LivingImage (Xenogen). One day later (4 days after infection), treatment with compounds <b>43</b> and compound <b>89</b> or vehicle control (PEG) was started by IP injection in groups of 5 mice and continued daily for 10 days. On days 5 and 10 after treatment started, mice were imaged again after anesthesia and injection of luciferin as described above. The ratio of infection is calculated, dividing parasite levels (luciferase signal) in each mouse at a particular day of treatment by the level before treatment (day 3 of infection).</div></div><div id="sec-18410-D9461910" class="NLM_sec NLM_sec_level_2"><div id="ac_i167" class="anchor-spacer"></div><h3 class="article-section__title" id="_i167"> Ethical Statements</h3><div class="NLM_p">All regulated procedures on living animals in Dundee were carried out under the authority of a project license issued by the Home Office under the Animals (Scientific Procedures) Act 1986, as amended in 2012 (and in compliance with EU Directive EU/2010/63). License applications have been approved by the University’s Ethical Review Committee (ERC) before submission to the Home Office. The ERC has a general remit to develop and oversee policy on all aspects of the use of animals on University premises and is a subcommittee of the University Court, its highest governing body.</div><div class="NLM_p last">This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, U.S. The protocol was approved by the Institutional Animal Care and Use Committee of New York University School of Medicine, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i168"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01852" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01852?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01852</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC traces of key compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular strings for all final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_001.pdf">jm9b01852_si_001.pdf (844.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_002.csv">jm9b01852_si_002.csv (6.76 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01852" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian H. Gilbert</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-1314" title="Orcid link">http://orcid.org/0000-0002-5238-1314</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#18713670367f71747a7d6a6c587c6d767c7d7d36797b366d73"><span class="__cf_email__" data-cfemail="3e571056105957525c5b4c4a7e5a4b505a5b5b105f5d104b55">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justin R. Harrison</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandipan Sarkar</span> - <span class="hlFld-Affiliation affiliation">Syngene
International Ltd, Biocon Park, SEZ, Bommasandra Industrial Area, Phase-IV, Bommasandra-Jigani
Link Road, Bangalore 560
099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shahienaz Hampton</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6600-9492" title="Orcid link">http://orcid.org/0000-0002-6600-9492</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Riley</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laste Stojanovski</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christer Sahlberg</span> - <span class="hlFld-Affiliation affiliation">Medivir, Lunastigen 7, 141 44 Huddinge, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pia Appelqvist</span> - <span class="hlFld-Affiliation affiliation">Medivir, Lunastigen 7, 141 44 Huddinge, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessey Erath</span> - <span class="hlFld-Affiliation affiliation">New
York University School of Medicine, 430 East 29th Street, Alexandria Center West Tower,
Room 511, Lab 524, New York, New York 10010, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinodhini Mathan</span> - <span class="hlFld-Affiliation affiliation">Syngene
International Ltd, Biocon Park, SEZ, Bommasandra Industrial Area, Phase-IV, Bommasandra-Jigani
Link Road, Bangalore 560
099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Rodriguez</span> - <span class="hlFld-Affiliation affiliation">New
York University School of Medicine, 430 East 29th Street, Alexandria Center West Tower,
Room 511, Lab 524, New York, New York 10010, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcel Kaiser</span> - <span class="hlFld-Affiliation affiliation">Swiss
Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, Basel CH-4051, Switzerland</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Basel, Petersplatz
1, Basel CH-4003, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dolores Gonzalez Pacanowska</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”, Avda. Conocimiento S/N, Parque Tecnológico
Ciencias de la Salud18016 Armilla, Granada Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin D. Read</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8536-0130" title="Orcid link">http://orcid.org/0000-0002-8536-0130</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nils Gunnar Johansson</span> - <span class="hlFld-Affiliation affiliation">Medivir, Lunastigen 7, 141 44 Huddinge, Sweden</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Some of the authors were employees of companies while this work was undertaken. This is indicated in the address list.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i169">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding for this work was provided by the European Union (Trypobase, 223238). We thank Gina MacKay for support with the NMR and mass spectrometry.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HPMC</td><td class="NLM_def"><p class="first last">hydroxypropyl methylcellulose</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MC</td><td class="NLM_def"><p class="first last">methylcellulose</p></td></tr><tr><td class="NLM_term">nd</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i171">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lidani, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damasceno, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrame, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messias-Reason, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandri, T. L.</span></span> <span> </span><span class="NLM_article-title">Chagas Disease: From Discovery to a Worldwide Health Problem</span>. <i>Front. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">166</span>, <span class="refDoi"> DOI: 10.3389/fpubh.2019.00166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.3389%2Ffpubh.2019.00166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=31312626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=166&author=K.+C.+F.+Lidaniauthor=F.+A.+Andradeauthor=L.+Baviaauthor=F.+S.+Damascenoauthor=M.+H.+Beltrameauthor=I.+J.+Messias-Reasonauthor=T.+L.+Sandri&title=Chagas+Disease%3A+From+Discovery+to+a+Worldwide+Health+Problem&doi=10.3389%2Ffpubh.2019.00166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas Disease: From Discovery to a Worldwide Health Problem</span></div><div class="casAuthors">Lidani Karita Claudia Freitas; Andrade Fabiana Antunes; Bavia Lorena; Messias-Reason Iara J; Sandri Thaisa Lucas; Damasceno Flavia Silva; Beltrame Marcia Holsbach; Sandri Thaisa Lucas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in public health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">166</span>
        ISSN:<span class="NLM_cas:issn">2296-2565</span>.
    </div><div class="casAbstract">Carlos Chagas discovered American trypanosomiasis, also named Chagas disease (CD) in his honor, just over a century ago.  He described the clinical aspects of the disease, characterized by its etiological agent (Trypanosoma cruzi) and identified its insect vector.  Initially, CD occurred only in Latin America and was considered a silent and poorly visible disease.  More recently, CD became a neglected worldwide disease with a high morbimortality rate and substantial social impact, emerging as a significant public health threat.  In this context, it is crucial to better understand better the epidemiological scenarios of CD and its transmission dynamics, involving people infected and at risk of infection, diversity of the parasite, vector species, and T. cruzi reservoirs.  Although efforts have been made by endemic and non-endemic countries to control, treat, and interrupt disease transmission, the cure or complete eradication of CD are still topics of great concern and require global attention.  Considering the current scenario of CD, also affecting non-endemic places such as Canada, USA, Europe, Australia, and Japan, in this review we aim to describe the spread of CD cases worldwide since its discovery until it has become a global public health concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdNDVSKB6ie-Lt9HypzAgQfW6udTcc2ebvCDTDu4npkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D&md5=e22d46895f7c7162d2a98b8787ea6637</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffpubh.2019.00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpubh.2019.00166%26sid%3Dliteratum%253Aachs%26aulast%3DLidani%26aufirst%3DK.%2BC.%2BF.%26aulast%3DAndrade%26aufirst%3DF.%2BA.%26aulast%3DBavia%26aufirst%3DL.%26aulast%3DDamasceno%26aufirst%3DF.%2BS.%26aulast%3DBeltrame%26aufirst%3DM.%2BH.%26aulast%3DMessias-Reason%26aufirst%3DI.%2BJ.%26aulast%3DSandri%26aufirst%3DT.%2BL.%26atitle%3DChagas%2520Disease%253A%2520From%2520Discovery%2520to%2520a%2520Worldwide%2520Health%2520Problem%26jtitle%3DFront.%2520Public%2520Health%26date%3D2019%26volume%3D7%26spage%3D166%26doi%3D10.3389%2Ffpubh.2019.00166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basanez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrend, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blok, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vlas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurarie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jervis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly-Hope, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rutte, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietman, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndeffo-Mbah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medley, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinsent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardus, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torr, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truscott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoueva, A.</span></span> <span> </span><span class="NLM_article-title">Quantitative Analyses and Modelling to Support Achievement of the 2020 Goals for Nine Neglected Tropical Diseases</span>. <i>Parasites Vectors</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">630</span>, <span class="refDoi"> DOI: 10.1186/s13071-015-1235-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1186%2Fs13071-015-1235-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=26652272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A280%3ADC%252BC28rhtl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=630&author=T.+D.+Hollingsworthauthor=E.+R.+Adamsauthor=R.+M.+Andersonauthor=K.+Atkinsauthor=S.+Bartschauthor=M.+G.+Basanezauthor=M.+Behrendauthor=D.+J.+Blokauthor=L.+A.+Chapmanauthor=L.+Coffengauthor=O.+Courtenayauthor=R.+E.+Crumpauthor=S.+J.+de+Vlasauthor=A.+Dobsonauthor=L.+Dysonauthor=H.+Farkasauthor=A.+P.+Galvaniauthor=M.+Gambhirauthor=D.+Gurarieauthor=M.+A.+Irvineauthor=S.+Jervisauthor=M.+J.+Keelingauthor=L.+Kelly-Hopeauthor=C.+Kingauthor=B.+Y.+Leeauthor=E.+A.+Le+Rutteauthor=T.+M.+Lietmanauthor=M.+Ndeffo-Mbahauthor=G.+F.+Medleyauthor=E.+Michaelauthor=A.+Pandeyauthor=J.+K.+Petersonauthor=A.+Pinsentauthor=T.+C.+Porcoauthor=J.+H.+Richardusauthor=L.+Reimerauthor=K.+S.+Rockauthor=B.+K.+Singhauthor=W.+Stolkauthor=S.+Swaminathanauthor=S.+J.+Torrauthor=J.+Townsendauthor=J.+Truscottauthor=M.+Walkerauthor=A.+Zoueva&title=Quantitative+Analyses+and+Modelling+to+Support+Achievement+of+the+2020+Goals+for+Nine+Neglected+Tropical+Diseases&doi=10.1186%2Fs13071-015-1235-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases</span></div><div class="casAuthors">Hollingsworth T Deirdre; Chapman Lloyd A C; Courtenay Orin; Crump Ron E; Dyson Louise; Farkas Hajnal; Irvine Michael A; Jervis Sarah; Keeling Matt J; Rock Kat S; Adams Emily R; Kelly-Hope Louise; Reimer Lisa; Torr Steve J; Anderson Roy M; Basanez Maria-Gloria; Truscott James; Walker Martin; Atkins Katherine; Medley Graham F; Bartsch Sarah; Lee Bruce Y; Behrend Matthew; Blok David J; Coffeng Luc; de Vlas Sake J; Le Rutte Epke A; Richardus Jan Hendrik; Stolk Wilma; Dobson Andy; Peterson Jennifer K; Galvani Alison P; Ndeffo-Mbah Martial; Pandey Abhishek; Townsend Jeffrey; Gambhir Manoj; Pinsent Amy; Gurarie David; King Charles; Lietman Thomas M; Porco Travis C; Michael Edwin; Singh Brajendra K; Swaminathan Subramanian; Zoueva Alexandra</div><div class="citationInfo"><span class="NLM_cas:title">Parasites & vectors</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">630</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quantitative analysis and mathematical models are useful tools in informing strategies to control or eliminate disease.  Currently, there is an urgent need to develop these tools to inform policy to achieve the 2020 goals for neglected tropical diseases (NTDs).  In this paper we give an overview of a collection of novel model-based analyses which aim to address key questions on the dynamics of transmission and control of nine NTDs: Chagas disease, visceral leishmaniasis, human African trypanosomiasis, leprosy, soil-transmitted helminths, schistosomiasis, lymphatic filariasis, onchocerciasis and trachoma.  Several common themes resonate throughout these analyses, including: the importance of epidemiological setting on the success of interventions; targeting groups who are at highest risk of infection or re-infection; and reaching populations who are not accessing interventions and may act as a reservoir for infection,.  The results also highlight the challenge of maintaining elimination 'as a public health problem' when true elimination is not reached.  The models elucidate the factors that may be contributing most to persistence of disease and discuss the requirements for eventually achieving true elimination, if that is possible.  Overall this collection presents new analyses to inform current control initiatives.  These papers form a base from which further development of the models and more rigorous validation against a variety of datasets can help to give more detailed advice.  At the moment, the models' predictions are being considered as the world prepares for a final push towards control or elimination of neglected tropical diseases by 2020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc5fXcz3Z5wNts4TFFB11gfW6udTcc2eafeDTV4oJ_yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rhtl2hsA%253D%253D&md5=0893a888adfad4c4b19994b67626f79a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs13071-015-1235-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13071-015-1235-1%26sid%3Dliteratum%253Aachs%26aulast%3DHollingsworth%26aufirst%3DT.%2BD.%26aulast%3DAdams%26aufirst%3DE.%2BR.%26aulast%3DAnderson%26aufirst%3DR.%2BM.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DBartsch%26aufirst%3DS.%26aulast%3DBasanez%26aufirst%3DM.%2BG.%26aulast%3DBehrend%26aufirst%3DM.%26aulast%3DBlok%26aufirst%3DD.%2BJ.%26aulast%3DChapman%26aufirst%3DL.%2BA.%26aulast%3DCoffeng%26aufirst%3DL.%26aulast%3DCourtenay%26aufirst%3DO.%26aulast%3DCrump%26aufirst%3DR.%2BE.%26aulast%3Dde%2BVlas%26aufirst%3DS.%2BJ.%26aulast%3DDobson%26aufirst%3DA.%26aulast%3DDyson%26aufirst%3DL.%26aulast%3DFarkas%26aufirst%3DH.%26aulast%3DGalvani%26aufirst%3DA.%2BP.%26aulast%3DGambhir%26aufirst%3DM.%26aulast%3DGurarie%26aufirst%3DD.%26aulast%3DIrvine%26aufirst%3DM.%2BA.%26aulast%3DJervis%26aufirst%3DS.%26aulast%3DKeeling%26aufirst%3DM.%2BJ.%26aulast%3DKelly-Hope%26aufirst%3DL.%26aulast%3DKing%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DLe%2BRutte%26aufirst%3DE.%2BA.%26aulast%3DLietman%26aufirst%3DT.%2BM.%26aulast%3DNdeffo-Mbah%26aufirst%3DM.%26aulast%3DMedley%26aufirst%3DG.%2BF.%26aulast%3DMichael%26aufirst%3DE.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DJ.%2BK.%26aulast%3DPinsent%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DT.%2BC.%26aulast%3DRichardus%26aufirst%3DJ.%2BH.%26aulast%3DReimer%26aufirst%3DL.%26aulast%3DRock%26aufirst%3DK.%2BS.%26aulast%3DSingh%26aufirst%3DB.%2BK.%26aulast%3DStolk%26aufirst%3DW.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DTorr%26aufirst%3DS.%2BJ.%26aulast%3DTownsend%26aufirst%3DJ.%26aulast%3DTruscott%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DZoueva%26aufirst%3DA.%26atitle%3DQuantitative%2520Analyses%2520and%2520Modelling%2520to%2520Support%2520Achievement%2520of%2520the%25202020%2520Goals%2520for%2520Nine%2520Neglected%2520Tropical%2520Diseases%26jtitle%3DParasites%2520Vectors%26date%3D2015%26volume%3D8%26spage%3D630%26doi%3D10.1186%2Fs13071-015-1235-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baragana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Challenges and Recent Progress in Drug Discovery for Tropical Diseases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0327-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1038%2Fs41586-018-0327-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=30046073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=498-506&author=M.+De%0ARyckerauthor=B.+Baraganaauthor=S.+L.+Duceauthor=I.+H.+Gilbert&title=Challenges+and+Recent+Progress+in+Drug+Discovery+for+Tropical+Diseases&doi=10.1038%2Fs41586-018-0327-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and recent progress in drug discovery for tropical diseases</span></div><div class="casAuthors">De Rycker, Manu; Baragana, Beatriz; Duce, Suzanne L.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7715</span>),
    <span class="NLM_cas:pages">498-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries.  These diseases predominantly affect the world's poorest people.  Currently available drugs are inadequate for the majority of these diseases, and there is an urgent need for new treatments.  This Review discusses some of the challenges involved in developing new drugs to treat these diseases and highlights recent progress.  While there have been notable successes, there is still a long way to go.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-L8-tHy6aTbVg90H21EOLACvtfcHk0lg7UdbUKB0zHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP&md5=3bc57ce68776462cf6a053efa276a989</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0327-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0327-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DBaragana%26aufirst%3DB.%26aulast%3DDuce%26aufirst%3DS.%2BL.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DChallenges%2520and%2520Recent%2520Progress%2520in%2520Drug%2520Discovery%2520for%2520Tropical%2520Diseases%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3D498%26epage%3D506%26doi%3D10.1038%2Fs41586-018-0327-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">CDC</span>. <a href="https://www.cdc.gov/parasites/chagas/biology.html" class="extLink">https://www.cdc.gov/parasites/chagas/biology.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CDC.+https%3A%2F%2Fwww.cdc.gov%2Fparasites%2Fchagas%2Fbiology.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">WHO</span>. <a href="https://apps.who.int/iris/bitstream/handle/10665/259404/9789241513166-eng.pdf?sequence=1&amp;isAllowed=y" class="extLink">https://apps.who.int/iris/bitstream/handle/10665/259404/9789241513166-eng.pdf?sequence=1=y</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO.+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F259404%2F9789241513166-eng.pdf%3Fsequence%3D1%3Dy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Dos-Santos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreto-De-Albuquerque, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berbert, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, B. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra Villa-Verde, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzoni, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savino, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotta-de-Almeida, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Meis, J.</span></span> <span> </span><span class="NLM_article-title">Unraveling Chagas Disease Transmission through the Oral Route: Gateways to <i>Trypanosoma cruzi</i> Infection and Target Tissues</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005507</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1371%2Fjournal.pntd.0005507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=28379959" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=D.+Silva-Dos-Santosauthor=J.+Barreto-De-Albuquerqueauthor=B.+Guerraauthor=O.+C.+Moreiraauthor=L.+R.+Berbertauthor=M.+T.+Ramosauthor=B.+A.+S.+Mascarenhasauthor=C.+Brittoauthor=A.+Morrotauthor=D.+M.+Serra+Villa-Verdeauthor=L.+R.+Garzoniauthor=W.+Savinoauthor=V.+Cotta-de-Almeidaauthor=J.+de+Meis&title=Unraveling+Chagas+Disease+Transmission+through+the+Oral+Route%3A+Gateways+to+Trypanosoma+cruzi+Infection+and+Target+Tissues&doi=10.1371%2Fjournal.pntd.0005507"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005507%26sid%3Dliteratum%253Aachs%26aulast%3DSilva-Dos-Santos%26aufirst%3DD.%26aulast%3DBarreto-De-Albuquerque%26aufirst%3DJ.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DMoreira%26aufirst%3DO.%2BC.%26aulast%3DBerbert%26aufirst%3DL.%2BR.%26aulast%3DRamos%26aufirst%3DM.%2BT.%26aulast%3DMascarenhas%26aufirst%3DB.%2BA.%2BS.%26aulast%3DBritto%26aufirst%3DC.%26aulast%3DMorrot%26aufirst%3DA.%26aulast%3DSerra%2BVilla-Verde%26aufirst%3DD.%2BM.%26aulast%3DGarzoni%26aufirst%3DL.%2BR.%26aulast%3DSavino%26aufirst%3DW.%26aulast%3DCotta-de-Almeida%26aufirst%3DV.%26aulast%3Dde%2BMeis%26aufirst%3DJ.%26atitle%3DUnraveling%2520Chagas%2520Disease%2520Transmission%2520through%2520the%2520Oral%2520Route%253A%2520Gateways%2520to%2520Trypanosoma%2520cruzi%2520Infection%2520and%2520Target%2520Tissues%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filigheddu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J. M.</span></span> <span> </span><span class="NLM_article-title">Orally-Transmitted Chagas Disease</span>. <i>Med. Clin. (Barcelona)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.medcli.2016.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.medcli.2016.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=27993415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FmtlCrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2017&pages=125-131&author=M.+T.+Filighedduauthor=M.+Gorgolasauthor=J.+M.+Ramos&title=Orally-Transmitted+Chagas+Disease&doi=10.1016%2Fj.medcli.2016.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Orally-transmitted Chagas disease</span></div><div class="casAuthors">Filigheddu Maria Teresa; Gorgolas Miguel; Ramos Jose Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Medicina clinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">125-131</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chagas disease is a zoonosis caused by protozoan parasite Trypanosoma cruzi, which is most frequently associated with a vectorial transmission.  However, in recent years we have observed a significant increase in the oral transmission of the disease, associated mainly with the consumption of drinks made from fruit or other vegetables contaminated with triatomine faeces or secretions from infected mammals.  After a latency period of 3 to 22 days after ingestion, the oral infection is characterized by more severe manifestations than those associated with vectorial transmission: prolonged fever, acute myocarditis with heart failure and, in some cases, meningoencephalitis.  Mortality can reach up to 33% of those infected.  The aim of this paper is to review this matter and to promote prevention practices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHdWlPP8eeFHO4gDb7JggCfW6udTcc2ebeoKbFuV38xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FmtlCrsQ%253D%253D&md5=ed789f8ac6d3114b0566926062b4c043</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.medcli.2016.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.medcli.2016.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DFiligheddu%26aufirst%3DM.%2BT.%26aulast%3DGorgolas%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DJ.%2BM.%26atitle%3DOrally-Transmitted%2520Chagas%2520Disease%26jtitle%3DMed.%2520Clin.%2520%2528Barcelona%2529%26date%3D2017%26volume%3D148%26spage%3D125%26epage%3D131%26doi%3D10.1016%2Fj.medcli.2016.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Valdez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarleton, R. L.</span></span> <span> </span><span class="NLM_article-title">Spontaneous Dormancy Protects <i>Trypanosoma Cruzi</i> During Extended Drug Exposure</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e34039</span> <span class="refDoi"> DOI: 10.7554/eLife.34039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.7554%2FeLife.34039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=29578409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSjtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&author=F.+J.+Sanchez-Valdezauthor=A.+Padillaauthor=W.+Wangauthor=D.+Orrauthor=R.+L.+Tarleton&title=Spontaneous+Dormancy+Protects+Trypanosoma+Cruzi+During+Extended+Drug+Exposure&doi=10.7554%2FeLife.34039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure</span></div><div class="casAuthors">Sanchez-Valdez, Fernando J.; Padilla, Angel; Wang, Wei; Orr, Dylan; Tarleton, Rick L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e34039/1-e34039/20</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The ability of the Chagas disease agent Trypanosoma cruzi to resist extended in vivo exposure to highly effective trypanocidal compds. prompted us to explore the potential for dormancy and its contribution to failed drug treatments in this infection.  We document the development of non-proliferating intracellular amastigotes in vivo and in vitro in the absence of drug treatment.  Non-proliferative amastigotes ultimately converted to trypomastigotes and established infections in new host cells.  Most significantly, dormant amastigotes were uniquely resistant to extended drug treatment in vivo and in vitro and could re-establish a flourishing infection after as many as 30 days of drug exposure.  These results demonstrate a dormancy state in T. cruzi that accounts for the failure of highly cytotoxic compds. to completely resolve the infection.  The ability of T. cruzi to establish dormancy throws into question current methods for identifying curative drugs but also suggests alternative therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxBdeTA7huDLVg90H21EOLACvtfcHk0lhx9QvVGgjv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSjtbrJ&md5=0af5ba24fb06183939ab6b0f6f008f4d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.7554%2FeLife.34039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.34039%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Valdez%26aufirst%3DF.%2BJ.%26aulast%3DPadilla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DOrr%26aufirst%3DD.%26aulast%3DTarleton%26aufirst%3DR.%2BL.%26atitle%3DSpontaneous%2520Dormancy%2520Protects%2520Trypanosoma%2520Cruzi%2520During%2520Extended%2520Drug%2520Exposure%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26doi%3D10.7554%2FeLife.34039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Anti-Trypanosomatid Drug Discovery: An Ongoing Challenge and a Continuing Need</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2016.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1038%2Fnrmicro.2016.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=28239154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=217-231&author=M.+C.+Fieldauthor=D.+Hornauthor=A.+H.+Fairlambauthor=M.+A.+Fergusonauthor=D.+W.+Grayauthor=K.+D.+Readauthor=M.+De+Ryckerauthor=L.+S.+Torrieauthor=P.+G.+Wyattauthor=S.+Wyllieauthor=I.+H.+Gilbert&title=Anti-Trypanosomatid+Drug+Discovery%3A+An+Ongoing+Challenge+and+a+Continuing+Need&doi=10.1038%2Fnrmicro.2016.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</span></div><div class="casAuthors">Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases.  These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal.  Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them.  In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled.  In addn., we consider the important challenges to drug discovery strategies and the new technologies that can address them.  The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBpRGL7YaP7Vg90H21EOLACvtfcHk0lh24rvQLIXXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D&md5=1585d954d6eb695196a6c8921a84e300</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2016.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2016.193%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BC.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DAnti-Trypanosomatid%2520Drug%2520Discovery%253A%2520An%2520Ongoing%2520Challenge%2520and%2520a%2520Continuing%2520Need%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D15%26spage%3D217%26epage%3D231%26doi%3D10.1038%2Fnrmicro.2016.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, S. L.</span></span> <span> </span><span class="NLM_article-title">Management of Trypanosomiasis and Leishmaniasis</span>. <i>Br. Med. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1093/bmb/lds031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1093%2Fbmb%2Flds031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=23137768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVOrsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=175-196&author=M.+P.+Barrettauthor=S.+L.+Croft&title=Management+of+Trypanosomiasis+and+Leishmaniasis&doi=10.1093%2Fbmb%2Flds031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Management of trypanosomiasis and leishmaniasis</span></div><div class="casAuthors">Barrett, Michael P.; Croft, Simon L.</div><div class="citationInfo"><span class="NLM_cas:title">British Medical Bulletin</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-196</span>CODEN:
                <span class="NLM_cas:coden">BMBUAQ</span>;
        ISSN:<span class="NLM_cas:issn">0007-1420</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Background The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress.  For HAT the only advances in treatment over the past two decades have been the introduction of an eflornithine/nifurtimox co-administration and a shorter regime of the old std. melarsoprol.  Sources of data PubMed.  Areas of Agreement There is a need for new safe, oral drugs for cost-effective treatment of patients and use in control programs for all the trypanosomatid diseases.  Areas of controversy Cutaneous leishmaniasis is not on the agenda and treatments are lagging behind.  Growing points There are three compds. in development for the treatment of the CNS stage of HAT: fexinidazole, currently due to entry into phase II clin. studies, a benzoxaborole (SCYX-7158) in phase I trials and a diamidine deriv. (CPD-0802), in advanced pre-clin. development.  For Chagas disease, two anti-fungal triazoles are now in clin. trial.  In addn., clin. studies with benznidazole, a drug previously recommended only for acute stage treatment, are close to completion to det. the effectiveness in the treatment of early chronic and indeterminate Chagas disease.  For visceral leishmaniasis new formulations, therapeutic switching, in particular AmBisome, and the potential for combinations of established drugs have significantly improved the opportunities for the treatment in the Indian subcontinent, but not in East Africa.  Areas timely for developing research Improved diagnostic tools are needed to support treatment, for test of cure in clin. trials and for monitoring/surveillance of populations in control programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3qCu_DPH8LrVg90H21EOLACvtfcHk0lh24rvQLIXXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVOrsbfO&md5=1da1b2e90ed07dc32777ca47a1be7f97</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fbmb%2Flds031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbmb%252Flds031%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DM.%2BP.%26aulast%3DCroft%26aufirst%3DS.%2BL.%26atitle%3DManagement%2520of%2520Trypanosomiasis%2520and%2520Leishmaniasis%26jtitle%3DBr.%2520Med.%2520Bull.%26date%3D2012%26volume%3D104%26spage%3D175%26epage%3D196%26doi%3D10.1093%2Fbmb%2Flds031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin-Neto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avezum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa-Estani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guhl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao-Melacini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span> <span> </span><span class="NLM_article-title">Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1306</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1056%2FNEJMoa1507574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=26323937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1295-1306&author=C.+A.+Morilloauthor=J.+A.+Marin-Netoauthor=A.+Avezumauthor=S.+Sosa-Estaniauthor=A.+Rassiauthor=F.+Rosasauthor=E.+Villenaauthor=R.+Quirozauthor=R.+Bonillaauthor=C.+Brittoauthor=F.+Guhlauthor=E.+Velazquezauthor=L.+Bonillaauthor=B.+Meeksauthor=P.+Rao-Melaciniauthor=J.+Pogueauthor=A.+Mattosauthor=J.+Lazdinsauthor=A.+Rassiauthor=S.+J.+Connollyauthor=S.+Yusuf&title=Randomized+Trial+of+Benznidazole+for+Chronic+Chagas%E2%80%99+Cardiomyopathy&doi=10.1056%2FNEJMoa1507574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of benznidazole for chronic Chagas' cardiomyopathy</span></div><div class="casAuthors">Morillo, C. A.; Marin-Neto, J. A.; Avezum, A.; Sosa-Estani, S.; Rassi, A., Jr.; Rosas, F.; Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; Guhl, F.; Velazquez, E.; Bonilla, L.; Meeks, B.; Rao-Melacini, P.; Pogue, J.; Mattos, A.; Lazdins, J.; Rassi, A.; Connolly, S. J.; Yusuf, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1295-1306</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.  We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years.  The primary outcome in the time-to-event anal. was the first event of any of the components of the composite outcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or other thromboembolic event.  The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and in 414 (29.1%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.07; P = 0.31).  At baseline, a polymerase-chain-reaction (PCR) assay was performed on blood samples obtained from 1896 patients; 60.5% had pos. results for Trypanosoma cruzi on PCR.  The rates of conversion to neg. PCR results (PCR conversion) were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, resp., at 2 years, and 46.7% and 33.1%, resp., at 5 years or more (P<0.001 for all comparisons).  The effect of treatment on PCR conversion varied according to geog. region: in Brazil, the odds ratio for PCR conversion was 3.03 (95% CI, 2.12 to 4.34) at 2 years and 1.87 (95% CI, 1.33 to 2.63) at 5 or more years; in Colombia and El Salvador, the odds ratio was 1.33 (95% CI, 0.90 to 1.98) at 2 years and 0.96 (95% CI, 0.63 to 1.45) at 5 or more years; and in Argentina and Bolivia, the odds ratio was 2.63 (95% CI, 1.89 to 3.66) at 2 years and 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction).  However, the rates of PCR conversion did not correspond to effects on clin. outcome (P = 0.16 for interaction).  Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clin. deterioration through 5 years of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz_0zFM1DyHLVg90H21EOLACvtfcHk0lh24rvQLIXXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSms7g%253D&md5=6386aadfc625824961ff33e01a93ab2e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507574%26sid%3Dliteratum%253Aachs%26aulast%3DMorillo%26aufirst%3DC.%2BA.%26aulast%3DMarin-Neto%26aufirst%3DJ.%2BA.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DSosa-Estani%26aufirst%3DS.%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DRosas%26aufirst%3DF.%26aulast%3DVillena%26aufirst%3DE.%26aulast%3DQuiroz%26aufirst%3DR.%26aulast%3DBonilla%26aufirst%3DR.%26aulast%3DBritto%26aufirst%3DC.%26aulast%3DGuhl%26aufirst%3DF.%26aulast%3DVelazquez%26aufirst%3DE.%26aulast%3DBonilla%26aufirst%3DL.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DRao-Melacini%26aufirst%3DP.%26aulast%3DPogue%26aufirst%3DJ.%26aulast%3DMattos%26aufirst%3DA.%26aulast%3DLazdins%26aufirst%3DJ.%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DConnolly%26aufirst%3DS.%2BJ.%26aulast%3DYusuf%26aufirst%3DS.%26atitle%3DRandomized%2520Trial%2520of%2520Benznidazole%2520for%2520Chronic%2520Chagas%25E2%2580%2599%2520Cardiomyopathy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1295%26epage%3D1306%26doi%3D10.1056%2FNEJMoa1507574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">DNDi</span>. <a href="https://www.dndi.org/wp-content/uploads/2019/03/2page_BenditatStudyOverview_ENG.pdf" class="extLink">https://www.dndi.org/wp-content/uploads/2019/03/2page_BenditatStudyOverview_ENG.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+https%3A%2F%2Fwww.dndi.org%2Fwp-content%2Fuploads%2F2019%2F03%2F2page_BenditatStudyOverview_ENG.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">DNDi</span>. <a href="https://www.dndi.org/diseases-projects/portfolio/new-benz-regimens/" class="extLink">https://www.dndi.org/diseases-projects/portfolio/new-benz-regimens/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+https%3A%2F%2Fwww.dndi.org%2Fdiseases-projects%2Fportfolio%2Fnew-benz-regimens%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waskin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa-Estani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Carmen Bangher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milesi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallagray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloscar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverria, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Molina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa-Estani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waskin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquatella, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holadyk-Gris, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangher, M.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scollo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Albizu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, C.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, N.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milesi, R.R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berli, M.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallagray, M.H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres, N.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloscar, J.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucci, J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellatorre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulantay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverria, L.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, F.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman Melgar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldasoro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posada, E.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Montalva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Molina, J.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Velez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes-Lopez, P.A.</span></span> <span> </span><span class="NLM_article-title">Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic <i>T. cruzi</i> Carriers: The Stop-Chagas Trial</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2016.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.jacc.2016.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=28231946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1Kiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=939-947&author=C.+A.+Morilloauthor=H.+Waskinauthor=S.+Sosa-Estaniauthor=M.+del+Carmen+Bangherauthor=C.+Cuneoauthor=R.+Milesiauthor=M.+Mallagrayauthor=W.+Aptauthor=J.+Beloscarauthor=J.+Gasconauthor=I.+Molinaauthor=L.+E.+Echeverriaauthor=H.+Colomboauthor=J.+A.+Perez-Molinaauthor=F.+Wyssauthor=B.+Meeksauthor=L.+R.+Bonillaauthor=P.+Gaoauthor=B.+Weiauthor=M.+McCarthyauthor=S.+Yusufauthor=C.+Morilloauthor=S.+Sosa-Estaniauthor=H.+Waskinauthor=B.+Meeksauthor=S.+Yusufauthor=R.+Diazauthor=H.+Acquatellaauthor=J.+Lazzariauthor=R.+Robertsauthor=M.+Trainaauthor=B.+Meeksauthor=L.+R.+Bonillaauthor=P.+Gaoauthor=A.+Taylorauthor=I.+Holadyk-Grisauthor=L.+Whalenauthor=M.C.+Bangherauthor=M.A.+Romeroauthor=N.+Pradoauthor=Y.+Hernandezauthor=M.+Fernandezauthor=A.+Riarteauthor=K.+Scolloauthor=C.+Lopez-Albizuauthor=C.A.+Cuneoauthor=N.C.+Gutierrezauthor=R.R.+Milesiauthor=M.A.+Berliauthor=M.H.+Mallagrayauthor=N.E.+Caceresauthor=J.S.+Beloscarauthor=J.M.+Petrucciauthor=H.+Colomboauthor=M.+Dellatorreauthor=A.+Pradoauthor=W.+Aptauthor=I.+Zulantayauthor=L.E.+Echeverriaauthor=D.+Isazaauthor=E.+Reyesauthor=F.S.+Wyssauthor=A.+Figueroaauthor=I.+Guzman+Melgarauthor=E.+Rodriguezauthor=J.+Gasconauthor=E.+Aldasoroauthor=E.J.+Posadaauthor=N.+Serretauthor=I.+Molinaauthor=A.+Sanchez-Montalvaauthor=J.A.+Perez-Molinaauthor=R.+Lopez-Velezauthor=P.A.+Reyes-Lopez&title=Benznidazole+and+Posaconazole+in+Eliminating+Parasites+in+Asymptomatic+T.+cruzi+Carriers%3A+The+Stop-Chagas+Trial&doi=10.1016%2Fj.jacc.2016.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers</span></div><div class="casAuthors">Morillo, Carlos A.; Waskin, Hetty; Sosa-Estani, Sergio; Bangher, Maria del Carmen; Cuneo, Carlos; Milesi, Rodolfo; Mallagray, Marcelo; Apt, Werner; Beloscar, Juan; Gascon, Joaquim; Molina, Israel; Echeverria, Luis E.; Colombo, Hugo; Perez-Molina, Jose Antonio; Wyss, Fernando; Meeks, Brandi; Bonilla, Laura R.; Gao, Peggy; Wei, Bo; McCarthy, Michael; Yusuf, Salim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-947</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Benznidazole is recommended for treatment of Chagas infection.  Effects of combination therapy with benznidazole and posaconazole have not been tested in Trypanosoma cruzi carriers.  The purpose of this study was to det. whether posaconazole alone or combined with benznidazole were superior to benznidazole monotherapy in eliminating T. cruzi parasites measured by real time polymerase chain reaction (RT-PCR) in asymptomatic Chagas carriers.  A prospective, multicenter randomized placebo-controlled study was conducted in 120 subjects from Latin America and Spain who were randomized to 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d.  T. cruzi DNA was detected by RT-PCR at 30, 60, 90, 120, 150, 180, and 360 days.  The primary efficacy outcome is the proportion of subjects with persistent neg. RT-PCR by day 180; the secondary outcome was neg. RT-PCR at 360 days.Only 13.3% of those receiving posaconazole and 10% receiving placebo achieved the primary outcome, compared with 80% receiving benznidazole + posaconazole and 86.7% receiving benznidazole monotherapy (p < 0.0001 vs. posaconazole/placebo).  Posaconazole monotherapy or posaconazole combined with benznidazole achieved high RT-PCR conversion rates during treatment (30 days; 93.3% and 88.9% and 60 days; 90%, and 92.3%) that were similar to benznidazole (89.7% and 89.3%); all were superior to placebo or posaconazole (10% and 16.7%, p < 0.0001).  This was not obsd. at 360 days; benznidazole + posaconazole and benznidazole monotherapy (both 96%) vs. placebo (17%) and posaconazole (16%, p < 0.0001).  Serious adverse events were rare (6 patients) and were obsd. in the benznidazole-treated patients.  Permanent discontinuation was reported in 19 patients (31.7%) receiving either benznidazole monotherapy or combined with posaconazole.  Posaconazole demonstrated trypanostatic activity during treatment, but it is ineffective long-term in asymptomatic T. cruzi carriers.  Benznidazole monotherapy is superior to posaconazole, with high RT-PCR conversion rates sustained at 1 yr.  Side effects lead to therapy discontinuation in 32%.  No advantages were obsd. with combined therapy vs. benznidazole monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF_im80mqEP7Vg90H21EOLACvtfcHk0lhmmih4evCezQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1Kiuro%253D&md5=d5021f5544dc42eba2af9d469db9da50</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2016.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2016.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DMorillo%26aufirst%3DC.%2BA.%26aulast%3DWaskin%26aufirst%3DH.%26aulast%3DSosa-Estani%26aufirst%3DS.%26aulast%3Ddel%2BCarmen%2BBangher%26aufirst%3DM.%26aulast%3DCuneo%26aufirst%3DC.%26aulast%3DMilesi%26aufirst%3DR.%26aulast%3DMallagray%26aufirst%3DM.%26aulast%3DApt%26aufirst%3DW.%26aulast%3DBeloscar%26aufirst%3DJ.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DEcheverria%26aufirst%3DL.%2BE.%26aulast%3DColombo%26aufirst%3DH.%26aulast%3DPerez-Molina%26aufirst%3DJ.%2BA.%26aulast%3DWyss%26aufirst%3DF.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DBonilla%26aufirst%3DL.%2BR.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DMcCarthy%26aufirst%3DM.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DMorillo%26aufirst%3DC.%26aulast%3DSosa-Estani%26aufirst%3DS.%26aulast%3DWaskin%26aufirst%3DH.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DAcquatella%26aufirst%3DH.%26aulast%3DLazzari%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DR.%26aulast%3DTraina%26aufirst%3DM.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DBonilla%26aufirst%3DL.%2BR.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DHoladyk-Gris%26aufirst%3DI.%26aulast%3DWhalen%26aufirst%3DL.%26aulast%3DBangher%26aufirst%3DM.C.%26aulast%3DRomero%26aufirst%3DM.A.%26aulast%3DPrado%26aufirst%3DN.%26aulast%3DHernandez%26aufirst%3DY.%26aulast%3DFernandez%26aufirst%3DM.%26aulast%3DRiarte%26aufirst%3DA.%26aulast%3DScollo%26aufirst%3DK.%26aulast%3DLopez-Albizu%26aufirst%3DC.%26aulast%3DCuneo%26aufirst%3DC.A.%26aulast%3DGutierrez%26aufirst%3DN.C.%26aulast%3DMilesi%26aufirst%3DR.R.%26aulast%3DBerli%26aufirst%3DM.A.%26aulast%3DMallagray%26aufirst%3DM.H.%26aulast%3DCaceres%26aufirst%3DN.E.%26aulast%3DBeloscar%26aufirst%3DJ.S.%26aulast%3DPetrucci%26aufirst%3DJ.M.%26aulast%3DColombo%26aufirst%3DH.%26aulast%3DDellatorre%26aufirst%3DM.%26aulast%3DPrado%26aufirst%3DA.%26aulast%3DApt%26aufirst%3DW.%26aulast%3DZulantay%26aufirst%3DI.%26aulast%3DEcheverria%26aufirst%3DL.E.%26aulast%3DIsaza%26aufirst%3DD.%26aulast%3DReyes%26aufirst%3DE.%26aulast%3DWyss%26aufirst%3DF.S.%26aulast%3DFigueroa%26aufirst%3DA.%26aulast%3DGuzman%2BMelgar%26aufirst%3DI.%26aulast%3DRodriguez%26aufirst%3DE.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DAldasoro%26aufirst%3DE.%26aulast%3DPosada%26aufirst%3DE.J.%26aulast%3DSerret%26aufirst%3DN.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DSanchez-Montalva%26aufirst%3DA.%26aulast%3DPerez-Molina%26aufirst%3DJ.A.%26aulast%3DLopez-Velez%26aufirst%3DR.%26aulast%3DReyes-Lopez%26aufirst%3DP.A.%26atitle%3DBenznidazole%2520and%2520Posaconazole%2520in%2520Eliminating%2520Parasites%2520in%2520Asymptomatic%2520T.%2520cruzi%2520Carriers%253A%2520The%2520Stop-Chagas%2520Trial%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2017%26volume%3D69%26spage%3D939%26epage%3D947%26doi%3D10.1016%2Fj.jacc.2016.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torrico, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Vega, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinazo, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schijman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, I. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strub-Wourgaft, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bournisen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto Rocha, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas Delgadillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magne Anzoleaga, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quechover, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, M. Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano Beltran, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalabar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas
Panozo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios Lopez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrico Terceros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez Galvez, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuellar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasco Arenas, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyos Delfin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Barra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarroel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncanson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diderichsen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, A. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sender, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, W.</span></span> <span> </span><span class="NLM_article-title">Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-Concept, Randomised, Placebo-Controlled Trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30538-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2FS1473-3099%2817%2930538-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=29352704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=419-430&author=F.+Torricoauthor=J.+Gasconauthor=L.+Ortizauthor=C.+Alonso-Vegaauthor=M.-J.+Pinazoauthor=A.+Schijmanauthor=I.+C+Almeidaauthor=F.+Alvesauthor=N.+Strub-Wourgaftauthor=I.+Ribeiroauthor=G.+Santinaauthor=B.+Blumauthor=E.+Correiaauthor=F.+Garcia-Bournisenauthor=M.+Vaillantauthor=J.+R.+Moralesauthor=J.+J.+Pinto+Rochaauthor=G.+Rojas+Delgadilloauthor=H.+R.+Magne+Anzoleagaauthor=N.+Mendozaauthor=R.+C.+Quechoverauthor=M.+Y.+E.+Caballeroauthor=D.+F.+Lozano+Beltranauthor=A.+M.+Zalabarauthor=L.+Rojas%0APanozoauthor=A.+Palacios+Lopezauthor=D.+Torrico+Tercerosauthor=V.+A.+Fernandez+Galvezauthor=L.+Cardozoauthor=G.+Cuellarauthor=R.+N.+Vasco+Arenasauthor=I.+Gonzalesauthor=C.+F.+Hoyos+Delfinauthor=L.+Garciaauthor=R.+Parradoauthor=A.+de+la+Barraauthor=N.+Montanoauthor=S.+Villarroelauthor=T.+Duffyauthor=M.+Bisioauthor=J.+C.+Ramirezauthor=F.+Duncansonauthor=M.+Eversonauthor=A.+Danielsauthor=M.+Asadaauthor=E.+Coxauthor=D.+Wescheauthor=P.+M.+Diderichsenauthor=A.+F+Marquesauthor=L.+Izquierdoauthor=S.+S.+Senderauthor=J.+C.+Reverterauthor=M.+Moralesauthor=W.+Jimenez&title=Treatment+of+Adult+Chronic+Indeterminate+Chagas+Disease+with+Benznidazole+and+Three+E1224+Dosing+Regimens%3A+A+Proof-of-Concept%2C+Randomised%2C+Placebo-Controlled+Trial&doi=10.1016%2FS1473-3099%2817%2930538-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial</span></div><div class="casAuthors">Torrico, Faustino; Gascon, Joaquim; Ortiz, Lourdes; Alonso-Vega, Cristina; Pinazo, Maria-Jesus; Schijman, Alejandro; Almeida, Igor C.; Alves, Fabiana; Strub-Wourgaft, Nathalie; Ribeiro, Isabela</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chagas disease is a major neglected vector-borne disease.  In this study, we investigated the safety and efficacy of three oral E1224 (a water-sol. ravuconazole prodrug) regimens and benznidazole vs. placebo in adult chronic indeterminate Chagas disease.  In this proof-of-concept, double-blind, randomised phase 2 clin. trial, we recruited adults (18-50 years) with confirmed diagnosis of Trypanosoma cruzi infection from two outpatient units in Bolivia.  Patients were randomised with a computer-generated randomisation list, which was stratified by center and used a block size of ten.  Patients were randomly assigned (1:1:1:1:1) to five oral treatment groups: high-dose E1224 (duration 8 wk, total dose 4000 mg), low-dose E1224 (8 wk, 2000 mg), short-dose E1224 (4 wk + 4 wk placebo, 2400 mg), benznidazole (60 days, 5 mg/kg per day), or placebo (8 wk, E1224-matched tablets).  Double-blinding was limited to the E1224 and placebo arms, and assessors were masked to all treatment allocations.  The primary efficacy endpoint was parasitol. response to E1224 at the end of treatment, assessed by PCR.  The secondary efficacy endpoints were parasitol. response to benznidazole at end of treatment, assessed by PCR; sustainability of parasitol. response until 12 mo; parasite clearance and changes in parasite load; incidence of conversion to neg. response in conventional and non-conventional (antigen trypomastigote chemiluminescent ELISA [AT CL-ELISA]) serol. response; changes in levels of biomarkers; and complete response.  The primary anal. population consisted of all randomised patients by their assigned treatment arms.  This trial is registered with ClinicalTrials.gov, no. NCT01489228.  Between July 19, 2011, and July 26, 2012, we screened 560 participants with confirmed Chagas disease, of whom 231 were enrolled and assigned to high-dose E1224 (n = 45), low-dose E1224 (n = 48), short-dose E1224 (n = 46), benznidazole (n = 45), or placebo (n = 47).  Parasite clearance was obsd. with E1224 during the treatment phase, but no sustained response was seen with low-dose and short-dose regimens, whereas 13 patients (29%, 95% CI 16.4-44.3) had sustained response with the high-dose regimen compared with four (9%, 2.4-20.4) in the placebo group (p < 0.0001).  Benznidazole had a rapid and sustained effect on parasite clearance, with 37 patients (82%, 67.9-92.0) with sustained response at 12-mo follow-up.  After 1 wk of treatment, mean quant. PCR repeated measurements showed a significant redn. in parasite load in all treatment arms vs. placebo.  Parasite levels in the low-dose and short-dose E1224 groups gradually returned to placebo levels.  Both treatments were well tolerated.  Reversible, dose-dependent liver enzyme increases were seen with E1224 and benznidazole.  A 187 (81%) participants developed treatment-emergent adverse events and six (3%) developed treatment-emergent serious adverse events.  Treatment-emergent adverse events were headaches, nausea, pruritus, peripheral neuropathy, and hypersensitivity.  E1224 is the first new chem. entity developed for Chagas disease in decades.  E1224 displayed a transient, suppressive effect on parasite clearance, whereas benznidazole showed early and sustained efficacy until 12 mo of follow-up.  Despite PCR limitations, our results support increased diagnosis and access to benznidazole std. regimen, and provide a development roadmap for novel benznidazole regimens in monotherapy and in combinations with E1224.  Drugs for Neglected Diseases initiative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqes8nnI-YsK7Vg90H21EOLACvtfcHk0lg2wqikES25SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D&md5=0d71e1af60fad81c14943af5e70ad8ad</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930538-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930538-8%26sid%3Dliteratum%253Aachs%26aulast%3DTorrico%26aufirst%3DF.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DOrtiz%26aufirst%3DL.%26aulast%3DAlonso-Vega%26aufirst%3DC.%26aulast%3DPinazo%26aufirst%3DM.-J.%26aulast%3DSchijman%26aufirst%3DA.%26aulast%3DAlmeida%26aufirst%3DI.%2BC%26aulast%3DAlves%26aufirst%3DF.%26aulast%3DStrub-Wourgaft%26aufirst%3DN.%26aulast%3DRibeiro%26aufirst%3DI.%26aulast%3DSantina%26aufirst%3DG.%26aulast%3DBlum%26aufirst%3DB.%26aulast%3DCorreia%26aufirst%3DE.%26aulast%3DGarcia-Bournisen%26aufirst%3DF.%26aulast%3DVaillant%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DJ.%2BR.%26aulast%3DPinto%2BRocha%26aufirst%3DJ.%2BJ.%26aulast%3DRojas%2BDelgadillo%26aufirst%3DG.%26aulast%3DMagne%2BAnzoleaga%26aufirst%3DH.%2BR.%26aulast%3DMendoza%26aufirst%3DN.%26aulast%3DQuechover%26aufirst%3DR.%2BC.%26aulast%3DCaballero%26aufirst%3DM.%2BY.%2BE.%26aulast%3DLozano%2BBeltran%26aufirst%3DD.%2BF.%26aulast%3DZalabar%26aufirst%3DA.%2BM.%26aulast%3DRojas%2BPanozo%26aufirst%3DL.%26aulast%3DPalacios%2BLopez%26aufirst%3DA.%26aulast%3DTorrico%2BTerceros%26aufirst%3DD.%26aulast%3DFernandez%2BGalvez%26aufirst%3DV.%2BA.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DCuellar%26aufirst%3DG.%26aulast%3DVasco%2BArenas%26aufirst%3DR.%2BN.%26aulast%3DGonzales%26aufirst%3DI.%26aulast%3DHoyos%2BDelfin%26aufirst%3DC.%2BF.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DParrado%26aufirst%3DR.%26aulast%3Dde%2Bla%2BBarra%26aufirst%3DA.%26aulast%3DMontano%26aufirst%3DN.%26aulast%3DVillarroel%26aufirst%3DS.%26aulast%3DDuffy%26aufirst%3DT.%26aulast%3DBisio%26aufirst%3DM.%26aulast%3DRamirez%26aufirst%3DJ.%2BC.%26aulast%3DDuncanson%26aufirst%3DF.%26aulast%3DEverson%26aufirst%3DM.%26aulast%3DDaniels%26aufirst%3DA.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DWesche%26aufirst%3DD.%26aulast%3DDiderichsen%26aufirst%3DP.%2BM.%26aulast%3DMarques%26aufirst%3DA.%2BF%26aulast%3DIzquierdo%26aufirst%3DL.%26aulast%3DSender%26aufirst%3DS.%2BS.%26aulast%3DReverter%26aufirst%3DJ.%2BC.%26aulast%3DMorales%26aufirst%3DM.%26aulast%3DJimenez%26aufirst%3DW.%26atitle%3DTreatment%2520of%2520Adult%2520Chronic%2520Indeterminate%2520Chagas%2520Disease%2520with%2520Benznidazole%2520and%2520Three%2520E1224%2520Dosing%2520Regimens%253A%2520A%2520Proof-of-Concept%252C%2520Randomised%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26spage%3D419%26epage%3D430%26doi%3D10.1016%2FS1473-3099%2817%2930538-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez i Prat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulleiro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serre, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabezos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Grau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Montalva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahissa, A.</span></span> <span> </span><span class="NLM_article-title">Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas’ Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1899</span>– <span class="NLM_lpage">1908</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1313122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1056%2FNEJMoa1313122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=24827034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1899-1908&author=I.+Molinaauthor=J.+Gomez+i+Pratauthor=F.+Salvadorauthor=B.+Trevinoauthor=E.+Sulleiroauthor=N.+Serreauthor=D.+Pouauthor=S.+Roureauthor=J.+Cabezosauthor=L.+Valerioauthor=A.+Blanco-Grauauthor=A.+Sanchez-Montalvaauthor=X.+Vidalauthor=A.+Pahissa&title=Randomized+Trial+of+Posaconazole+and+Benznidazole+for+Chronic+Chagas%E2%80%99+Disease&doi=10.1056%2FNEJMoa1313122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of posaconazole and benznidazole for chronic Chagas' disease</span></div><div class="casAuthors">Molina, Israel; Gomez i Prat, Jordi; Salvador, Fernando; Trevino, Begona; Sulleiro, Elena; Serre, Nuria; Pou, Diana; Roure, Silvia; Cabezos, Juan; Valerio, Lluis; Blanco-Grau, Albert; Sanchez-Montalva, Adrian; Vidal, Xavier; Pahissa, Albert</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1899-1908, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been assocd. with low cure rates in the chronic stage of the disease and which have considerable toxicity.  Posaconazole has shown trypanocidal activity in murine models.  Methods: We performed a prospective, randomized clin. trial to assess the efficacy and safety of posaconazole as compared with the efficacy and safety of benznidazole in adults with chronic Trypanosoma cruzi infection.  We randomly assigned patients to receive posaconazole at a dose of 400 mg twice daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice daily (low-dose posaconazole), or benznidazole at a dose of 150 mg twice daily; all the study drugs were administered for 60 days.  We assessed antiparasitic activity by testing for the presence of T. cruzi DNA, using real-time polymerase-chain- reaction (rt-PCR) assays, during the treatment period and 10 mo after the end of treatment.  Posaconazole absorption was assessed on day 14.  Results: The intention-to-treat population included 78 patients.  During the treatment period, all the patients tested neg. for T. cruzi DNA on rt-PCR assay beyond day 14, except for 2 patients in the low-dose posaconazole group who tested pos. on day 60.  During the follow-up period, in the intention-to-treat anal., 92% of the patients receiving low-dose posaconazole and 81% receiving high-dose posaconazole, as compared with 38% receiving benznidazole, tested pos. for T. cruzi DNA on rt-PCR assay (P<0.01 for the comparison of the benznidazole group with either posaconazole group); in the perprotocol anal., 90% of the patients receiving low-dose posaconazole and 80% of those receiving high-dose posaconazole, as compared with 6% receiving benznidazole, tested pos. on rt-PCR assay (P<0.001 for the comparison of the benznidazole group with either posaconazole group).  In the benznidazole group, treatment was discontinued in 5 patients because of severe cutaneous reactions; in the posaconazole groups, 4 patients had aminotransferase levels that were more than 3 times the upper limit of the normal range, but there were no discontinuations of treatment.  Conclusions: Posaconazole showed antitrypanosomal activity in patients with chronic Chagas' disease.  However, significantly more patients in the posaconazole groups than in the benznidazole group had treatment failure during follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2K1SHT3rRSLVg90H21EOLACvtfcHk0lhc2-ASO-WGYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbjF&md5=ff26dd08abd3cf46144913378efb9b5c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1313122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1313122%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DGomez%2Bi%2BPrat%26aufirst%3DJ.%26aulast%3DSalvador%26aufirst%3DF.%26aulast%3DTrevino%26aufirst%3DB.%26aulast%3DSulleiro%26aufirst%3DE.%26aulast%3DSerre%26aufirst%3DN.%26aulast%3DPou%26aufirst%3DD.%26aulast%3DRoure%26aufirst%3DS.%26aulast%3DCabezos%26aufirst%3DJ.%26aulast%3DValerio%26aufirst%3DL.%26aulast%3DBlanco-Grau%26aufirst%3DA.%26aulast%3DSanchez-Montalva%26aufirst%3DA.%26aulast%3DVidal%26aufirst%3DX.%26aulast%3DPahissa%26aufirst%3DA.%26atitle%3DRandomized%2520Trial%2520of%2520Posaconazole%2520and%2520Benznidazole%2520for%2520Chronic%2520Chagas%25E2%2580%2599%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1899%26epage%3D1908%26doi%3D10.1056%2FNEJMoa1313122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">DNDi</span>. <a href="http://Https://Www.Dndi.Org/Diseases-Projects/Portfolio/Fexinidazole-Chagas/" class="extLink">Https://Www.Dndi.Org/Diseases-Projects/Portfolio/Fexinidazole-Chagas/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+Https%3A%2F%2FWww.Dndi.Org%2FDiseases-Projects%2FPortfolio%2FFexinidazole-Chagas%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">DNDi</span>. <a href="http://Https://Www.Dndi.Org/Diseases-Projects/Portfolio/" class="extLink">Https://Www.Dndi.Org/Diseases-Projects/Portfolio/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+Https%3A%2F%2FWww.Dndi.Org%2FDiseases-Projects%2FPortfolio%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, N. J.</span></span> <span> </span><span class="NLM_article-title">Validity of Ligand Efficiency Metrics</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">618</span>, <span class="refDoi"> DOI: 10.1021/ml500146d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500146d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVShsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=616-618&author=C.+W.+Murrayauthor=D.+A.+Erlansonauthor=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynoldsauthor=N.+J.+Richmond&title=Validity+of+Ligand+Efficiency+Metrics&doi=10.1021%2Fml500146d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Validity of Ligand Efficiency Metrics</span></div><div class="casAuthors">Murray, Christopher W.; Erlanson, Daniel A.; Hopkins, Andrew L.; Keseru, Gyorgy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.; Richmond, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">616-618</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A recent viewpoint article (Improving the plausibility of success with inefficient metrics. ACS Med. Chem. Lett.2014, 5, 2-5) argued that the std. definition of ligand efficiency (LE) is math. invalid.  In this viewpoint, we address this criticism and show categorically that the definition of LE is math. valid.  LE and other metrics such as lipophilic ligand efficiency (LLE) can be useful during the multiparameter optimization challenge faced by medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJHYI4FCEJbVg90H21EOLACvtfcHk0lhc2-ASO-WGYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVShsbs%253D&md5=5bc436490def9fa7af0f3e7ed241ee4e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml500146d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500146d%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26aulast%3DRichmond%26aufirst%3DN.%2BJ.%26atitle%3DValidity%2520of%2520Ligand%2520Efficiency%2520Metrics%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D616%26epage%3D618%26doi%3D10.1021%2Fml500146d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velcicky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soicke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalz, H. G.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Cyanomethylation of Aryl Halides through Domino Suzuki Coupling-Isoxazole Fragmentation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">6948</span>– <span class="NLM_lpage">6951</span>, <span class="refDoi"> DOI: 10.1021/ja201743j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja201743j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=6948-6951&author=J.+Velcickyauthor=A.+Soickeauthor=R.+Steinerauthor=H.+G.+Schmalz&title=Palladium-Catalyzed+Cyanomethylation+of+Aryl+Halides+through+Domino+Suzuki+Coupling-Isoxazole+Fragmentation&doi=10.1021%2Fja201743j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cyanomethylation of Aryl Halides through Domino Suzuki Coupling-Isoxazole Fragmentation</span></div><div class="casAuthors">Velcicky, Juraj; Soicke, Arne; Steiner, Roland; Schmalz, Hans-Gunther</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6948-6951</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A one-pot protocol for the cyanomethylation of aryl halides through a palladium-catalyzed reaction with isoxazole-4-boronic acid pinacol ester was developed.  Mechanistically, the reaction proceeds through (1) Suzuki coupling, (2) base-induced fragmentation, and (3) deformylation as shown by characterization of all postulated intermediates.  Under optimized conditions (PdCl2dppf, KF, DMSO/H2O, 130 °C) a broad spectrum of aryl bromides could be converted into arylacetonitriles with up to 88% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok14-knI07mbVg90H21EOLACvtfcHk0lgcAX8v97iDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVCksbc%253D&md5=8028f8c75215996acf1871b1bce3b7d8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja201743j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja201743j%26sid%3Dliteratum%253Aachs%26aulast%3DVelcicky%26aufirst%3DJ.%26aulast%3DSoicke%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DR.%26aulast%3DSchmalz%26aufirst%3DH.%2BG.%26atitle%3DPalladium-Catalyzed%2520Cyanomethylation%2520of%2520Aryl%2520Halides%2520through%2520Domino%2520Suzuki%2520Coupling-Isoxazole%2520Fragmentation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D6948%26epage%3D6951%26doi%3D10.1021%2Fja201743j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onomura, O.</span></span> <span> </span><span class="NLM_article-title">Efficient Oxidation of Cycloalkanols by Sodium Nitrite with Molecular Oxygen in Trifluoroacetic Acid</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">8221</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2004.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.tetlet.2004.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=8221-8224&author=Y.+Matsumuraauthor=Y.+Yamamotoauthor=N.+Moriyamaauthor=S.+Furukuboauthor=F.+Iwasakiauthor=O.+Onomura&title=Efficient+Oxidation+of+Cycloalkanols+by+Sodium+Nitrite+with+Molecular+Oxygen+in+Trifluoroacetic+Acid&doi=10.1016%2Fj.tetlet.2004.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient oxidation of cycloalkanols by sodium nitrite with molecular oxygen in trifluoroacetic acid</span></div><div class="casAuthors">Matsumura, Yoshihiro; Yamamoto, Yutaka; Moriyama, Noriaki; Furukubo, Shigeru; Iwasaki, Fumiaki; Onomura, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8221-8224</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxidn. of aliph. cycloalkanols by sodium nitrite in trifluoroacetic acid gave α,ω-dicarboxylic acids in good yields.  Adipic acid was obtained in a quant. yield from cyclohexanol using 1 equiv of sodium nitrite under oxygen atm. but the oxidn. required more than 3 equiv of sodium nitrite under nitrogen atm.  The oxidn. method was applicable to the conversion of 1-alkanols to the corresponding carboxylic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorqRG54kP7KrVg90H21EOLACvtfcHk0lgcAX8v97iDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D&md5=fc450e4a001627d5693336c3f256a9a8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2004.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2004.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DN.%26aulast%3DFurukubo%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DF.%26aulast%3DOnomura%26aufirst%3DO.%26atitle%3DEfficient%2520Oxidation%2520of%2520Cycloalkanols%2520by%2520Sodium%2520Nitrite%2520with%2520Molecular%2520Oxygen%2520in%2520Trifluoroacetic%2520Acid%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D45%26spage%3D8221%26epage%3D8224%26doi%3D10.1016%2Fj.tetlet.2004.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renz, M.</span></span> <span> </span><span class="NLM_article-title">Ketonization of Carboxylic Acids by Decarboxylation: Mechanism and Scope</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200400546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1002%2Fejoc.200400546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=979-988&author=M.+Renz&title=Ketonization+of+Carboxylic+Acids+by+Decarboxylation%3A+Mechanism+and+Scope&doi=10.1002%2Fejoc.200400546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200400546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200400546%26sid%3Dliteratum%253Aachs%26aulast%3DRenz%26aufirst%3DM.%26atitle%3DKetonization%2520of%2520Carboxylic%2520Acids%2520by%2520Decarboxylation%253A%2520Mechanism%2520and%2520Scope%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2005%26volume%3D2005%26spage%3D979%26epage%3D988%26doi%3D10.1002%2Fejoc.200400546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcantoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambri, L.</span></span> <span> </span><span class="NLM_article-title">Unusual and Unexpected Reactivity of T-Butyl Dicarbonate (Boc2o) with Alcohols in the Presence of Magnesium Perchlorate. A New and General Route to T-Butyl Ethers</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/ol047704o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol047704o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=427-430&author=G.+Bartoliauthor=M.+Boscoauthor=M.+Locatelliauthor=E.+Marcantoniauthor=P.+Melchiorreauthor=L.+Sambri&title=Unusual+and+Unexpected+Reactivity+of+T-Butyl+Dicarbonate+%28Boc2o%29+with+Alcohols+in+the+Presence+of+Magnesium+Perchlorate.+A+New+and+General+Route+to+T-Butyl+Ethers&doi=10.1021%2Fol047704o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual and Unexpected Reactivity of t-Butyl Dicarbonate (Boc2O) with Alcohols in the Presence of Magnesium Perchlorate. A New and General Route to t-Butyl Ethers</span></div><div class="casAuthors">Bartoli, Giuseppe; Bosco, Marcella; Locatelli, Manuela; Marcantoni, Enrico; Melchiorre, Paolo; Sambri, Letizia</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new mild method for protecting alcs. as t-Bu ethers is reported.  The reaction proceeds with Mg(ClO4)2 and Boc2O and shows general applicability.  The deprotection of t-Bu ethers has also been revisited.  Preliminary results indicate the CeCl3·7H2O/NaI system is a very suitable catalyst for their removal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqdo5o1Y49RrVg90H21EOLACvtfcHk0lgcAX8v97iDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ensQ%253D%253D&md5=295b06fe47c63d44aaf8dde54823d06c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fol047704o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol047704o%26sid%3Dliteratum%253Aachs%26aulast%3DBartoli%26aufirst%3DG.%26aulast%3DBosco%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DM.%26aulast%3DMarcantoni%26aufirst%3DE.%26aulast%3DMelchiorre%26aufirst%3DP.%26aulast%3DSambri%26aufirst%3DL.%26atitle%3DUnusual%2520and%2520Unexpected%2520Reactivity%2520of%2520T-Butyl%2520Dicarbonate%2520%2528Boc2o%2529%2520with%2520Alcohols%2520in%2520the%2520Presence%2520of%2520Magnesium%2520Perchlorate.%2520A%2520New%2520and%2520General%2520Route%2520to%2520T-Butyl%2520Ethers%26jtitle%3DOrg.%2520Lett.%26date%3D2005%26volume%3D7%26spage%3D427%26epage%3D430%26doi%3D10.1021%2Fol047704o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortes Francisco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell-Saward, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLatchie, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span> <span> </span><span class="NLM_article-title">Bioluminescence Imaging of Chronic <i>Trypanosoma cruzi</i> Infections Reveals Tissue-Specific Parasite Dynamics and Heart Disease in the Absence of Locally Persistent Infection</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1111/cmi.12297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1111%2Fcmi.12297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=24712539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWltbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1285-1300&author=M.+D.+Lewisauthor=A.+Fortes+Franciscoauthor=M.+C.+Taylorauthor=H.+Burrell-Sawardauthor=A.+P.+McLatchieauthor=M.+A.+Milesauthor=J.+M.+Kelly&title=Bioluminescence+Imaging+of+Chronic+Trypanosoma+cruzi+Infections+Reveals+Tissue-Specific+Parasite+Dynamics+and+Heart+Disease+in+the+Absence+of+Locally+Persistent+Infection&doi=10.1111%2Fcmi.12297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection</span></div><div class="casAuthors">Lewis, Michael D.; Fortes Francisco, Amanda; Taylor, Martin C.; Burrell-Saward, Hollie; McLatchie, Alex P.; Miles, Michael A.; Kelly, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1285-1300</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Chronic Trypanosoma cruzi infections lead to cardiomyopathy in 20-30% of cases.  A causal link between cardiac infection and pathol. has been difficult to establish because of a lack of robust methods to detect scarce, focally distributed parasites within tissues.  We developed a highly sensitive bioluminescence imaging system based on T. cruzi expressing a novel luciferase that emits tissue-penetrating orange-red light.  This enabled long-term serial evaluation of parasite burdens in individual mice with an in vivo limit of detection of significantly less than 1000 parasites.  Parasite distributions during chronic infections were highly focal and spatiotemporally dynamic, but did not localize to the heart.  End-point ex vivo bioluminescence imaging allowed tissue-specific quantification of parasite loads with minimal sampling bias.  During chronic infections, the gastro-intestinal tract, specifically the colon and stomach, was the only site where T. cruzi infection was consistently obsd.  Quant. PCR-inferred parasite loads correlated with ex vivo bioluminescence and confirmed the gut as the parasite reservoir.  Chronically infected mice developed myocarditis and cardiac fibrosis, despite the absence of locally persistent parasites.  These data identify the gut as a permissive niche for long-term T. cruzi infection and show that canonical features of Chagas disease can occur without continual myocardium-specific infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyZb4PqY1d6LVg90H21EOLACvtfcHk0lgfy-v4A3KNYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWltbfK&md5=bda234eede9a5091550a48fdcd977327</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fcmi.12297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcmi.12297%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DFortes%2BFrancisco%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DM.%2BC.%26aulast%3DBurrell-Saward%26aufirst%3DH.%26aulast%3DMcLatchie%26aufirst%3DA.%2BP.%26aulast%3DMiles%26aufirst%3DM.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26atitle%3DBioluminescence%2520Imaging%2520of%2520Chronic%2520Trypanosoma%2520cruzi%2520Infections%2520Reveals%2520Tissue-Specific%2520Parasite%2520Dynamics%2520and%2520Heart%2520Disease%2520in%2520the%2520Absence%2520of%2520Locally%2520Persistent%2520Infection%26jtitle%3DCell.%2520Microbiol.%26date%3D2014%26volume%3D16%26spage%3D1285%26epage%3D1300%26doi%3D10.1111%2Fcmi.12297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span> <span> </span><span class="NLM_article-title">Development of <i>Trypanosoma cruzi</i> i<i>n vitro</i> Assays to Identify Compounds Suitable for Progression in Chagas’ Disease Drug Discovery</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0006612</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0006612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1371%2Fjournal.pntd.0006612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=30001347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OrurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&author=L.+M.+MacLeanauthor=J.+Thomasauthor=M.+D.+Lewisauthor=I.+Cotilloauthor=D.+W.+Grayauthor=M.+De+Rycker&title=Development+of+Trypanosoma+cruzi+in+vitro+Assays+to+Identify+Compounds+Suitable+for+Progression+in+Chagas%E2%80%99+Disease+Drug+Discovery&doi=10.1371%2Fjournal.pntd.0006612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery</span></div><div class="casAuthors">MacLean, Lorna M.; Thomas, John; Lewis, Michael D.; Cotillo, Ignacio; Gray, David W.; De Rycker, Manu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0006612/1-e0006612/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Chagas' disease is responsible for significant mortality and morbidity in Latin America.  Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed.  However, recent efforts have proved unsuccessful with failure of the ergosterol biosynthesis inhibitor posaconazole in phase II clin. trials despite promising in vitro and in vivo studies.  The lack of translation between lab. expts. and clin. outcome is a major issue for further drug discovery efforts.  Our goal was to identify cell-based assays that could differentiate current nitro-arom. drugs nifurtimox and benznidazole from posaconazole.  Using a panel of T. cruzi strains including the six major lineages (TcI-VI), we found that strain PAH179 (TcV) was markedly less susceptible to posaconazole in vitro.  Detn. of parasite doubling and cycling times as well as EdU labeling expts. all indicate that this lack of sensitivity is due to the slow doubling and cycling time of strain PAH179.  This is in accordance with ergosterol biosynthesis inhibition by posaconazole leading to critically low ergosterol levels only after multiple rounds of division, and is further supported by the lack of effect of posaconazole on the nonreplicative trypomastigote form.  A washout expt. with prolonged posaconazole treatment showed that, even for more rapidly replicating strains, this compd. cannot clear all parasites, indicative of a heterogeneous parasite population in vitro and potentially the presence of quiescent parasites.  Benznidazole in contrast was able to kill all parasites.  The work presented here shows clear differentiation between the nitro-arom. drugs and posaconazole in several assays, and suggests that in vitro there may be clin. relevant heterogeneity in the parasite population that can be revealed in long-term washout expts.  Based on these findings we have adjusted our in vitro screening cascade so that only the most promising compds. are progressed to in vivo expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3xmuV5jnr5rVg90H21EOLACvtfcHk0lgfy-v4A3KNYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OrurbI&md5=4af966ae8554bc00e9f86531dfb96c48</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0006612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0006612%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DL.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520Trypanosoma%2520cruzi%2520in%2520vitro%2520Assays%2520to%2520Identify%2520Compounds%2520Suitable%2520for%2520Progression%2520in%2520Chagas%25E2%2580%2599%2520Disease%2520Drug%2520Discovery%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2018%26volume%3D12%26doi%3D10.1371%2Fjournal.pntd.0006612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onomura, O.</span></span> <span> </span><span class="NLM_article-title">Efficient Oxidation of Cycloalkanols by Sodium Nitrite with Molecular Oxygen in Trifluoroacetic Acid</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">8221</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2004.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.tetlet.2004.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=8221-8224&author=Y.+Matsumuraauthor=Y.+Yamamotoauthor=N.+Moriyamaauthor=S.+Furukuboauthor=F.+Iwasakiauthor=O.+Onomura&title=Efficient+Oxidation+of+Cycloalkanols+by+Sodium+Nitrite+with+Molecular+Oxygen+in+Trifluoroacetic+Acid&doi=10.1016%2Fj.tetlet.2004.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient oxidation of cycloalkanols by sodium nitrite with molecular oxygen in trifluoroacetic acid</span></div><div class="casAuthors">Matsumura, Yoshihiro; Yamamoto, Yutaka; Moriyama, Noriaki; Furukubo, Shigeru; Iwasaki, Fumiaki; Onomura, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8221-8224</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxidn. of aliph. cycloalkanols by sodium nitrite in trifluoroacetic acid gave α,ω-dicarboxylic acids in good yields.  Adipic acid was obtained in a quant. yield from cyclohexanol using 1 equiv of sodium nitrite under oxygen atm. but the oxidn. required more than 3 equiv of sodium nitrite under nitrogen atm.  The oxidn. method was applicable to the conversion of 1-alkanols to the corresponding carboxylic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorqRG54kP7KrVg90H21EOLACvtfcHk0lj1suTxUJistg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D&md5=fc450e4a001627d5693336c3f256a9a8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2004.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2004.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DN.%26aulast%3DFurukubo%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DF.%26aulast%3DOnomura%26aufirst%3DO.%26atitle%3DEfficient%2520Oxidation%2520of%2520Cycloalkanols%2520by%2520Sodium%2520Nitrite%2520with%2520Molecular%2520Oxygen%2520in%2520Trifluoroacetic%2520Acid%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D45%26spage%3D8221%26epage%3D8224%26doi%3D10.1016%2Fj.tetlet.2004.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueren-Calabuig, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span> <span> </span><span class="NLM_article-title">The Qi Site of Cytochrome b is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i></span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.9b00426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.9b00426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+J.+Wallauthor=S.+Carvalhoauthor=R.+Milneauthor=J.+A.+Bueren-Calabuigauthor=S.+Monizauthor=J.+Cantizani-Perezauthor=L.+MacLeanauthor=A.+Kesslerauthor=I.+Cotilloauthor=L.+Sastryauthor=S.+Manthriauthor=S.+Pattersonauthor=F.+Zuccottoauthor=S.+Thompsonauthor=J.+Martinauthor=M.+Marcoauthor=T.+J.+Milesauthor=M.+De+Ryckerauthor=M.+G.+Thomasauthor=A.+H.+Fairlambauthor=I.+H.+Gilbertauthor=S.+Wyllie&title=The+Qi+Site+of+Cytochrome+b+is+a+Promiscuous+Drug+Target+in+Trypanosoma+cruzi+and+Leishmania+donovani&doi=10.1021%2Facsinfecdis.9b00426"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.9b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.9b00426%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DCarvalho%26aufirst%3DS.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DBueren-Calabuig%26aufirst%3DJ.%2BA.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DCantizani-Perez%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DKessler%26aufirst%3DA.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DSastry%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyllie%26aufirst%3DS.%26atitle%3DThe%2520Qi%2520Site%2520of%2520Cytochrome%2520b%2520is%2520a%2520Promiscuous%2520Drug%2520Target%2520in%2520Trypanosoma%2520cruzi%2520and%2520Leishmania%2520donovani%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26doi%3D10.1021%2Facsinfecdis.9b00426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hamed  Memariani</span>, <span class="hlFld-ContribAuthor ">Mojtaba  Memariani</span>. </span><span class="cited-content_cbyCitation_article-title">Melittin as a promising anti-protozoan peptide: current knowledge and future prospects. </span><span class="cited-content_cbyCitation_journal-name">AMB Express</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13568-021-01229-1" title="DOI URL">https://doi.org/10.1186/s13568-021-01229-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13568-021-01229-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13568-021-01229-1%26sid%3Dliteratum%253Aachs%26jtitle%3DAMB%2520Express%26atitle%3DMelittin%252Bas%252Ba%252Bpromising%252Banti-protozoan%252Bpeptide%25253A%252Bcurrent%252Bknowledge%252Band%252Bfuture%252Bprospects%26aulast%3DMemariani%26aufirst%3DHamed%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0034.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of compounds used to treat Chagas disease.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Hit molecule and generic structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Procedure B for the Synthesis of 6-Acetamide-R3-Substituted Quinazolinediones</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternative Quinazolinedione Synthesis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Procedure C for the Synthesis of 4-Substituted Cyclohexylamines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Aryl Substituent at R<sup>6</sup><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) cyclohexylethylamine, HATU, NMM, DMF, rt, 16 h; (b) ethyl chloroformate, 90 °C, 1.5 h, then KOH, EtOH, 85 °C, 3.5 h; (c) ArB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub>, water, dioxane, 90 °C, 16 h.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0013.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 3-(<i>tert</i>-Butyl)cyclopentanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0014.jpeg" id="rightTab-GRAPHIC-d7e1223-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of 2-(<i>tert</i>-Butyl)tetrahydro-2<i>H</i>-pyran-4-amines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0015.jpeg" id="rightTab-GRAPHIC-d7e1260-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of (1<i>R</i>,4<i>R</i>)-4-(2-Fluoropropan-2-yl)cyclohexanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of 2-(<i>tert</i>-Butyl)-1,3-dioxan-5-amines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of (1<i>R</i>,4<i>R</i>)-4-(<i>tert</i>-Butoxy)cyclohexanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of (1<i>R</i>,4R)-4-Isopropoxycyclohexanamine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Pyrido-Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) concentrated HNO<sub>3</sub>, concentrated H<sub>2</sub>SO<sub>4</sub>, 0 °C to rt, 16 h then 70 °C, 4 h; (b) LiOH, THF, MeOH, water, rt, 17 h; (c) amine, BOP, Et<sub>3</sub>N, DMF, rt, 24 h; (d) carbonyl diimidazole, THF, 85 °C, 48 h; (e) Pd/C, H<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, MeOH, rt, 2 h; (f) Ac<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h.</p></p></figure><figure data-id="fig3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mean blood concentration–time profile of <b>43</b> following single IP administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mean blood concentration–time profile of <b>43</b> following single oral administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mean blood concentration–time profile of <b>89</b> following single intraperitoneal administration at 30 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data. Dose Formulation: 10% DMSO; 60% PEG400; 30% Milli-Q water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mean blood concentration–time profile of <b>89</b> following single intraperitoneal administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data. Dose formulation: 0.5% w/v HPMC with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mean blood concentration–time profile of <b>89</b> following single oral administration at 10 mg/kg to the female NMRI mouse. Gray lines are individual animal profiles. The dark blue line is mean data. Dose formulation: 0.5% w/v HPMC with 0.4% v/v Tween 80 and 0.5% v/v benzyl alcohol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/medium/jm9b01852_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Ratio of parasitemia levels for mice infected with <i>T. cruzi</i> after treatment with compounds for 5 days and 10 days compared to starting levels of parasitemia. Data is based on 5 mice in each group, except for vehicles with MC (4 mice) and oral <b>43</b> (3 mice). The error bars show the standard deviation. PEG is 10% DMSO; 60% PEG400; 30% water; MC is 0.5% MC, 0.4% Tween 80, and 0.5% benzyl alcohol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01852/20200323/images/large/jm9b01852_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01852&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i171">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lidani, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damasceno, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrame, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messias-Reason, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandri, T. L.</span></span> <span> </span><span class="NLM_article-title">Chagas Disease: From Discovery to a Worldwide Health Problem</span>. <i>Front. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">166</span>, <span class="refDoi"> DOI: 10.3389/fpubh.2019.00166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.3389%2Ffpubh.2019.00166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=31312626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=166&author=K.+C.+F.+Lidaniauthor=F.+A.+Andradeauthor=L.+Baviaauthor=F.+S.+Damascenoauthor=M.+H.+Beltrameauthor=I.+J.+Messias-Reasonauthor=T.+L.+Sandri&title=Chagas+Disease%3A+From+Discovery+to+a+Worldwide+Health+Problem&doi=10.3389%2Ffpubh.2019.00166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas Disease: From Discovery to a Worldwide Health Problem</span></div><div class="casAuthors">Lidani Karita Claudia Freitas; Andrade Fabiana Antunes; Bavia Lorena; Messias-Reason Iara J; Sandri Thaisa Lucas; Damasceno Flavia Silva; Beltrame Marcia Holsbach; Sandri Thaisa Lucas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in public health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">166</span>
        ISSN:<span class="NLM_cas:issn">2296-2565</span>.
    </div><div class="casAbstract">Carlos Chagas discovered American trypanosomiasis, also named Chagas disease (CD) in his honor, just over a century ago.  He described the clinical aspects of the disease, characterized by its etiological agent (Trypanosoma cruzi) and identified its insect vector.  Initially, CD occurred only in Latin America and was considered a silent and poorly visible disease.  More recently, CD became a neglected worldwide disease with a high morbimortality rate and substantial social impact, emerging as a significant public health threat.  In this context, it is crucial to better understand better the epidemiological scenarios of CD and its transmission dynamics, involving people infected and at risk of infection, diversity of the parasite, vector species, and T. cruzi reservoirs.  Although efforts have been made by endemic and non-endemic countries to control, treat, and interrupt disease transmission, the cure or complete eradication of CD are still topics of great concern and require global attention.  Considering the current scenario of CD, also affecting non-endemic places such as Canada, USA, Europe, Australia, and Japan, in this review we aim to describe the spread of CD cases worldwide since its discovery until it has become a global public health concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdNDVSKB6ie-Lt9HypzAgQfW6udTcc2eZA6kBg6znpOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D&md5=e22d46895f7c7162d2a98b8787ea6637</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffpubh.2019.00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpubh.2019.00166%26sid%3Dliteratum%253Aachs%26aulast%3DLidani%26aufirst%3DK.%2BC.%2BF.%26aulast%3DAndrade%26aufirst%3DF.%2BA.%26aulast%3DBavia%26aufirst%3DL.%26aulast%3DDamasceno%26aufirst%3DF.%2BS.%26aulast%3DBeltrame%26aufirst%3DM.%2BH.%26aulast%3DMessias-Reason%26aufirst%3DI.%2BJ.%26aulast%3DSandri%26aufirst%3DT.%2BL.%26atitle%3DChagas%2520Disease%253A%2520From%2520Discovery%2520to%2520a%2520Worldwide%2520Health%2520Problem%26jtitle%3DFront.%2520Public%2520Health%26date%3D2019%26volume%3D7%26spage%3D166%26doi%3D10.3389%2Ffpubh.2019.00166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basanez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrend, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blok, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vlas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurarie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jervis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly-Hope, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rutte, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietman, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndeffo-Mbah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medley, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinsent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardus, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torr, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truscott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoueva, A.</span></span> <span> </span><span class="NLM_article-title">Quantitative Analyses and Modelling to Support Achievement of the 2020 Goals for Nine Neglected Tropical Diseases</span>. <i>Parasites Vectors</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">630</span>, <span class="refDoi"> DOI: 10.1186/s13071-015-1235-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1186%2Fs13071-015-1235-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=26652272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A280%3ADC%252BC28rhtl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=630&author=T.+D.+Hollingsworthauthor=E.+R.+Adamsauthor=R.+M.+Andersonauthor=K.+Atkinsauthor=S.+Bartschauthor=M.+G.+Basanezauthor=M.+Behrendauthor=D.+J.+Blokauthor=L.+A.+Chapmanauthor=L.+Coffengauthor=O.+Courtenayauthor=R.+E.+Crumpauthor=S.+J.+de+Vlasauthor=A.+Dobsonauthor=L.+Dysonauthor=H.+Farkasauthor=A.+P.+Galvaniauthor=M.+Gambhirauthor=D.+Gurarieauthor=M.+A.+Irvineauthor=S.+Jervisauthor=M.+J.+Keelingauthor=L.+Kelly-Hopeauthor=C.+Kingauthor=B.+Y.+Leeauthor=E.+A.+Le+Rutteauthor=T.+M.+Lietmanauthor=M.+Ndeffo-Mbahauthor=G.+F.+Medleyauthor=E.+Michaelauthor=A.+Pandeyauthor=J.+K.+Petersonauthor=A.+Pinsentauthor=T.+C.+Porcoauthor=J.+H.+Richardusauthor=L.+Reimerauthor=K.+S.+Rockauthor=B.+K.+Singhauthor=W.+Stolkauthor=S.+Swaminathanauthor=S.+J.+Torrauthor=J.+Townsendauthor=J.+Truscottauthor=M.+Walkerauthor=A.+Zoueva&title=Quantitative+Analyses+and+Modelling+to+Support+Achievement+of+the+2020+Goals+for+Nine+Neglected+Tropical+Diseases&doi=10.1186%2Fs13071-015-1235-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases</span></div><div class="casAuthors">Hollingsworth T Deirdre; Chapman Lloyd A C; Courtenay Orin; Crump Ron E; Dyson Louise; Farkas Hajnal; Irvine Michael A; Jervis Sarah; Keeling Matt J; Rock Kat S; Adams Emily R; Kelly-Hope Louise; Reimer Lisa; Torr Steve J; Anderson Roy M; Basanez Maria-Gloria; Truscott James; Walker Martin; Atkins Katherine; Medley Graham F; Bartsch Sarah; Lee Bruce Y; Behrend Matthew; Blok David J; Coffeng Luc; de Vlas Sake J; Le Rutte Epke A; Richardus Jan Hendrik; Stolk Wilma; Dobson Andy; Peterson Jennifer K; Galvani Alison P; Ndeffo-Mbah Martial; Pandey Abhishek; Townsend Jeffrey; Gambhir Manoj; Pinsent Amy; Gurarie David; King Charles; Lietman Thomas M; Porco Travis C; Michael Edwin; Singh Brajendra K; Swaminathan Subramanian; Zoueva Alexandra</div><div class="citationInfo"><span class="NLM_cas:title">Parasites & vectors</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">630</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quantitative analysis and mathematical models are useful tools in informing strategies to control or eliminate disease.  Currently, there is an urgent need to develop these tools to inform policy to achieve the 2020 goals for neglected tropical diseases (NTDs).  In this paper we give an overview of a collection of novel model-based analyses which aim to address key questions on the dynamics of transmission and control of nine NTDs: Chagas disease, visceral leishmaniasis, human African trypanosomiasis, leprosy, soil-transmitted helminths, schistosomiasis, lymphatic filariasis, onchocerciasis and trachoma.  Several common themes resonate throughout these analyses, including: the importance of epidemiological setting on the success of interventions; targeting groups who are at highest risk of infection or re-infection; and reaching populations who are not accessing interventions and may act as a reservoir for infection,.  The results also highlight the challenge of maintaining elimination 'as a public health problem' when true elimination is not reached.  The models elucidate the factors that may be contributing most to persistence of disease and discuss the requirements for eventually achieving true elimination, if that is possible.  Overall this collection presents new analyses to inform current control initiatives.  These papers form a base from which further development of the models and more rigorous validation against a variety of datasets can help to give more detailed advice.  At the moment, the models' predictions are being considered as the world prepares for a final push towards control or elimination of neglected tropical diseases by 2020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc5fXcz3Z5wNts4TFFB11gfW6udTcc2eZA6kBg6znpOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rhtl2hsA%253D%253D&md5=0893a888adfad4c4b19994b67626f79a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs13071-015-1235-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13071-015-1235-1%26sid%3Dliteratum%253Aachs%26aulast%3DHollingsworth%26aufirst%3DT.%2BD.%26aulast%3DAdams%26aufirst%3DE.%2BR.%26aulast%3DAnderson%26aufirst%3DR.%2BM.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DBartsch%26aufirst%3DS.%26aulast%3DBasanez%26aufirst%3DM.%2BG.%26aulast%3DBehrend%26aufirst%3DM.%26aulast%3DBlok%26aufirst%3DD.%2BJ.%26aulast%3DChapman%26aufirst%3DL.%2BA.%26aulast%3DCoffeng%26aufirst%3DL.%26aulast%3DCourtenay%26aufirst%3DO.%26aulast%3DCrump%26aufirst%3DR.%2BE.%26aulast%3Dde%2BVlas%26aufirst%3DS.%2BJ.%26aulast%3DDobson%26aufirst%3DA.%26aulast%3DDyson%26aufirst%3DL.%26aulast%3DFarkas%26aufirst%3DH.%26aulast%3DGalvani%26aufirst%3DA.%2BP.%26aulast%3DGambhir%26aufirst%3DM.%26aulast%3DGurarie%26aufirst%3DD.%26aulast%3DIrvine%26aufirst%3DM.%2BA.%26aulast%3DJervis%26aufirst%3DS.%26aulast%3DKeeling%26aufirst%3DM.%2BJ.%26aulast%3DKelly-Hope%26aufirst%3DL.%26aulast%3DKing%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DLe%2BRutte%26aufirst%3DE.%2BA.%26aulast%3DLietman%26aufirst%3DT.%2BM.%26aulast%3DNdeffo-Mbah%26aufirst%3DM.%26aulast%3DMedley%26aufirst%3DG.%2BF.%26aulast%3DMichael%26aufirst%3DE.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DJ.%2BK.%26aulast%3DPinsent%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DT.%2BC.%26aulast%3DRichardus%26aufirst%3DJ.%2BH.%26aulast%3DReimer%26aufirst%3DL.%26aulast%3DRock%26aufirst%3DK.%2BS.%26aulast%3DSingh%26aufirst%3DB.%2BK.%26aulast%3DStolk%26aufirst%3DW.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DTorr%26aufirst%3DS.%2BJ.%26aulast%3DTownsend%26aufirst%3DJ.%26aulast%3DTruscott%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DZoueva%26aufirst%3DA.%26atitle%3DQuantitative%2520Analyses%2520and%2520Modelling%2520to%2520Support%2520Achievement%2520of%2520the%25202020%2520Goals%2520for%2520Nine%2520Neglected%2520Tropical%2520Diseases%26jtitle%3DParasites%2520Vectors%26date%3D2015%26volume%3D8%26spage%3D630%26doi%3D10.1186%2Fs13071-015-1235-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baragana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Challenges and Recent Progress in Drug Discovery for Tropical Diseases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0327-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1038%2Fs41586-018-0327-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=30046073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=498-506&author=M.+De%0ARyckerauthor=B.+Baraganaauthor=S.+L.+Duceauthor=I.+H.+Gilbert&title=Challenges+and+Recent+Progress+in+Drug+Discovery+for+Tropical+Diseases&doi=10.1038%2Fs41586-018-0327-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and recent progress in drug discovery for tropical diseases</span></div><div class="casAuthors">De Rycker, Manu; Baragana, Beatriz; Duce, Suzanne L.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7715</span>),
    <span class="NLM_cas:pages">498-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries.  These diseases predominantly affect the world's poorest people.  Currently available drugs are inadequate for the majority of these diseases, and there is an urgent need for new treatments.  This Review discusses some of the challenges involved in developing new drugs to treat these diseases and highlights recent progress.  While there have been notable successes, there is still a long way to go.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-L8-tHy6aTbVg90H21EOLACvtfcHk0ljyE-zxU8_wiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP&md5=3bc57ce68776462cf6a053efa276a989</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0327-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0327-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DBaragana%26aufirst%3DB.%26aulast%3DDuce%26aufirst%3DS.%2BL.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DChallenges%2520and%2520Recent%2520Progress%2520in%2520Drug%2520Discovery%2520for%2520Tropical%2520Diseases%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3D498%26epage%3D506%26doi%3D10.1038%2Fs41586-018-0327-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">CDC</span>. <a href="https://www.cdc.gov/parasites/chagas/biology.html" class="extLink">https://www.cdc.gov/parasites/chagas/biology.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CDC.+https%3A%2F%2Fwww.cdc.gov%2Fparasites%2Fchagas%2Fbiology.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">WHO</span>. <a href="https://apps.who.int/iris/bitstream/handle/10665/259404/9789241513166-eng.pdf?sequence=1&amp;isAllowed=y" class="extLink">https://apps.who.int/iris/bitstream/handle/10665/259404/9789241513166-eng.pdf?sequence=1=y</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO.+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F259404%2F9789241513166-eng.pdf%3Fsequence%3D1%3Dy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Dos-Santos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreto-De-Albuquerque, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berbert, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, B. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra Villa-Verde, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzoni, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savino, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotta-de-Almeida, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Meis, J.</span></span> <span> </span><span class="NLM_article-title">Unraveling Chagas Disease Transmission through the Oral Route: Gateways to <i>Trypanosoma cruzi</i> Infection and Target Tissues</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005507</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1371%2Fjournal.pntd.0005507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=28379959" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=D.+Silva-Dos-Santosauthor=J.+Barreto-De-Albuquerqueauthor=B.+Guerraauthor=O.+C.+Moreiraauthor=L.+R.+Berbertauthor=M.+T.+Ramosauthor=B.+A.+S.+Mascarenhasauthor=C.+Brittoauthor=A.+Morrotauthor=D.+M.+Serra+Villa-Verdeauthor=L.+R.+Garzoniauthor=W.+Savinoauthor=V.+Cotta-de-Almeidaauthor=J.+de+Meis&title=Unraveling+Chagas+Disease+Transmission+through+the+Oral+Route%3A+Gateways+to+Trypanosoma+cruzi+Infection+and+Target+Tissues&doi=10.1371%2Fjournal.pntd.0005507"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005507%26sid%3Dliteratum%253Aachs%26aulast%3DSilva-Dos-Santos%26aufirst%3DD.%26aulast%3DBarreto-De-Albuquerque%26aufirst%3DJ.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DMoreira%26aufirst%3DO.%2BC.%26aulast%3DBerbert%26aufirst%3DL.%2BR.%26aulast%3DRamos%26aufirst%3DM.%2BT.%26aulast%3DMascarenhas%26aufirst%3DB.%2BA.%2BS.%26aulast%3DBritto%26aufirst%3DC.%26aulast%3DMorrot%26aufirst%3DA.%26aulast%3DSerra%2BVilla-Verde%26aufirst%3DD.%2BM.%26aulast%3DGarzoni%26aufirst%3DL.%2BR.%26aulast%3DSavino%26aufirst%3DW.%26aulast%3DCotta-de-Almeida%26aufirst%3DV.%26aulast%3Dde%2BMeis%26aufirst%3DJ.%26atitle%3DUnraveling%2520Chagas%2520Disease%2520Transmission%2520through%2520the%2520Oral%2520Route%253A%2520Gateways%2520to%2520Trypanosoma%2520cruzi%2520Infection%2520and%2520Target%2520Tissues%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filigheddu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J. M.</span></span> <span> </span><span class="NLM_article-title">Orally-Transmitted Chagas Disease</span>. <i>Med. Clin. (Barcelona)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.medcli.2016.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.medcli.2016.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=27993415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FmtlCrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2017&pages=125-131&author=M.+T.+Filighedduauthor=M.+Gorgolasauthor=J.+M.+Ramos&title=Orally-Transmitted+Chagas+Disease&doi=10.1016%2Fj.medcli.2016.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Orally-transmitted Chagas disease</span></div><div class="casAuthors">Filigheddu Maria Teresa; Gorgolas Miguel; Ramos Jose Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Medicina clinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">125-131</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chagas disease is a zoonosis caused by protozoan parasite Trypanosoma cruzi, which is most frequently associated with a vectorial transmission.  However, in recent years we have observed a significant increase in the oral transmission of the disease, associated mainly with the consumption of drinks made from fruit or other vegetables contaminated with triatomine faeces or secretions from infected mammals.  After a latency period of 3 to 22 days after ingestion, the oral infection is characterized by more severe manifestations than those associated with vectorial transmission: prolonged fever, acute myocarditis with heart failure and, in some cases, meningoencephalitis.  Mortality can reach up to 33% of those infected.  The aim of this paper is to review this matter and to promote prevention practices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHdWlPP8eeFHO4gDb7JggCfW6udTcc2eZr1ocZPYnkybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FmtlCrsQ%253D%253D&md5=ed789f8ac6d3114b0566926062b4c043</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.medcli.2016.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.medcli.2016.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DFiligheddu%26aufirst%3DM.%2BT.%26aulast%3DGorgolas%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DJ.%2BM.%26atitle%3DOrally-Transmitted%2520Chagas%2520Disease%26jtitle%3DMed.%2520Clin.%2520%2528Barcelona%2529%26date%3D2017%26volume%3D148%26spage%3D125%26epage%3D131%26doi%3D10.1016%2Fj.medcli.2016.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Valdez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarleton, R. L.</span></span> <span> </span><span class="NLM_article-title">Spontaneous Dormancy Protects <i>Trypanosoma Cruzi</i> During Extended Drug Exposure</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e34039</span> <span class="refDoi"> DOI: 10.7554/eLife.34039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.7554%2FeLife.34039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=29578409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSjtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&author=F.+J.+Sanchez-Valdezauthor=A.+Padillaauthor=W.+Wangauthor=D.+Orrauthor=R.+L.+Tarleton&title=Spontaneous+Dormancy+Protects+Trypanosoma+Cruzi+During+Extended+Drug+Exposure&doi=10.7554%2FeLife.34039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure</span></div><div class="casAuthors">Sanchez-Valdez, Fernando J.; Padilla, Angel; Wang, Wei; Orr, Dylan; Tarleton, Rick L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e34039/1-e34039/20</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The ability of the Chagas disease agent Trypanosoma cruzi to resist extended in vivo exposure to highly effective trypanocidal compds. prompted us to explore the potential for dormancy and its contribution to failed drug treatments in this infection.  We document the development of non-proliferating intracellular amastigotes in vivo and in vitro in the absence of drug treatment.  Non-proliferative amastigotes ultimately converted to trypomastigotes and established infections in new host cells.  Most significantly, dormant amastigotes were uniquely resistant to extended drug treatment in vivo and in vitro and could re-establish a flourishing infection after as many as 30 days of drug exposure.  These results demonstrate a dormancy state in T. cruzi that accounts for the failure of highly cytotoxic compds. to completely resolve the infection.  The ability of T. cruzi to establish dormancy throws into question current methods for identifying curative drugs but also suggests alternative therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxBdeTA7huDLVg90H21EOLACvtfcHk0lhPIdNRcFw6ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSjtbrJ&md5=0af5ba24fb06183939ab6b0f6f008f4d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.7554%2FeLife.34039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.34039%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Valdez%26aufirst%3DF.%2BJ.%26aulast%3DPadilla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DOrr%26aufirst%3DD.%26aulast%3DTarleton%26aufirst%3DR.%2BL.%26atitle%3DSpontaneous%2520Dormancy%2520Protects%2520Trypanosoma%2520Cruzi%2520During%2520Extended%2520Drug%2520Exposure%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26doi%3D10.7554%2FeLife.34039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Anti-Trypanosomatid Drug Discovery: An Ongoing Challenge and a Continuing Need</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2016.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1038%2Fnrmicro.2016.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=28239154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=217-231&author=M.+C.+Fieldauthor=D.+Hornauthor=A.+H.+Fairlambauthor=M.+A.+Fergusonauthor=D.+W.+Grayauthor=K.+D.+Readauthor=M.+De+Ryckerauthor=L.+S.+Torrieauthor=P.+G.+Wyattauthor=S.+Wyllieauthor=I.+H.+Gilbert&title=Anti-Trypanosomatid+Drug+Discovery%3A+An+Ongoing+Challenge+and+a+Continuing+Need&doi=10.1038%2Fnrmicro.2016.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</span></div><div class="casAuthors">Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases.  These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal.  Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them.  In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled.  In addn., we consider the important challenges to drug discovery strategies and the new technologies that can address them.  The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBpRGL7YaP7Vg90H21EOLACvtfcHk0lgn71l6PLpEHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D&md5=1585d954d6eb695196a6c8921a84e300</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2016.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2016.193%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BC.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DAnti-Trypanosomatid%2520Drug%2520Discovery%253A%2520An%2520Ongoing%2520Challenge%2520and%2520a%2520Continuing%2520Need%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D15%26spage%3D217%26epage%3D231%26doi%3D10.1038%2Fnrmicro.2016.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, S. L.</span></span> <span> </span><span class="NLM_article-title">Management of Trypanosomiasis and Leishmaniasis</span>. <i>Br. Med. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1093/bmb/lds031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1093%2Fbmb%2Flds031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=23137768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVOrsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=175-196&author=M.+P.+Barrettauthor=S.+L.+Croft&title=Management+of+Trypanosomiasis+and+Leishmaniasis&doi=10.1093%2Fbmb%2Flds031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Management of trypanosomiasis and leishmaniasis</span></div><div class="casAuthors">Barrett, Michael P.; Croft, Simon L.</div><div class="citationInfo"><span class="NLM_cas:title">British Medical Bulletin</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-196</span>CODEN:
                <span class="NLM_cas:coden">BMBUAQ</span>;
        ISSN:<span class="NLM_cas:issn">0007-1420</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Background The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress.  For HAT the only advances in treatment over the past two decades have been the introduction of an eflornithine/nifurtimox co-administration and a shorter regime of the old std. melarsoprol.  Sources of data PubMed.  Areas of Agreement There is a need for new safe, oral drugs for cost-effective treatment of patients and use in control programs for all the trypanosomatid diseases.  Areas of controversy Cutaneous leishmaniasis is not on the agenda and treatments are lagging behind.  Growing points There are three compds. in development for the treatment of the CNS stage of HAT: fexinidazole, currently due to entry into phase II clin. studies, a benzoxaborole (SCYX-7158) in phase I trials and a diamidine deriv. (CPD-0802), in advanced pre-clin. development.  For Chagas disease, two anti-fungal triazoles are now in clin. trial.  In addn., clin. studies with benznidazole, a drug previously recommended only for acute stage treatment, are close to completion to det. the effectiveness in the treatment of early chronic and indeterminate Chagas disease.  For visceral leishmaniasis new formulations, therapeutic switching, in particular AmBisome, and the potential for combinations of established drugs have significantly improved the opportunities for the treatment in the Indian subcontinent, but not in East Africa.  Areas timely for developing research Improved diagnostic tools are needed to support treatment, for test of cure in clin. trials and for monitoring/surveillance of populations in control programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3qCu_DPH8LrVg90H21EOLACvtfcHk0lgn71l6PLpEHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVOrsbfO&md5=1da1b2e90ed07dc32777ca47a1be7f97</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fbmb%2Flds031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbmb%252Flds031%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DM.%2BP.%26aulast%3DCroft%26aufirst%3DS.%2BL.%26atitle%3DManagement%2520of%2520Trypanosomiasis%2520and%2520Leishmaniasis%26jtitle%3DBr.%2520Med.%2520Bull.%26date%3D2012%26volume%3D104%26spage%3D175%26epage%3D196%26doi%3D10.1093%2Fbmb%2Flds031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin-Neto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avezum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa-Estani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guhl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao-Melacini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span> <span> </span><span class="NLM_article-title">Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1306</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1056%2FNEJMoa1507574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=26323937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1295-1306&author=C.+A.+Morilloauthor=J.+A.+Marin-Netoauthor=A.+Avezumauthor=S.+Sosa-Estaniauthor=A.+Rassiauthor=F.+Rosasauthor=E.+Villenaauthor=R.+Quirozauthor=R.+Bonillaauthor=C.+Brittoauthor=F.+Guhlauthor=E.+Velazquezauthor=L.+Bonillaauthor=B.+Meeksauthor=P.+Rao-Melaciniauthor=J.+Pogueauthor=A.+Mattosauthor=J.+Lazdinsauthor=A.+Rassiauthor=S.+J.+Connollyauthor=S.+Yusuf&title=Randomized+Trial+of+Benznidazole+for+Chronic+Chagas%E2%80%99+Cardiomyopathy&doi=10.1056%2FNEJMoa1507574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of benznidazole for chronic Chagas' cardiomyopathy</span></div><div class="casAuthors">Morillo, C. A.; Marin-Neto, J. A.; Avezum, A.; Sosa-Estani, S.; Rassi, A., Jr.; Rosas, F.; Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; Guhl, F.; Velazquez, E.; Bonilla, L.; Meeks, B.; Rao-Melacini, P.; Pogue, J.; Mattos, A.; Lazdins, J.; Rassi, A.; Connolly, S. J.; Yusuf, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1295-1306</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.  We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years.  The primary outcome in the time-to-event anal. was the first event of any of the components of the composite outcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or other thromboembolic event.  The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and in 414 (29.1%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.07; P = 0.31).  At baseline, a polymerase-chain-reaction (PCR) assay was performed on blood samples obtained from 1896 patients; 60.5% had pos. results for Trypanosoma cruzi on PCR.  The rates of conversion to neg. PCR results (PCR conversion) were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, resp., at 2 years, and 46.7% and 33.1%, resp., at 5 years or more (P<0.001 for all comparisons).  The effect of treatment on PCR conversion varied according to geog. region: in Brazil, the odds ratio for PCR conversion was 3.03 (95% CI, 2.12 to 4.34) at 2 years and 1.87 (95% CI, 1.33 to 2.63) at 5 or more years; in Colombia and El Salvador, the odds ratio was 1.33 (95% CI, 0.90 to 1.98) at 2 years and 0.96 (95% CI, 0.63 to 1.45) at 5 or more years; and in Argentina and Bolivia, the odds ratio was 2.63 (95% CI, 1.89 to 3.66) at 2 years and 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction).  However, the rates of PCR conversion did not correspond to effects on clin. outcome (P = 0.16 for interaction).  Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clin. deterioration through 5 years of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz_0zFM1DyHLVg90H21EOLACvtfcHk0lhEY4-VT-USZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSms7g%253D&md5=6386aadfc625824961ff33e01a93ab2e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507574%26sid%3Dliteratum%253Aachs%26aulast%3DMorillo%26aufirst%3DC.%2BA.%26aulast%3DMarin-Neto%26aufirst%3DJ.%2BA.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DSosa-Estani%26aufirst%3DS.%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DRosas%26aufirst%3DF.%26aulast%3DVillena%26aufirst%3DE.%26aulast%3DQuiroz%26aufirst%3DR.%26aulast%3DBonilla%26aufirst%3DR.%26aulast%3DBritto%26aufirst%3DC.%26aulast%3DGuhl%26aufirst%3DF.%26aulast%3DVelazquez%26aufirst%3DE.%26aulast%3DBonilla%26aufirst%3DL.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DRao-Melacini%26aufirst%3DP.%26aulast%3DPogue%26aufirst%3DJ.%26aulast%3DMattos%26aufirst%3DA.%26aulast%3DLazdins%26aufirst%3DJ.%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DConnolly%26aufirst%3DS.%2BJ.%26aulast%3DYusuf%26aufirst%3DS.%26atitle%3DRandomized%2520Trial%2520of%2520Benznidazole%2520for%2520Chronic%2520Chagas%25E2%2580%2599%2520Cardiomyopathy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1295%26epage%3D1306%26doi%3D10.1056%2FNEJMoa1507574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">DNDi</span>. <a href="https://www.dndi.org/wp-content/uploads/2019/03/2page_BenditatStudyOverview_ENG.pdf" class="extLink">https://www.dndi.org/wp-content/uploads/2019/03/2page_BenditatStudyOverview_ENG.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+https%3A%2F%2Fwww.dndi.org%2Fwp-content%2Fuploads%2F2019%2F03%2F2page_BenditatStudyOverview_ENG.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">DNDi</span>. <a href="https://www.dndi.org/diseases-projects/portfolio/new-benz-regimens/" class="extLink">https://www.dndi.org/diseases-projects/portfolio/new-benz-regimens/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+https%3A%2F%2Fwww.dndi.org%2Fdiseases-projects%2Fportfolio%2Fnew-benz-regimens%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waskin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa-Estani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Carmen Bangher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milesi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallagray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloscar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverria, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Molina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa-Estani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waskin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquatella, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holadyk-Gris, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangher, M.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scollo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Albizu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, C.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, N.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milesi, R.R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berli, M.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallagray, M.H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres, N.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloscar, J.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucci, J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellatorre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulantay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverria, L.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, F.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman Melgar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldasoro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posada, E.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Montalva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Molina, J.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Velez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes-Lopez, P.A.</span></span> <span> </span><span class="NLM_article-title">Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic <i>T. cruzi</i> Carriers: The Stop-Chagas Trial</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2016.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.jacc.2016.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=28231946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1Kiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=939-947&author=C.+A.+Morilloauthor=H.+Waskinauthor=S.+Sosa-Estaniauthor=M.+del+Carmen+Bangherauthor=C.+Cuneoauthor=R.+Milesiauthor=M.+Mallagrayauthor=W.+Aptauthor=J.+Beloscarauthor=J.+Gasconauthor=I.+Molinaauthor=L.+E.+Echeverriaauthor=H.+Colomboauthor=J.+A.+Perez-Molinaauthor=F.+Wyssauthor=B.+Meeksauthor=L.+R.+Bonillaauthor=P.+Gaoauthor=B.+Weiauthor=M.+McCarthyauthor=S.+Yusufauthor=C.+Morilloauthor=S.+Sosa-Estaniauthor=H.+Waskinauthor=B.+Meeksauthor=S.+Yusufauthor=R.+Diazauthor=H.+Acquatellaauthor=J.+Lazzariauthor=R.+Robertsauthor=M.+Trainaauthor=B.+Meeksauthor=L.+R.+Bonillaauthor=P.+Gaoauthor=A.+Taylorauthor=I.+Holadyk-Grisauthor=L.+Whalenauthor=M.C.+Bangherauthor=M.A.+Romeroauthor=N.+Pradoauthor=Y.+Hernandezauthor=M.+Fernandezauthor=A.+Riarteauthor=K.+Scolloauthor=C.+Lopez-Albizuauthor=C.A.+Cuneoauthor=N.C.+Gutierrezauthor=R.R.+Milesiauthor=M.A.+Berliauthor=M.H.+Mallagrayauthor=N.E.+Caceresauthor=J.S.+Beloscarauthor=J.M.+Petrucciauthor=H.+Colomboauthor=M.+Dellatorreauthor=A.+Pradoauthor=W.+Aptauthor=I.+Zulantayauthor=L.E.+Echeverriaauthor=D.+Isazaauthor=E.+Reyesauthor=F.S.+Wyssauthor=A.+Figueroaauthor=I.+Guzman+Melgarauthor=E.+Rodriguezauthor=J.+Gasconauthor=E.+Aldasoroauthor=E.J.+Posadaauthor=N.+Serretauthor=I.+Molinaauthor=A.+Sanchez-Montalvaauthor=J.A.+Perez-Molinaauthor=R.+Lopez-Velezauthor=P.A.+Reyes-Lopez&title=Benznidazole+and+Posaconazole+in+Eliminating+Parasites+in+Asymptomatic+T.+cruzi+Carriers%3A+The+Stop-Chagas+Trial&doi=10.1016%2Fj.jacc.2016.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers</span></div><div class="casAuthors">Morillo, Carlos A.; Waskin, Hetty; Sosa-Estani, Sergio; Bangher, Maria del Carmen; Cuneo, Carlos; Milesi, Rodolfo; Mallagray, Marcelo; Apt, Werner; Beloscar, Juan; Gascon, Joaquim; Molina, Israel; Echeverria, Luis E.; Colombo, Hugo; Perez-Molina, Jose Antonio; Wyss, Fernando; Meeks, Brandi; Bonilla, Laura R.; Gao, Peggy; Wei, Bo; McCarthy, Michael; Yusuf, Salim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-947</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Benznidazole is recommended for treatment of Chagas infection.  Effects of combination therapy with benznidazole and posaconazole have not been tested in Trypanosoma cruzi carriers.  The purpose of this study was to det. whether posaconazole alone or combined with benznidazole were superior to benznidazole monotherapy in eliminating T. cruzi parasites measured by real time polymerase chain reaction (RT-PCR) in asymptomatic Chagas carriers.  A prospective, multicenter randomized placebo-controlled study was conducted in 120 subjects from Latin America and Spain who were randomized to 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d.  T. cruzi DNA was detected by RT-PCR at 30, 60, 90, 120, 150, 180, and 360 days.  The primary efficacy outcome is the proportion of subjects with persistent neg. RT-PCR by day 180; the secondary outcome was neg. RT-PCR at 360 days.Only 13.3% of those receiving posaconazole and 10% receiving placebo achieved the primary outcome, compared with 80% receiving benznidazole + posaconazole and 86.7% receiving benznidazole monotherapy (p < 0.0001 vs. posaconazole/placebo).  Posaconazole monotherapy or posaconazole combined with benznidazole achieved high RT-PCR conversion rates during treatment (30 days; 93.3% and 88.9% and 60 days; 90%, and 92.3%) that were similar to benznidazole (89.7% and 89.3%); all were superior to placebo or posaconazole (10% and 16.7%, p < 0.0001).  This was not obsd. at 360 days; benznidazole + posaconazole and benznidazole monotherapy (both 96%) vs. placebo (17%) and posaconazole (16%, p < 0.0001).  Serious adverse events were rare (6 patients) and were obsd. in the benznidazole-treated patients.  Permanent discontinuation was reported in 19 patients (31.7%) receiving either benznidazole monotherapy or combined with posaconazole.  Posaconazole demonstrated trypanostatic activity during treatment, but it is ineffective long-term in asymptomatic T. cruzi carriers.  Benznidazole monotherapy is superior to posaconazole, with high RT-PCR conversion rates sustained at 1 yr.  Side effects lead to therapy discontinuation in 32%.  No advantages were obsd. with combined therapy vs. benznidazole monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF_im80mqEP7Vg90H21EOLACvtfcHk0lg1DGQcm2Erwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1Kiuro%253D&md5=d5021f5544dc42eba2af9d469db9da50</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2016.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2016.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DMorillo%26aufirst%3DC.%2BA.%26aulast%3DWaskin%26aufirst%3DH.%26aulast%3DSosa-Estani%26aufirst%3DS.%26aulast%3Ddel%2BCarmen%2BBangher%26aufirst%3DM.%26aulast%3DCuneo%26aufirst%3DC.%26aulast%3DMilesi%26aufirst%3DR.%26aulast%3DMallagray%26aufirst%3DM.%26aulast%3DApt%26aufirst%3DW.%26aulast%3DBeloscar%26aufirst%3DJ.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DEcheverria%26aufirst%3DL.%2BE.%26aulast%3DColombo%26aufirst%3DH.%26aulast%3DPerez-Molina%26aufirst%3DJ.%2BA.%26aulast%3DWyss%26aufirst%3DF.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DBonilla%26aufirst%3DL.%2BR.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DMcCarthy%26aufirst%3DM.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DMorillo%26aufirst%3DC.%26aulast%3DSosa-Estani%26aufirst%3DS.%26aulast%3DWaskin%26aufirst%3DH.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DAcquatella%26aufirst%3DH.%26aulast%3DLazzari%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DR.%26aulast%3DTraina%26aufirst%3DM.%26aulast%3DMeeks%26aufirst%3DB.%26aulast%3DBonilla%26aufirst%3DL.%2BR.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DHoladyk-Gris%26aufirst%3DI.%26aulast%3DWhalen%26aufirst%3DL.%26aulast%3DBangher%26aufirst%3DM.C.%26aulast%3DRomero%26aufirst%3DM.A.%26aulast%3DPrado%26aufirst%3DN.%26aulast%3DHernandez%26aufirst%3DY.%26aulast%3DFernandez%26aufirst%3DM.%26aulast%3DRiarte%26aufirst%3DA.%26aulast%3DScollo%26aufirst%3DK.%26aulast%3DLopez-Albizu%26aufirst%3DC.%26aulast%3DCuneo%26aufirst%3DC.A.%26aulast%3DGutierrez%26aufirst%3DN.C.%26aulast%3DMilesi%26aufirst%3DR.R.%26aulast%3DBerli%26aufirst%3DM.A.%26aulast%3DMallagray%26aufirst%3DM.H.%26aulast%3DCaceres%26aufirst%3DN.E.%26aulast%3DBeloscar%26aufirst%3DJ.S.%26aulast%3DPetrucci%26aufirst%3DJ.M.%26aulast%3DColombo%26aufirst%3DH.%26aulast%3DDellatorre%26aufirst%3DM.%26aulast%3DPrado%26aufirst%3DA.%26aulast%3DApt%26aufirst%3DW.%26aulast%3DZulantay%26aufirst%3DI.%26aulast%3DEcheverria%26aufirst%3DL.E.%26aulast%3DIsaza%26aufirst%3DD.%26aulast%3DReyes%26aufirst%3DE.%26aulast%3DWyss%26aufirst%3DF.S.%26aulast%3DFigueroa%26aufirst%3DA.%26aulast%3DGuzman%2BMelgar%26aufirst%3DI.%26aulast%3DRodriguez%26aufirst%3DE.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DAldasoro%26aufirst%3DE.%26aulast%3DPosada%26aufirst%3DE.J.%26aulast%3DSerret%26aufirst%3DN.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DSanchez-Montalva%26aufirst%3DA.%26aulast%3DPerez-Molina%26aufirst%3DJ.A.%26aulast%3DLopez-Velez%26aufirst%3DR.%26aulast%3DReyes-Lopez%26aufirst%3DP.A.%26atitle%3DBenznidazole%2520and%2520Posaconazole%2520in%2520Eliminating%2520Parasites%2520in%2520Asymptomatic%2520T.%2520cruzi%2520Carriers%253A%2520The%2520Stop-Chagas%2520Trial%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2017%26volume%3D69%26spage%3D939%26epage%3D947%26doi%3D10.1016%2Fj.jacc.2016.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torrico, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Vega, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinazo, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schijman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, I. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strub-Wourgaft, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bournisen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto Rocha, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas Delgadillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magne Anzoleaga, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quechover, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, M. Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano Beltran, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalabar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas
Panozo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios Lopez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrico Terceros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez Galvez, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuellar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasco Arenas, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyos Delfin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Barra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarroel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncanson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diderichsen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, A. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sender, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, W.</span></span> <span> </span><span class="NLM_article-title">Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-Concept, Randomised, Placebo-Controlled Trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30538-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2FS1473-3099%2817%2930538-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=29352704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=419-430&author=F.+Torricoauthor=J.+Gasconauthor=L.+Ortizauthor=C.+Alonso-Vegaauthor=M.-J.+Pinazoauthor=A.+Schijmanauthor=I.+C+Almeidaauthor=F.+Alvesauthor=N.+Strub-Wourgaftauthor=I.+Ribeiroauthor=G.+Santinaauthor=B.+Blumauthor=E.+Correiaauthor=F.+Garcia-Bournisenauthor=M.+Vaillantauthor=J.+R.+Moralesauthor=J.+J.+Pinto+Rochaauthor=G.+Rojas+Delgadilloauthor=H.+R.+Magne+Anzoleagaauthor=N.+Mendozaauthor=R.+C.+Quechoverauthor=M.+Y.+E.+Caballeroauthor=D.+F.+Lozano+Beltranauthor=A.+M.+Zalabarauthor=L.+Rojas%0APanozoauthor=A.+Palacios+Lopezauthor=D.+Torrico+Tercerosauthor=V.+A.+Fernandez+Galvezauthor=L.+Cardozoauthor=G.+Cuellarauthor=R.+N.+Vasco+Arenasauthor=I.+Gonzalesauthor=C.+F.+Hoyos+Delfinauthor=L.+Garciaauthor=R.+Parradoauthor=A.+de+la+Barraauthor=N.+Montanoauthor=S.+Villarroelauthor=T.+Duffyauthor=M.+Bisioauthor=J.+C.+Ramirezauthor=F.+Duncansonauthor=M.+Eversonauthor=A.+Danielsauthor=M.+Asadaauthor=E.+Coxauthor=D.+Wescheauthor=P.+M.+Diderichsenauthor=A.+F+Marquesauthor=L.+Izquierdoauthor=S.+S.+Senderauthor=J.+C.+Reverterauthor=M.+Moralesauthor=W.+Jimenez&title=Treatment+of+Adult+Chronic+Indeterminate+Chagas+Disease+with+Benznidazole+and+Three+E1224+Dosing+Regimens%3A+A+Proof-of-Concept%2C+Randomised%2C+Placebo-Controlled+Trial&doi=10.1016%2FS1473-3099%2817%2930538-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial</span></div><div class="casAuthors">Torrico, Faustino; Gascon, Joaquim; Ortiz, Lourdes; Alonso-Vega, Cristina; Pinazo, Maria-Jesus; Schijman, Alejandro; Almeida, Igor C.; Alves, Fabiana; Strub-Wourgaft, Nathalie; Ribeiro, Isabela</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chagas disease is a major neglected vector-borne disease.  In this study, we investigated the safety and efficacy of three oral E1224 (a water-sol. ravuconazole prodrug) regimens and benznidazole vs. placebo in adult chronic indeterminate Chagas disease.  In this proof-of-concept, double-blind, randomised phase 2 clin. trial, we recruited adults (18-50 years) with confirmed diagnosis of Trypanosoma cruzi infection from two outpatient units in Bolivia.  Patients were randomised with a computer-generated randomisation list, which was stratified by center and used a block size of ten.  Patients were randomly assigned (1:1:1:1:1) to five oral treatment groups: high-dose E1224 (duration 8 wk, total dose 4000 mg), low-dose E1224 (8 wk, 2000 mg), short-dose E1224 (4 wk + 4 wk placebo, 2400 mg), benznidazole (60 days, 5 mg/kg per day), or placebo (8 wk, E1224-matched tablets).  Double-blinding was limited to the E1224 and placebo arms, and assessors were masked to all treatment allocations.  The primary efficacy endpoint was parasitol. response to E1224 at the end of treatment, assessed by PCR.  The secondary efficacy endpoints were parasitol. response to benznidazole at end of treatment, assessed by PCR; sustainability of parasitol. response until 12 mo; parasite clearance and changes in parasite load; incidence of conversion to neg. response in conventional and non-conventional (antigen trypomastigote chemiluminescent ELISA [AT CL-ELISA]) serol. response; changes in levels of biomarkers; and complete response.  The primary anal. population consisted of all randomised patients by their assigned treatment arms.  This trial is registered with ClinicalTrials.gov, no. NCT01489228.  Between July 19, 2011, and July 26, 2012, we screened 560 participants with confirmed Chagas disease, of whom 231 were enrolled and assigned to high-dose E1224 (n = 45), low-dose E1224 (n = 48), short-dose E1224 (n = 46), benznidazole (n = 45), or placebo (n = 47).  Parasite clearance was obsd. with E1224 during the treatment phase, but no sustained response was seen with low-dose and short-dose regimens, whereas 13 patients (29%, 95% CI 16.4-44.3) had sustained response with the high-dose regimen compared with four (9%, 2.4-20.4) in the placebo group (p < 0.0001).  Benznidazole had a rapid and sustained effect on parasite clearance, with 37 patients (82%, 67.9-92.0) with sustained response at 12-mo follow-up.  After 1 wk of treatment, mean quant. PCR repeated measurements showed a significant redn. in parasite load in all treatment arms vs. placebo.  Parasite levels in the low-dose and short-dose E1224 groups gradually returned to placebo levels.  Both treatments were well tolerated.  Reversible, dose-dependent liver enzyme increases were seen with E1224 and benznidazole.  A 187 (81%) participants developed treatment-emergent adverse events and six (3%) developed treatment-emergent serious adverse events.  Treatment-emergent adverse events were headaches, nausea, pruritus, peripheral neuropathy, and hypersensitivity.  E1224 is the first new chem. entity developed for Chagas disease in decades.  E1224 displayed a transient, suppressive effect on parasite clearance, whereas benznidazole showed early and sustained efficacy until 12 mo of follow-up.  Despite PCR limitations, our results support increased diagnosis and access to benznidazole std. regimen, and provide a development roadmap for novel benznidazole regimens in monotherapy and in combinations with E1224.  Drugs for Neglected Diseases initiative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqes8nnI-YsK7Vg90H21EOLACvtfcHk0lgxVFk1IYUEyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D&md5=0d71e1af60fad81c14943af5e70ad8ad</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930538-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930538-8%26sid%3Dliteratum%253Aachs%26aulast%3DTorrico%26aufirst%3DF.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DOrtiz%26aufirst%3DL.%26aulast%3DAlonso-Vega%26aufirst%3DC.%26aulast%3DPinazo%26aufirst%3DM.-J.%26aulast%3DSchijman%26aufirst%3DA.%26aulast%3DAlmeida%26aufirst%3DI.%2BC%26aulast%3DAlves%26aufirst%3DF.%26aulast%3DStrub-Wourgaft%26aufirst%3DN.%26aulast%3DRibeiro%26aufirst%3DI.%26aulast%3DSantina%26aufirst%3DG.%26aulast%3DBlum%26aufirst%3DB.%26aulast%3DCorreia%26aufirst%3DE.%26aulast%3DGarcia-Bournisen%26aufirst%3DF.%26aulast%3DVaillant%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DJ.%2BR.%26aulast%3DPinto%2BRocha%26aufirst%3DJ.%2BJ.%26aulast%3DRojas%2BDelgadillo%26aufirst%3DG.%26aulast%3DMagne%2BAnzoleaga%26aufirst%3DH.%2BR.%26aulast%3DMendoza%26aufirst%3DN.%26aulast%3DQuechover%26aufirst%3DR.%2BC.%26aulast%3DCaballero%26aufirst%3DM.%2BY.%2BE.%26aulast%3DLozano%2BBeltran%26aufirst%3DD.%2BF.%26aulast%3DZalabar%26aufirst%3DA.%2BM.%26aulast%3DRojas%2BPanozo%26aufirst%3DL.%26aulast%3DPalacios%2BLopez%26aufirst%3DA.%26aulast%3DTorrico%2BTerceros%26aufirst%3DD.%26aulast%3DFernandez%2BGalvez%26aufirst%3DV.%2BA.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DCuellar%26aufirst%3DG.%26aulast%3DVasco%2BArenas%26aufirst%3DR.%2BN.%26aulast%3DGonzales%26aufirst%3DI.%26aulast%3DHoyos%2BDelfin%26aufirst%3DC.%2BF.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DParrado%26aufirst%3DR.%26aulast%3Dde%2Bla%2BBarra%26aufirst%3DA.%26aulast%3DMontano%26aufirst%3DN.%26aulast%3DVillarroel%26aufirst%3DS.%26aulast%3DDuffy%26aufirst%3DT.%26aulast%3DBisio%26aufirst%3DM.%26aulast%3DRamirez%26aufirst%3DJ.%2BC.%26aulast%3DDuncanson%26aufirst%3DF.%26aulast%3DEverson%26aufirst%3DM.%26aulast%3DDaniels%26aufirst%3DA.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DWesche%26aufirst%3DD.%26aulast%3DDiderichsen%26aufirst%3DP.%2BM.%26aulast%3DMarques%26aufirst%3DA.%2BF%26aulast%3DIzquierdo%26aufirst%3DL.%26aulast%3DSender%26aufirst%3DS.%2BS.%26aulast%3DReverter%26aufirst%3DJ.%2BC.%26aulast%3DMorales%26aufirst%3DM.%26aulast%3DJimenez%26aufirst%3DW.%26atitle%3DTreatment%2520of%2520Adult%2520Chronic%2520Indeterminate%2520Chagas%2520Disease%2520with%2520Benznidazole%2520and%2520Three%2520E1224%2520Dosing%2520Regimens%253A%2520A%2520Proof-of-Concept%252C%2520Randomised%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26spage%3D419%26epage%3D430%26doi%3D10.1016%2FS1473-3099%2817%2930538-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez i Prat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulleiro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serre, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabezos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Grau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Montalva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahissa, A.</span></span> <span> </span><span class="NLM_article-title">Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas’ Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1899</span>– <span class="NLM_lpage">1908</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1313122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1056%2FNEJMoa1313122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=24827034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1899-1908&author=I.+Molinaauthor=J.+Gomez+i+Pratauthor=F.+Salvadorauthor=B.+Trevinoauthor=E.+Sulleiroauthor=N.+Serreauthor=D.+Pouauthor=S.+Roureauthor=J.+Cabezosauthor=L.+Valerioauthor=A.+Blanco-Grauauthor=A.+Sanchez-Montalvaauthor=X.+Vidalauthor=A.+Pahissa&title=Randomized+Trial+of+Posaconazole+and+Benznidazole+for+Chronic+Chagas%E2%80%99+Disease&doi=10.1056%2FNEJMoa1313122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of posaconazole and benznidazole for chronic Chagas' disease</span></div><div class="casAuthors">Molina, Israel; Gomez i Prat, Jordi; Salvador, Fernando; Trevino, Begona; Sulleiro, Elena; Serre, Nuria; Pou, Diana; Roure, Silvia; Cabezos, Juan; Valerio, Lluis; Blanco-Grau, Albert; Sanchez-Montalva, Adrian; Vidal, Xavier; Pahissa, Albert</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1899-1908, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been assocd. with low cure rates in the chronic stage of the disease and which have considerable toxicity.  Posaconazole has shown trypanocidal activity in murine models.  Methods: We performed a prospective, randomized clin. trial to assess the efficacy and safety of posaconazole as compared with the efficacy and safety of benznidazole in adults with chronic Trypanosoma cruzi infection.  We randomly assigned patients to receive posaconazole at a dose of 400 mg twice daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice daily (low-dose posaconazole), or benznidazole at a dose of 150 mg twice daily; all the study drugs were administered for 60 days.  We assessed antiparasitic activity by testing for the presence of T. cruzi DNA, using real-time polymerase-chain- reaction (rt-PCR) assays, during the treatment period and 10 mo after the end of treatment.  Posaconazole absorption was assessed on day 14.  Results: The intention-to-treat population included 78 patients.  During the treatment period, all the patients tested neg. for T. cruzi DNA on rt-PCR assay beyond day 14, except for 2 patients in the low-dose posaconazole group who tested pos. on day 60.  During the follow-up period, in the intention-to-treat anal., 92% of the patients receiving low-dose posaconazole and 81% receiving high-dose posaconazole, as compared with 38% receiving benznidazole, tested pos. for T. cruzi DNA on rt-PCR assay (P<0.01 for the comparison of the benznidazole group with either posaconazole group); in the perprotocol anal., 90% of the patients receiving low-dose posaconazole and 80% of those receiving high-dose posaconazole, as compared with 6% receiving benznidazole, tested pos. on rt-PCR assay (P<0.001 for the comparison of the benznidazole group with either posaconazole group).  In the benznidazole group, treatment was discontinued in 5 patients because of severe cutaneous reactions; in the posaconazole groups, 4 patients had aminotransferase levels that were more than 3 times the upper limit of the normal range, but there were no discontinuations of treatment.  Conclusions: Posaconazole showed antitrypanosomal activity in patients with chronic Chagas' disease.  However, significantly more patients in the posaconazole groups than in the benznidazole group had treatment failure during follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2K1SHT3rRSLVg90H21EOLACvtfcHk0lhqtrMBQyxETg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbjF&md5=ff26dd08abd3cf46144913378efb9b5c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1313122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1313122%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DGomez%2Bi%2BPrat%26aufirst%3DJ.%26aulast%3DSalvador%26aufirst%3DF.%26aulast%3DTrevino%26aufirst%3DB.%26aulast%3DSulleiro%26aufirst%3DE.%26aulast%3DSerre%26aufirst%3DN.%26aulast%3DPou%26aufirst%3DD.%26aulast%3DRoure%26aufirst%3DS.%26aulast%3DCabezos%26aufirst%3DJ.%26aulast%3DValerio%26aufirst%3DL.%26aulast%3DBlanco-Grau%26aufirst%3DA.%26aulast%3DSanchez-Montalva%26aufirst%3DA.%26aulast%3DVidal%26aufirst%3DX.%26aulast%3DPahissa%26aufirst%3DA.%26atitle%3DRandomized%2520Trial%2520of%2520Posaconazole%2520and%2520Benznidazole%2520for%2520Chronic%2520Chagas%25E2%2580%2599%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1899%26epage%3D1908%26doi%3D10.1056%2FNEJMoa1313122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">DNDi</span>. <a href="http://Https://Www.Dndi.Org/Diseases-Projects/Portfolio/Fexinidazole-Chagas/" class="extLink">Https://Www.Dndi.Org/Diseases-Projects/Portfolio/Fexinidazole-Chagas/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+Https%3A%2F%2FWww.Dndi.Org%2FDiseases-Projects%2FPortfolio%2FFexinidazole-Chagas%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">DNDi</span>. <a href="http://Https://Www.Dndi.Org/Diseases-Projects/Portfolio/" class="extLink">Https://Www.Dndi.Org/Diseases-Projects/Portfolio/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DNDi.+Https%3A%2F%2FWww.Dndi.Org%2FDiseases-Projects%2FPortfolio%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, N. J.</span></span> <span> </span><span class="NLM_article-title">Validity of Ligand Efficiency Metrics</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">618</span>, <span class="refDoi"> DOI: 10.1021/ml500146d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500146d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVShsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=616-618&author=C.+W.+Murrayauthor=D.+A.+Erlansonauthor=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynoldsauthor=N.+J.+Richmond&title=Validity+of+Ligand+Efficiency+Metrics&doi=10.1021%2Fml500146d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Validity of Ligand Efficiency Metrics</span></div><div class="casAuthors">Murray, Christopher W.; Erlanson, Daniel A.; Hopkins, Andrew L.; Keseru, Gyorgy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.; Richmond, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">616-618</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A recent viewpoint article (Improving the plausibility of success with inefficient metrics. ACS Med. Chem. Lett.2014, 5, 2-5) argued that the std. definition of ligand efficiency (LE) is math. invalid.  In this viewpoint, we address this criticism and show categorically that the definition of LE is math. valid.  LE and other metrics such as lipophilic ligand efficiency (LLE) can be useful during the multiparameter optimization challenge faced by medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJHYI4FCEJbVg90H21EOLACvtfcHk0lhqtrMBQyxETg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVShsbs%253D&md5=5bc436490def9fa7af0f3e7ed241ee4e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml500146d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500146d%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26aulast%3DRichmond%26aufirst%3DN.%2BJ.%26atitle%3DValidity%2520of%2520Ligand%2520Efficiency%2520Metrics%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D616%26epage%3D618%26doi%3D10.1021%2Fml500146d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velcicky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soicke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalz, H. G.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Cyanomethylation of Aryl Halides through Domino Suzuki Coupling-Isoxazole Fragmentation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">6948</span>– <span class="NLM_lpage">6951</span>, <span class="refDoi"> DOI: 10.1021/ja201743j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja201743j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=6948-6951&author=J.+Velcickyauthor=A.+Soickeauthor=R.+Steinerauthor=H.+G.+Schmalz&title=Palladium-Catalyzed+Cyanomethylation+of+Aryl+Halides+through+Domino+Suzuki+Coupling-Isoxazole+Fragmentation&doi=10.1021%2Fja201743j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cyanomethylation of Aryl Halides through Domino Suzuki Coupling-Isoxazole Fragmentation</span></div><div class="casAuthors">Velcicky, Juraj; Soicke, Arne; Steiner, Roland; Schmalz, Hans-Gunther</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6948-6951</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A one-pot protocol for the cyanomethylation of aryl halides through a palladium-catalyzed reaction with isoxazole-4-boronic acid pinacol ester was developed.  Mechanistically, the reaction proceeds through (1) Suzuki coupling, (2) base-induced fragmentation, and (3) deformylation as shown by characterization of all postulated intermediates.  Under optimized conditions (PdCl2dppf, KF, DMSO/H2O, 130 °C) a broad spectrum of aryl bromides could be converted into arylacetonitriles with up to 88% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok14-knI07mbVg90H21EOLACvtfcHk0ljDUyO-Oc6hfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVCksbc%253D&md5=8028f8c75215996acf1871b1bce3b7d8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja201743j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja201743j%26sid%3Dliteratum%253Aachs%26aulast%3DVelcicky%26aufirst%3DJ.%26aulast%3DSoicke%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DR.%26aulast%3DSchmalz%26aufirst%3DH.%2BG.%26atitle%3DPalladium-Catalyzed%2520Cyanomethylation%2520of%2520Aryl%2520Halides%2520through%2520Domino%2520Suzuki%2520Coupling-Isoxazole%2520Fragmentation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D6948%26epage%3D6951%26doi%3D10.1021%2Fja201743j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onomura, O.</span></span> <span> </span><span class="NLM_article-title">Efficient Oxidation of Cycloalkanols by Sodium Nitrite with Molecular Oxygen in Trifluoroacetic Acid</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">8221</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2004.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.tetlet.2004.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=8221-8224&author=Y.+Matsumuraauthor=Y.+Yamamotoauthor=N.+Moriyamaauthor=S.+Furukuboauthor=F.+Iwasakiauthor=O.+Onomura&title=Efficient+Oxidation+of+Cycloalkanols+by+Sodium+Nitrite+with+Molecular+Oxygen+in+Trifluoroacetic+Acid&doi=10.1016%2Fj.tetlet.2004.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient oxidation of cycloalkanols by sodium nitrite with molecular oxygen in trifluoroacetic acid</span></div><div class="casAuthors">Matsumura, Yoshihiro; Yamamoto, Yutaka; Moriyama, Noriaki; Furukubo, Shigeru; Iwasaki, Fumiaki; Onomura, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8221-8224</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxidn. of aliph. cycloalkanols by sodium nitrite in trifluoroacetic acid gave α,ω-dicarboxylic acids in good yields.  Adipic acid was obtained in a quant. yield from cyclohexanol using 1 equiv of sodium nitrite under oxygen atm. but the oxidn. required more than 3 equiv of sodium nitrite under nitrogen atm.  The oxidn. method was applicable to the conversion of 1-alkanols to the corresponding carboxylic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorqRG54kP7KrVg90H21EOLACvtfcHk0ljDUyO-Oc6hfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D&md5=fc450e4a001627d5693336c3f256a9a8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2004.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2004.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DN.%26aulast%3DFurukubo%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DF.%26aulast%3DOnomura%26aufirst%3DO.%26atitle%3DEfficient%2520Oxidation%2520of%2520Cycloalkanols%2520by%2520Sodium%2520Nitrite%2520with%2520Molecular%2520Oxygen%2520in%2520Trifluoroacetic%2520Acid%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D45%26spage%3D8221%26epage%3D8224%26doi%3D10.1016%2Fj.tetlet.2004.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renz, M.</span></span> <span> </span><span class="NLM_article-title">Ketonization of Carboxylic Acids by Decarboxylation: Mechanism and Scope</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200400546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1002%2Fejoc.200400546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=979-988&author=M.+Renz&title=Ketonization+of+Carboxylic+Acids+by+Decarboxylation%3A+Mechanism+and+Scope&doi=10.1002%2Fejoc.200400546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200400546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200400546%26sid%3Dliteratum%253Aachs%26aulast%3DRenz%26aufirst%3DM.%26atitle%3DKetonization%2520of%2520Carboxylic%2520Acids%2520by%2520Decarboxylation%253A%2520Mechanism%2520and%2520Scope%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2005%26volume%3D2005%26spage%3D979%26epage%3D988%26doi%3D10.1002%2Fejoc.200400546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcantoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambri, L.</span></span> <span> </span><span class="NLM_article-title">Unusual and Unexpected Reactivity of T-Butyl Dicarbonate (Boc2o) with Alcohols in the Presence of Magnesium Perchlorate. A New and General Route to T-Butyl Ethers</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/ol047704o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol047704o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=427-430&author=G.+Bartoliauthor=M.+Boscoauthor=M.+Locatelliauthor=E.+Marcantoniauthor=P.+Melchiorreauthor=L.+Sambri&title=Unusual+and+Unexpected+Reactivity+of+T-Butyl+Dicarbonate+%28Boc2o%29+with+Alcohols+in+the+Presence+of+Magnesium+Perchlorate.+A+New+and+General+Route+to+T-Butyl+Ethers&doi=10.1021%2Fol047704o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual and Unexpected Reactivity of t-Butyl Dicarbonate (Boc2O) with Alcohols in the Presence of Magnesium Perchlorate. A New and General Route to t-Butyl Ethers</span></div><div class="casAuthors">Bartoli, Giuseppe; Bosco, Marcella; Locatelli, Manuela; Marcantoni, Enrico; Melchiorre, Paolo; Sambri, Letizia</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new mild method for protecting alcs. as t-Bu ethers is reported.  The reaction proceeds with Mg(ClO4)2 and Boc2O and shows general applicability.  The deprotection of t-Bu ethers has also been revisited.  Preliminary results indicate the CeCl3·7H2O/NaI system is a very suitable catalyst for their removal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqdo5o1Y49RrVg90H21EOLACvtfcHk0lj4grYdLem2lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ensQ%253D%253D&md5=295b06fe47c63d44aaf8dde54823d06c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fol047704o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol047704o%26sid%3Dliteratum%253Aachs%26aulast%3DBartoli%26aufirst%3DG.%26aulast%3DBosco%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DM.%26aulast%3DMarcantoni%26aufirst%3DE.%26aulast%3DMelchiorre%26aufirst%3DP.%26aulast%3DSambri%26aufirst%3DL.%26atitle%3DUnusual%2520and%2520Unexpected%2520Reactivity%2520of%2520T-Butyl%2520Dicarbonate%2520%2528Boc2o%2529%2520with%2520Alcohols%2520in%2520the%2520Presence%2520of%2520Magnesium%2520Perchlorate.%2520A%2520New%2520and%2520General%2520Route%2520to%2520T-Butyl%2520Ethers%26jtitle%3DOrg.%2520Lett.%26date%3D2005%26volume%3D7%26spage%3D427%26epage%3D430%26doi%3D10.1021%2Fol047704o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortes Francisco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell-Saward, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLatchie, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span> <span> </span><span class="NLM_article-title">Bioluminescence Imaging of Chronic <i>Trypanosoma cruzi</i> Infections Reveals Tissue-Specific Parasite Dynamics and Heart Disease in the Absence of Locally Persistent Infection</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1111/cmi.12297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1111%2Fcmi.12297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=24712539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWltbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1285-1300&author=M.+D.+Lewisauthor=A.+Fortes+Franciscoauthor=M.+C.+Taylorauthor=H.+Burrell-Sawardauthor=A.+P.+McLatchieauthor=M.+A.+Milesauthor=J.+M.+Kelly&title=Bioluminescence+Imaging+of+Chronic+Trypanosoma+cruzi+Infections+Reveals+Tissue-Specific+Parasite+Dynamics+and+Heart+Disease+in+the+Absence+of+Locally+Persistent+Infection&doi=10.1111%2Fcmi.12297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection</span></div><div class="casAuthors">Lewis, Michael D.; Fortes Francisco, Amanda; Taylor, Martin C.; Burrell-Saward, Hollie; McLatchie, Alex P.; Miles, Michael A.; Kelly, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1285-1300</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Chronic Trypanosoma cruzi infections lead to cardiomyopathy in 20-30% of cases.  A causal link between cardiac infection and pathol. has been difficult to establish because of a lack of robust methods to detect scarce, focally distributed parasites within tissues.  We developed a highly sensitive bioluminescence imaging system based on T. cruzi expressing a novel luciferase that emits tissue-penetrating orange-red light.  This enabled long-term serial evaluation of parasite burdens in individual mice with an in vivo limit of detection of significantly less than 1000 parasites.  Parasite distributions during chronic infections were highly focal and spatiotemporally dynamic, but did not localize to the heart.  End-point ex vivo bioluminescence imaging allowed tissue-specific quantification of parasite loads with minimal sampling bias.  During chronic infections, the gastro-intestinal tract, specifically the colon and stomach, was the only site where T. cruzi infection was consistently obsd.  Quant. PCR-inferred parasite loads correlated with ex vivo bioluminescence and confirmed the gut as the parasite reservoir.  Chronically infected mice developed myocarditis and cardiac fibrosis, despite the absence of locally persistent parasites.  These data identify the gut as a permissive niche for long-term T. cruzi infection and show that canonical features of Chagas disease can occur without continual myocardium-specific infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyZb4PqY1d6LVg90H21EOLACvtfcHk0lh-foIdDDYZAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWltbfK&md5=bda234eede9a5091550a48fdcd977327</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fcmi.12297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcmi.12297%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DFortes%2BFrancisco%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DM.%2BC.%26aulast%3DBurrell-Saward%26aufirst%3DH.%26aulast%3DMcLatchie%26aufirst%3DA.%2BP.%26aulast%3DMiles%26aufirst%3DM.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26atitle%3DBioluminescence%2520Imaging%2520of%2520Chronic%2520Trypanosoma%2520cruzi%2520Infections%2520Reveals%2520Tissue-Specific%2520Parasite%2520Dynamics%2520and%2520Heart%2520Disease%2520in%2520the%2520Absence%2520of%2520Locally%2520Persistent%2520Infection%26jtitle%3DCell.%2520Microbiol.%26date%3D2014%26volume%3D16%26spage%3D1285%26epage%3D1300%26doi%3D10.1111%2Fcmi.12297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span> <span> </span><span class="NLM_article-title">Development of <i>Trypanosoma cruzi</i> i<i>n vitro</i> Assays to Identify Compounds Suitable for Progression in Chagas’ Disease Drug Discovery</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0006612</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0006612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1371%2Fjournal.pntd.0006612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=30001347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OrurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&author=L.+M.+MacLeanauthor=J.+Thomasauthor=M.+D.+Lewisauthor=I.+Cotilloauthor=D.+W.+Grayauthor=M.+De+Rycker&title=Development+of+Trypanosoma+cruzi+in+vitro+Assays+to+Identify+Compounds+Suitable+for+Progression+in+Chagas%E2%80%99+Disease+Drug+Discovery&doi=10.1371%2Fjournal.pntd.0006612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery</span></div><div class="casAuthors">MacLean, Lorna M.; Thomas, John; Lewis, Michael D.; Cotillo, Ignacio; Gray, David W.; De Rycker, Manu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0006612/1-e0006612/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Chagas' disease is responsible for significant mortality and morbidity in Latin America.  Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed.  However, recent efforts have proved unsuccessful with failure of the ergosterol biosynthesis inhibitor posaconazole in phase II clin. trials despite promising in vitro and in vivo studies.  The lack of translation between lab. expts. and clin. outcome is a major issue for further drug discovery efforts.  Our goal was to identify cell-based assays that could differentiate current nitro-arom. drugs nifurtimox and benznidazole from posaconazole.  Using a panel of T. cruzi strains including the six major lineages (TcI-VI), we found that strain PAH179 (TcV) was markedly less susceptible to posaconazole in vitro.  Detn. of parasite doubling and cycling times as well as EdU labeling expts. all indicate that this lack of sensitivity is due to the slow doubling and cycling time of strain PAH179.  This is in accordance with ergosterol biosynthesis inhibition by posaconazole leading to critically low ergosterol levels only after multiple rounds of division, and is further supported by the lack of effect of posaconazole on the nonreplicative trypomastigote form.  A washout expt. with prolonged posaconazole treatment showed that, even for more rapidly replicating strains, this compd. cannot clear all parasites, indicative of a heterogeneous parasite population in vitro and potentially the presence of quiescent parasites.  Benznidazole in contrast was able to kill all parasites.  The work presented here shows clear differentiation between the nitro-arom. drugs and posaconazole in several assays, and suggests that in vitro there may be clin. relevant heterogeneity in the parasite population that can be revealed in long-term washout expts.  Based on these findings we have adjusted our in vitro screening cascade so that only the most promising compds. are progressed to in vivo expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3xmuV5jnr5rVg90H21EOLACvtfcHk0lh08T-PuFP3Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OrurbI&md5=4af966ae8554bc00e9f86531dfb96c48</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0006612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0006612%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DL.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520Trypanosoma%2520cruzi%2520in%2520vitro%2520Assays%2520to%2520Identify%2520Compounds%2520Suitable%2520for%2520Progression%2520in%2520Chagas%25E2%2580%2599%2520Disease%2520Drug%2520Discovery%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2018%26volume%3D12%26doi%3D10.1371%2Fjournal.pntd.0006612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onomura, O.</span></span> <span> </span><span class="NLM_article-title">Efficient Oxidation of Cycloalkanols by Sodium Nitrite with Molecular Oxygen in Trifluoroacetic Acid</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">8221</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2004.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=10.1016%2Fj.tetlet.2004.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=8221-8224&author=Y.+Matsumuraauthor=Y.+Yamamotoauthor=N.+Moriyamaauthor=S.+Furukuboauthor=F.+Iwasakiauthor=O.+Onomura&title=Efficient+Oxidation+of+Cycloalkanols+by+Sodium+Nitrite+with+Molecular+Oxygen+in+Trifluoroacetic+Acid&doi=10.1016%2Fj.tetlet.2004.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient oxidation of cycloalkanols by sodium nitrite with molecular oxygen in trifluoroacetic acid</span></div><div class="casAuthors">Matsumura, Yoshihiro; Yamamoto, Yutaka; Moriyama, Noriaki; Furukubo, Shigeru; Iwasaki, Fumiaki; Onomura, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8221-8224</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxidn. of aliph. cycloalkanols by sodium nitrite in trifluoroacetic acid gave α,ω-dicarboxylic acids in good yields.  Adipic acid was obtained in a quant. yield from cyclohexanol using 1 equiv of sodium nitrite under oxygen atm. but the oxidn. required more than 3 equiv of sodium nitrite under nitrogen atm.  The oxidn. method was applicable to the conversion of 1-alkanols to the corresponding carboxylic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorqRG54kP7KrVg90H21EOLACvtfcHk0lh08T-PuFP3Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFGgur4%253D&md5=fc450e4a001627d5693336c3f256a9a8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2004.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2004.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DN.%26aulast%3DFurukubo%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DF.%26aulast%3DOnomura%26aufirst%3DO.%26atitle%3DEfficient%2520Oxidation%2520of%2520Cycloalkanols%2520by%2520Sodium%2520Nitrite%2520with%2520Molecular%2520Oxygen%2520in%2520Trifluoroacetic%2520Acid%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D45%26spage%3D8221%26epage%3D8224%26doi%3D10.1016%2Fj.tetlet.2004.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueren-Calabuig, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span> <span> </span><span class="NLM_article-title">The Qi Site of Cytochrome b is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i></span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.9b00426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.9b00426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+J.+Wallauthor=S.+Carvalhoauthor=R.+Milneauthor=J.+A.+Bueren-Calabuigauthor=S.+Monizauthor=J.+Cantizani-Perezauthor=L.+MacLeanauthor=A.+Kesslerauthor=I.+Cotilloauthor=L.+Sastryauthor=S.+Manthriauthor=S.+Pattersonauthor=F.+Zuccottoauthor=S.+Thompsonauthor=J.+Martinauthor=M.+Marcoauthor=T.+J.+Milesauthor=M.+De+Ryckerauthor=M.+G.+Thomasauthor=A.+H.+Fairlambauthor=I.+H.+Gilbertauthor=S.+Wyllie&title=The+Qi+Site+of+Cytochrome+b+is+a+Promiscuous+Drug+Target+in+Trypanosoma+cruzi+and+Leishmania+donovani&doi=10.1021%2Facsinfecdis.9b00426"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.9b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.9b00426%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DCarvalho%26aufirst%3DS.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DBueren-Calabuig%26aufirst%3DJ.%2BA.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DCantizani-Perez%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DKessler%26aufirst%3DA.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DSastry%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyllie%26aufirst%3DS.%26atitle%3DThe%2520Qi%2520Site%2520of%2520Cytochrome%2520b%2520is%2520a%2520Promiscuous%2520Drug%2520Target%2520in%2520Trypanosoma%2520cruzi%2520and%2520Leishmania%2520donovani%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26doi%3D10.1021%2Facsinfecdis.9b00426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i168"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01852">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_57546"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01852?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01852</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC traces of key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular strings for all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_001.pdf">jm9b01852_si_001.pdf (844.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01852/suppl_file/jm9b01852_si_002.csv">jm9b01852_si_002.csv (6.76 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01852&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01852%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01852" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679949b4ec3222c0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
